Target-Disease Portfolio for Indication Expansion

Pchem targets available for virtual screening can be connected to several diseases.

OpenTargets DB provides comprehensive insights into the relationships between genes, diseases, and drugs by combining data from various sources, including genomics, transcriptomics, and clinical research. Each gene from Phchem target-based screens will have multiple scored associations to multiple diseases based on qualitative and quantitative information from mentioned data sources so that indications recorded in Pchem can be expanded to a wide range of indications in multiple therapeutic areas.

Targets association to different therapeutic areas as defined in OpenTargetsDB.

Graph view of the interconnection of target and diseases associations through different disease types.

Check target associations to therapeutic areas

PubChemAssay	gene	assayType	testedComopunds	activeCompounds	therapeuticArea	associationScore	numberOfEvidences
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	disorder of visual system	0.2680927432524	36
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	gastrointestinal disease	0.2981091823051	433
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	immune system disease	0.3315736578395	2047
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	phenotype	0.25168062231905	2176
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	phenotype	0.25168062231905	2176
HTS for Beta-2AR agonists via FAP method	ADRB2	targetBased	339297	1446	immune system disease	0.25240706701657	86
Fluorescence polarization assay for PLK1 inhibitors	PLK1	targetBased	97099	518	genetic, familial or congenital disease	0.25499741538679	170
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	targetBased	364065	10181	genetic, familial or congenital disease	0.25499741538679	170
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	NCF1	targetBased	217454	1142	immune system disease	0.25674937311193	212
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	targetBased	331671	10022	gastrointestinal disease	0.25817151429536	56
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	DRD2	targetBased	359518	300	biological_process	0.25993515763855	51
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	DRD2	targetBased	335652	1779	biological_process	0.25993515763855	51
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	DRD2	targetBased	362274	1056	biological_process	0.25993515763855	51
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	DRD2	targetBased	336308	6862	biological_process	0.25993515763855	51
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	DRD2	targetBased	357537	806	biological_process	0.25993515763855	51
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	DRD2	targetBased	339887	1178	biological_process	0.25993515763855	51
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	integumentary system disease	0.26050221008225	20
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	nervous system disease	0.26154504893848	363
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	endocrine system disease	0.26399330309157	293
Nrf2 qHTS screen for inhibitors	NFE2L2	targetBased	360873	7438	nervous system disease	0.26457216257395	487
qHTS of Nrf2 Activators	NFE2L2	pathwayBased	403871	1243	nervous system disease	0.26457216257395	487
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	reproductive system or breast disease	0.26565064297067	425
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	reproductive system or breast disease	0.26565064297067	425
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	reproductive system or breast disease	0.26565064297067	425
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	reproductive system or breast disease	0.26565064297067	425
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	reproductive system or breast disease	0.26565064297067	425
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	reproductive system or breast disease	0.26565064297067	425
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	targetBased	356517	1139	gastrointestinal disease	0.26636181111914	5746
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	pancreas disease	0.26666347855833	182
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17	targetBased	369953	3080	integumentary system disease	0.26829646163786	300
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	targetBased	86095	1114	endocrine system disease	0.26898256344608	290
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1	targetBased	359207	1432	gastrointestinal disease	0.26976163988946	302
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	disorder of visual system	0.27026191982487	86
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	urinary system disease	0.27048913576062	294
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	urinary system disease	0.27048913576062	294
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	musculoskeletal or connective tissue disease	0.27065598057118	486
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	gastrointestinal disease	0.27152326731022	115
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	gastrointestinal disease	0.27437888372023	2809
HTS for Beta-2AR agonists via FAP method	ADRB2	targetBased	339297	1446	nervous system disease	0.27716338116998	227
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	hematologic disease	0.28000788404909	254
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	targetBased	369953	2602	genetic, familial or congenital disease	0.28450304061011	172
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	cancer or benign tumor	0.28493762505645	1556
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	nervous system disease	0.28659700171939	178
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	nervous system disease	0.28659700171939	178
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	disorder of visual system	0.28978101796452	105
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	nervous system disease	0.29008594265646	28
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	nervous system disease	0.29008594265646	28
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	targetBased	86095	1114	nervous system disease	0.29052652776483	1040
qHTS Assay for Activators of ClpP	CLPP	targetBased	338378	6439	reproductive system or breast disease	0.29148492887276	69
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	targetBased	86095	1114	genetic, familial or congenital disease	0.29276179147728	1228
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA	targetBased	90878	289	hematologic disease	0.29389767362962	495
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA	targetBased	90878	289	immune system disease	0.29389967196901	718
Factor XIIa 1536 HTS	F12	targetBased	217430	649	hematologic disease	0.29572516568838	48
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	nervous system disease	0.29656006501162	116
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	nervous system disease	0.29656006501162	116
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	382	urinary system disease	0.29806660386618	429
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	3253	urinary system disease	0.29806660386618	429
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	respiratory or thoracic disease	0.30173159139841	169
HTS for BAP1 Enzyme inhibitors	BAP1	targetBased	71016	346	nervous system disease	0.30235176519497	73
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	nutritional or metabolic disease	0.30302057533838	289
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	genetic, familial or congenital disease	0.30361954806293	374
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	genetic, familial or congenital disease	0.30361954806293	374
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	genetic, familial or congenital disease	0.30361954806293	374
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	genetic, familial or congenital disease	0.30668259286341	420
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	genetic, familial or congenital disease	0.30691282800427	445
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	endocrine system disease	0.30967928171503	191
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	respiratory or thoracic disease	0.31595798980029	3696
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	respiratory or thoracic disease	0.31595798980029	3696
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	respiratory or thoracic disease	0.31595798980029	3696
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	respiratory or thoracic disease	0.31595798980029	3696
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	respiratory or thoracic disease	0.31595798980029	3696
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	genetic, familial or congenital disease	0.31665707417776	410
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	genetic, familial or congenital disease	0.31665707417776	410
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	gastrointestinal disease	0.31768133228557	1458
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM	targetBased	347933	673	genetic, familial or congenital disease	0.31769939659088	4380
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cardiovascular disease	0.31797034761677	1080
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	cardiovascular disease	0.31797034761677	1080
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	cardiovascular disease	0.31797034761677	1080
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	cardiovascular disease	0.31797034761677	1080
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	cardiovascular disease	0.31797034761677	1080
Thrombin 1536 HTS	F2	targetBased	217233	557	genetic, familial or congenital disease	0.31807826184725	847
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1	targetBased	359207	1432	immune system disease	0.31901006929432	3384
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	nervous system disease	0.31935959126188	1585
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	genetic, familial or congenital disease	0.32001034464186	635
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	genetic, familial or congenital disease	0.32001034464186	635
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2	targetBased	57013	201	cancer or benign tumor	0.32048611172855	6196
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	endocrine system disease	0.32082601661493	1178
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	integumentary system disease	0.32268748240652	4236
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	integumentary system disease	0.32268748240652	4236
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	integumentary system disease	0.32268748240652	4236
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	integumentary system disease	0.32268748240652	4236
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	integumentary system disease	0.32268748240652	4236
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	genetic, familial or congenital disease	0.32427221620001	2715
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF	targetBased	642362	5830	genetic, familial or congenital disease	0.32427221620001	2715
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2	targetBased	57013	201	genetic, familial or congenital disease	0.32640881494042	1440
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	cancer or benign tumor	0.32789616656231	5369
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	nutritional or metabolic disease	0.33201346422892	3186
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA	targetBased	302297	1165	nutritional or metabolic disease	0.33201346422892	3186
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP	pathwayBased	193400	1987	nervous system disease	0.33849210488635	2147
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP	pathwayBased	193714	1590	nervous system disease	0.33849210488635	2147
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP	targetBased	404343	257	nervous system disease	0.33849210488635	2147
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	cardiovascular disease	0.34418896052887	18
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cancer or benign tumor	0.34587473161897	75778
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	cancer or benign tumor	0.34587473161897	75778
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	cancer or benign tumor	0.34587473161897	75778
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	cancer or benign tumor	0.34587473161897	75778
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	cancer or benign tumor	0.34587473161897	75778
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	infectious disease	0.45493526245424	2876
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	infectious disease	0.45493526245424	2876
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	immune system disease	0.60635796999633	320
Thrombin 1536 HTS	F2	targetBased	217233	557	cardiovascular disease	0.68203646141334	837
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	cardiovascular disease	0.81671884749676	943
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	760	phenotype	0.250200632097744	71
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	498	phenotype	0.250200632097744	71
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	genetic, familial or congenital disease	0.250262056164513	222
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10	targetBased	369953	2294	nervous system disease	0.250296402050232	126
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	urinary system disease	0.250398735099291	440
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	musculoskeletal or connective tissue disease	0.250478737006694	502
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	hematologic disease	0.250479936208494	92
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	targetBased	326024	5748	nervous system disease	0.250484257364276	119
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	targetBased	326024	1387	nervous system disease	0.250484257364276	119
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	targetBased	335239	2035	nervous system disease	0.250601682845216	222
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	targetBased	335239	279	nervous system disease	0.250601682845216	222
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6	targetBased	362098	692	hematologic disease	0.250793839583365	74
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	infectious disease	0.250879772540052	248
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	infectious disease	0.250879772540052	248
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	infectious disease	0.250879772540052	248
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	infectious disease	0.250879772540052	248
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	infectious disease	0.250879772540052	248
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	infectious disease	0.250879772540052	248
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	integumentary system disease	0.250964511037462	124
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	integumentary system disease	0.250964511037462	124
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	cardiovascular disease	0.251087575798833	148
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	cardiovascular disease	0.251087575798833	148
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	nutritional or metabolic disease	0.251365844569418	267
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	NCF1	targetBased	217454	1142	genetic, familial or congenital disease	0.251602320838694	204
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	hematologic disease	0.251756640346989	806
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	targetBased	125268	2463	urinary system disease	0.252301220512274	139
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	targetBased	125268	2463	genetic, familial or congenital disease	0.252340718544495	175
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	nutritional or metabolic disease	0.252477008280183	59
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	cancer or benign tumor	0.252861866890854	893
Luminescent HTS for small molecule inhibitors of MT1-MMP transcription	MMP14	targetBased	86733	537	genetic, familial or congenital disease	0.252911127977307	236
uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay	MMP14	targetBased	361500	222	genetic, familial or congenital disease	0.252911127977307	236
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	targetBased	331671	10022	integumentary system disease	0.253011513845307	58
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1	targetBased	359207	1189	immune system disease	0.253034375831582	19
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1	targetBased	63676	1938	immune system disease	0.253034375831582	19
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1	targetBased	359207	316	immune system disease	0.253034375831582	19
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1	targetBased	63656	2179	immune system disease	0.253034375831582	19
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1	targetBased	359207	4555	immune system disease	0.253034375831582	19
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	urinary system disease	0.253062605621121	61
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	reproductive system or breast disease	0.253385745175792	27
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	reproductive system or breast disease	0.253385745175792	27
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	nervous system disease	0.253417170477464	502
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	nervous system disease	0.253419503182497	441
qHTS of GLP-1 Receptor Agonists	GLP1R	targetBased	373462	23	nervous system disease	0.253419503182497	441
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R	targetBased	405130	6428	nervous system disease	0.253419503182497	441
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	integumentary system disease	0.253657003198063	180
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	infectious disease	0.253844364497365	365
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	infectious disease	0.253844364497365	365
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	targetBased	362274	1085	genetic, familial or congenital disease	0.253935470120429	77
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	gastrointestinal disease	0.253949704640608	284
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	gastrointestinal disease	0.253949704640608	284
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1	targetBased	359207	1189	genetic, familial or congenital disease	0.253978380225788	76
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1	targetBased	63676	1938	genetic, familial or congenital disease	0.253978380225788	76
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1	targetBased	359207	316	genetic, familial or congenital disease	0.253978380225788	76
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1	targetBased	63656	2179	genetic, familial or congenital disease	0.253978380225788	76
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1	targetBased	359207	4555	genetic, familial or congenital disease	0.253978380225788	76
A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.	GMNN	targetBased	343234	9888	musculoskeletal or connective tissue disease	0.254533548578496	10
A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.	GMNN	targetBased	342279	6233	musculoskeletal or connective tissue disease	0.254533548578496	10
Allosteric Modulators of D1 Receptors: Primary Screen	DRD1	targetBased	57705	3413	psychiatric disorder	0.254566245723456	244
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	DRD1	targetBased	361330	3713	psychiatric disorder	0.254566245723456	244
Antagonist of Human D 1 Dopamine Receptor: qHTS	DRD1	targetBased	355805	11440	psychiatric disorder	0.254566245723456	244
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	gastrointestinal disease	0.254736303304555	874
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	nutritional or metabolic disease	0.254867189176116	138
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM	targetBased	347933	673	endocrine system disease	0.254936411644818	49
USP8 deubiquitinase inhibition: Primary qHTS	USP8	targetBased	47480	2010	cancer or benign tumor	0.255006987794919	283
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2	targetBased	57013	201	reproductive system or breast disease	0.255073450047621	485
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	MEN1	targetBased	263421	615	musculoskeletal or connective tissue disease	0.255124041681584	352
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	cancer or benign tumor	0.255139886274783	190
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	phenotype	0.255441825504248	114
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	phenotype	0.255441825504248	114
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	phenotype	0.255441825504248	114
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	targetBased	369953	2353	cancer or benign tumor	0.255509261207295	156
E3 Ligase HTS_1536	MDM2	targetBased	207811	220	nervous system disease	0.255739201707619	424
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	gastrointestinal disease	0.255795785917352	248
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1	targetBased	338373	1061	cancer or benign tumor	0.255849051734753	145
Primary qHTS for Inhibitors of ATXN expression	ATXN2	targetBased	358434	2554	genetic, familial or congenital disease	0.256119746159216	348
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	nervous system disease	0.256238027661274	92
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	respiratory or thoracic disease	0.256252172428189	305
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	nervous system disease	0.256264087235402	339
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	nervous system disease	0.256416533995387	244
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	phenotype	0.256452530114953	134
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	measurement	0.256605646252661	65
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	measurement	0.256605646252661	65
Nrf2 qHTS screen for inhibitors	NFE2L2	targetBased	360873	7438	urinary system disease	0.256937163214503	230
qHTS of Nrf2 Activators	NFE2L2	pathwayBased	403871	1243	urinary system disease	0.256937163214503	230
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	targetBased	369953	3123	genetic, familial or congenital disease	0.256959537909618	84
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	nervous system disease	0.257034032374441	257
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	nervous system disease	0.257034032374441	257
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR	targetBased	324747	7988	immune system disease	0.257225965698231	779
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	genetic, familial or congenital disease	0.257377110790748	333
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	phenotype	0.257715109620676	201
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	phenotype	0.257715109620676	201
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	genetic, familial or congenital disease	0.257916964061772	164
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	genetic, familial or congenital disease	0.257916964061772	164
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	cancer or benign tumor	0.257956336640594	349
Luminescent HTS for small molecule inhibitors of MT1-MMP transcription	MMP14	targetBased	86733	537	musculoskeletal or connective tissue disease	0.258123475118061	136
uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay	MMP14	targetBased	361500	222	musculoskeletal or connective tissue disease	0.258123475118061	136
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS	targetBased	385746	932	cancer or benign tumor	0.258267181126456	544
Colorimetric Assay for Inhibitors for NALP1	NLRP1	targetBased	280024	1717	integumentary system disease	0.258280684229034	114
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	targetBased	331671	10022	nervous system disease	0.258333359458804	111
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11	targetBased	325630	216	cancer or benign tumor	0.258461715889144	1211
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	cardiovascular disease	0.258561709095275	107
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	reproductive system or breast disease	0.258824475434152	40
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	psychiatric disorder	0.258974142506334	98
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	cancer or benign tumor	0.259060193170509	157
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	targetBased	315412	318	nervous system disease	0.259075755673923	122
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	urinary system disease	0.259241048271146	16
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	phenotype	0.259270215951928	196
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	phenotype	0.259270215951928	196
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM	targetBased	347933	673	gastrointestinal disease	0.259300711784485	44
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	cardiovascular disease	0.259414960129501	2510
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	psychiatric disorder	0.259966092514974	265
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	targetBased	86095	1114	musculoskeletal or connective tissue disease	0.260166925315013	970
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	endocrine system disease	0.260212993132567	2701
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	reproductive system or breast disease	0.260476547988866	46
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	cancer or benign tumor	0.260631469551519	152
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	cancer or benign tumor	0.260657429966008	162
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	cancer or benign tumor	0.260657429966008	162
HTS for BAP1 Enzyme inhibitors	BAP1	targetBased	71016	346	urinary system disease	0.260696168490879	82
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	gastrointestinal disease	0.260881738372858	91
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF	targetBased	642362	5830	gastrointestinal disease	0.260881738372858	91
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	nervous system disease	0.261270514738945	254
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	genetic, familial or congenital disease	0.261524165538828	107
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	genetic, familial or congenital disease	0.261524165538828	107
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	DRD2	targetBased	359518	300	genetic, familial or congenital disease	0.261579902300551	679
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	DRD2	targetBased	335652	1779	genetic, familial or congenital disease	0.261579902300551	679
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	DRD2	targetBased	362274	1056	genetic, familial or congenital disease	0.261579902300551	679
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	DRD2	targetBased	336308	6862	genetic, familial or congenital disease	0.261579902300551	679
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	DRD2	targetBased	357537	806	genetic, familial or congenital disease	0.261579902300551	679
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	DRD2	targetBased	339887	1178	genetic, familial or congenital disease	0.261579902300551	679
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	respiratory or thoracic disease	0.262004337131526	317
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	respiratory or thoracic disease	0.262064681773521	163
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM	targetBased	347933	673	reproductive system or breast disease	0.262162020659698	81
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	nervous system disease	0.262236795192853	791
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	nervous system disease	0.262236795192853	791
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9	targetBased	305610	3794	nervous system disease	0.262436515993694	34
qHTS of D3 Dopamine Receptor Agonist: qHTS	DRD3	targetBased	407539	2380	psychiatric disorder	0.262443028121728	659
qHTS of D3 Dopamine Receptor Antagonist: qHTS	DRD3	targetBased	364051	9106	psychiatric disorder	0.262443028121728	659
qHTS of D3 Dopamine Receptor Potentiators: qHTS	DRD3	targetBased	407539	2380	psychiatric disorder	0.262443028121728	659
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	hematologic disease	0.262589496411515	30
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	hematologic disease	0.262589496411515	30
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	760	cancer or benign tumor	0.263106263572671	120
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	498	cancer or benign tumor	0.263106263572671	120
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	genetic, familial or congenital disease	0.263205646198894	399
Thrombin 1536 HTS	F2	targetBased	217233	557	nervous system disease	0.263306356432243	238
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	psychiatric disorder	0.263378003131404	772
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	psychiatric disorder	0.263378003131404	772
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	nervous system disease	0.263573834835848	1113
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	nervous system disease	0.263573834835848	1113
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17	targetBased	369953	3080	gastrointestinal disease	0.263599855350939	432
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL1B	pathwayBased	362051	17187	musculoskeletal or connective tissue disease	0.263660875002061	3763
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	immune system disease	0.263705729449629	1498
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	targetBased	309684	1662	cancer or benign tumor	0.263728643811699	389
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	nervous system disease	0.263850692215293	98
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	nervous system disease	0.263850692215293	98
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	nervous system disease	0.263850692215293	98
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	pregnancy or perinatal disease	0.263937233490496	18
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	pregnancy or perinatal disease	0.263937233490496	18
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	pregnancy or perinatal disease	0.263937233490496	18
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	pregnancy or perinatal disease	0.263937233490496	18
qHTS of D3 Dopamine Receptor Agonist: qHTS	DRD3	targetBased	407539	2380	phenotype	0.263975468887278	134
qHTS of D3 Dopamine Receptor Antagonist: qHTS	DRD3	targetBased	364051	9106	phenotype	0.263975468887278	134
qHTS of D3 Dopamine Receptor Potentiators: qHTS	DRD3	targetBased	407539	2380	phenotype	0.263975468887278	134
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	nervous system disease	0.264217781858885	1470
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17	targetBased	369953	3080	musculoskeletal or connective tissue disease	0.264277627919279	299
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	targetBased	368927	620	cancer or benign tumor	0.264660195850273	245
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pancreas disease	0.264940403954813	68
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pancreas disease	0.264940403954813	68
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	gastrointestinal disease	0.265204098812013	327
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	musculoskeletal or connective tissue disease	0.265219766572666	22
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	pancreas disease	0.265322192854308	36
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS	targetBased	385746	932	phenotype	0.265440757044351	452
qHTS for Inhibitors of Glutaminase (GLS)	GLS	targetBased	405291	844	genetic, familial or congenital disease	0.265477009361552	125
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	reproductive system or breast disease	0.265477798460451	206
qHTS of D3 Dopamine Receptor Agonist: qHTS	DRD3	targetBased	407539	2380	genetic, familial or congenital disease	0.265516513708577	333
qHTS of D3 Dopamine Receptor Antagonist: qHTS	DRD3	targetBased	364051	9106	genetic, familial or congenital disease	0.265516513708577	333
qHTS of D3 Dopamine Receptor Potentiators: qHTS	DRD3	targetBased	407539	2380	genetic, familial or congenital disease	0.265516513708577	333
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	targetBased	369953	3123	integumentary system disease	0.265538854023612	66
Dicer-mediated maturation of pre-microRNA	DICER1	targetBased	46715	2829	musculoskeletal or connective tissue disease	0.265585412565148	118
Nrf2 qHTS screen for inhibitors	NFE2L2	targetBased	360873	7438	reproductive system or breast disease	0.265650659657604	169
qHTS of Nrf2 Activators	NFE2L2	pathwayBased	403871	1243	reproductive system or breast disease	0.265650659657604	169
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	phenotype	0.265692956809599	551
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17	targetBased	369953	3080	genetic, familial or congenital disease	0.265735276815921	466
USP8 deubiquitinase inhibition: Primary qHTS	USP8	targetBased	47480	2010	reproductive system or breast disease	0.265883288728466	85
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR	targetBased	324747	7988	genetic, familial or congenital disease	0.265958647391539	769
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17	targetBased	369953	3080	immune system disease	0.266077014033366	336
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	nervous system disease	0.266243720751926	412
HTS for BAP1 Enzyme inhibitors	BAP1	targetBased	71016	346	endocrine system disease	0.266266066924607	75
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	endocrine system disease	0.266274632043547	1910
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	endocrine system disease	0.266274632043547	1910
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	targetBased	353950	4145	cancer or benign tumor	0.266490137894434	1295
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL	targetBased	195560	517	measurement	0.266820347911369	76
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	genetic, familial or congenital disease	0.266962845511349	355
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	genetic, familial or congenital disease	0.266962845511349	355
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	cancer or benign tumor	0.267304237031556	26227
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	respiratory or thoracic disease	0.267305170653675	225
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	nervous system disease	0.267489653849628	123
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	biological_process	0.267591240947233	278
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	biological_process	0.267591240947233	278
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9	targetBased	305610	3794	genetic, familial or congenital disease	0.267641441826259	36
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	targetBased	369953	2353	reproductive system or breast disease	0.267718944034859	73
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	nutritional or metabolic disease	0.268229135393374	30
Fluorescence polarization assay for PLK1 inhibitors	PLK1	targetBased	97099	518	nervous system disease	0.268878090339532	133
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	targetBased	364065	10181	nervous system disease	0.268878090339532	133
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1	targetBased	359207	1432	nervous system disease	0.268943902043269	169
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	targetBased	369953	1241	genetic, familial or congenital disease	0.269031769083984	33
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	targetBased	86095	1114	psychiatric disorder	0.269244007323558	65
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	measurement	0.269523218251014	139
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	measurement	0.269523218251014	139
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	integumentary system disease	0.269533734198049	394
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	endocrine system disease	0.269578919973986	47
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex	PRKACB	targetBased	343468	273	genetic, familial or congenital disease	0.269585267626121	23
Dicer-mediated maturation of pre-microRNA	DICER1	targetBased	46715	2829	reproductive system or breast disease	0.269745214643302	230
Thrombin 1536 HTS	F2	targetBased	217233	557	phenotype	0.269858141245707	1570
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	musculoskeletal or connective tissue disease	0.269934602960982	298
Nrf2 qHTS screen for inhibitors	NFE2L2	targetBased	360873	7438	respiratory or thoracic disease	0.270135376355121	370
qHTS of Nrf2 Activators	NFE2L2	pathwayBased	403871	1243	respiratory or thoracic disease	0.270135376355121	370
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	nervous system disease	0.270185824920767	728
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	nervous system disease	0.270185824920767	728
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	nervous system disease	0.270185824920767	728
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	nervous system disease	0.270185824920767	728
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	nervous system disease	0.270185824920767	728
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	nervous system disease	0.270185824920767	728
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	reproductive system or breast disease	0.270278401206253	162
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	reproductive system or breast disease	0.270278401206253	162
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL1B	pathwayBased	362051	17187	cardiovascular disease	0.270296398314003	2855
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	nervous system disease	0.270331831334349	2414
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	targetBased	189132	4127	genetic, familial or congenital disease	0.270367429118424	519
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	nervous system disease	0.270519163611425	62
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	gastrointestinal disease	0.270614413856281	159
A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.	GMNN	targetBased	343234	9888	genetic, familial or congenital disease	0.270727669603473	73
A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.	GMNN	targetBased	342279	6233	genetic, familial or congenital disease	0.270727669603473	73
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	measurement	0.270885538045029	449
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	measurement	0.270885538045029	449
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	immune system disease	0.270896618776566	237
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	endocrine system disease	0.271017473102193	232
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	targetBased	369953	2602	cardiovascular disease	0.271019914176172	78
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	measurement	0.271136588663287	684
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	psychiatric disorder	0.271159071852503	1192
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	psychiatric disorder	0.271159071852503	1192
High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits	GNAI3	targetBased	204125	876	genetic, familial or congenital disease	0.271247238734177	75
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	immune system disease	0.271472278963004	134
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	immune system disease	0.271472278963004	134
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	MEN1	targetBased	263421	615	nervous system disease	0.271544049152734	438
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	reproductive system or breast disease	0.271554766936928	1411
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	targetBased	86095	1114	reproductive system or breast disease	0.271674611375097	913
Primary qHTS for Inhibitors of ATXN expression	ATXN2	targetBased	358434	2554	nervous system disease	0.271701326322461	336
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	cancer or benign tumor	0.271920279416352	357
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	cancer or benign tumor	0.271920279416352	357
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	hematologic disease	0.272020239690185	119
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	hematologic disease	0.272020239690185	119
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	respiratory or thoracic disease	0.272030589176179	160
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	integumentary system disease	0.272194444747796	1140
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2	targetBased	57013	201	nervous system disease	0.272230595674442	465
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	nervous system disease	0.272307500144212	312
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	genetic, familial or congenital disease	0.272466694956396	105
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	endocrine system disease	0.272542586019146	329
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	psychiatric disorder	0.272875102942208	194
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	psychiatric disorder	0.272875102942208	194
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	urinary system disease	0.272885783802447	176
HTS for Tumor Hsp90 Inhibitors	HSP90AA1	targetBased	63696	220	cancer or benign tumor	0.273126364876218	1118
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	targetBased	290726	2649	cancer or benign tumor	0.273126364876218	1118
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	disorder of visual system	0.273714146187464	14
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	disorder of visual system	0.273714146187464	14
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10	targetBased	369953	2294	genetic, familial or congenital disease	0.274069457479068	124
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	CFTR	targetBased	343786	1253	phenotype	0.274148596179842	502
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	CFTR	targetBased	296501	2737	phenotype	0.274148596179842	502
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	psychiatric disorder	0.274189145238068	542
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	psychiatric disorder	0.274189145238068	542
Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2)	GPT2	targetBased	98912	236	genetic, familial or congenital disease	0.274352401874573	45
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	gastrointestinal disease	0.274561257666288	2850
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	gastrointestinal disease	0.274561257666288	2850
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	respiratory or thoracic disease	0.274632786857521	413
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	nervous system disease	0.274646421628902	1497
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	nervous system disease	0.274646421628902	1497
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	nutritional or metabolic disease	0.274740226586422	4508
qHTS of GLP-1 Receptor Agonists	GLP1R	targetBased	373462	23	nutritional or metabolic disease	0.274740226586422	4508
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R	targetBased	405130	6428	nutritional or metabolic disease	0.274740226586422	4508
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	nutritional or metabolic disease	0.275113242930035	1298
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	nutritional or metabolic disease	0.275113242930035	1298
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	targetBased	324747	2221	nutritional or metabolic disease	0.275133213980949	51
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	targetBased	362274	1085	psychiatric disorder	0.276041578162085	76
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	integumentary system disease	0.276360418913388	26
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	integumentary system disease	0.276360418913388	26
Nrf2 qHTS screen for inhibitors	NFE2L2	targetBased	360873	7438	endocrine system disease	0.276387815694226	531
qHTS of Nrf2 Activators	NFE2L2	pathwayBased	403871	1243	endocrine system disease	0.276387815694226	531
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	musculoskeletal or connective tissue disease	0.276513519408763	350
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	cardiovascular disease	0.276670691554651	353
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	pancreas disease	0.276681893646445	4146
qHTS of GLP-1 Receptor Agonists	GLP1R	targetBased	373462	23	pancreas disease	0.276681893646445	4146
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R	targetBased	405130	6428	pancreas disease	0.276681893646445	4146
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A	targetBased	310014	1321	psychiatric disorder	0.277346183588462	384
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	urinary system disease	0.277768187042269	159
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	reproductive system or breast disease	0.277896347118708	234
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	targetBased	86095	1114	cancer or benign tumor	0.277932160960647	2158
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	psychiatric disorder	0.278227858903815	106
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	gastrointestinal disease	0.278303064132598	4612
qHTS of GLP-1 Receptor Agonists	GLP1R	targetBased	373462	23	gastrointestinal disease	0.278303064132598	4612
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R	targetBased	405130	6428	gastrointestinal disease	0.278303064132598	4612
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	phenotype	0.278368371017333	949
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	phenotype	0.278368371017333	949
Dicer-mediated maturation of pre-microRNA	DICER1	targetBased	46715	2829	respiratory or thoracic disease	0.278969248284901	179
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6	targetBased	362098	692	disorder of visual system	0.279022374592434	31
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	phenotype	0.279024756582729	228
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	phenotype	0.279024756582729	228
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	targetBased	331671	10022	cancer or benign tumor	0.279130290252003	817
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	musculoskeletal or connective tissue disease	0.279260982101527	123
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	musculoskeletal or connective tissue disease	0.279260982101527	123
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	nutritional or metabolic disease	0.279538031152616	117
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	urinary system disease	0.279549165177453	1600
USP8 deubiquitinase inhibition: Primary qHTS	USP8	targetBased	47480	2010	nervous system disease	0.279879802494676	142
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	targetBased	362274	1085	nervous system disease	0.280363171330822	99
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	cancer or benign tumor	0.280383626834031	834
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	nervous system disease	0.280453737595432	138
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	gastrointestinal disease	0.280710885313529	1047
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	gastrointestinal disease	0.280710885313529	1047
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	endocrine system disease	0.280726325145351	4689
qHTS of GLP-1 Receptor Agonists	GLP1R	targetBased	373462	23	endocrine system disease	0.280726325145351	4689
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R	targetBased	405130	6428	endocrine system disease	0.280726325145351	4689
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B	targetBased	292323	567	phenotype	0.280933990781892	160
Colorimetric Assay for Inhibitors for NALP1	NLRP1	targetBased	280024	1717	disorder of visual system	0.281085244250405	55
Allosteric Modulators of D1 Receptors: Primary Screen	DRD1	targetBased	57705	3413	nervous system disease	0.281085634232961	361
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	DRD1	targetBased	361330	3713	nervous system disease	0.281085634232961	361
Antagonist of Human D 1 Dopamine Receptor: qHTS	DRD1	targetBased	355805	11440	nervous system disease	0.281085634232961	361
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1	targetBased	359207	1189	nervous system disease	0.281148745570026	137
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1	targetBased	63676	1938	nervous system disease	0.281148745570026	137
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1	targetBased	359207	316	nervous system disease	0.281148745570026	137
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1	targetBased	63656	2179	nervous system disease	0.281148745570026	137
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1	targetBased	359207	4555	nervous system disease	0.281148745570026	137
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6	targetBased	362098	692	integumentary system disease	0.281276995229199	51
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	phenotype	0.281853912575745	1142
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	immune system disease	0.281862731126412	851
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	immune system disease	0.281862731126412	851
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	immune system disease	0.281862731126412	851
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	immune system disease	0.281862731126412	851
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	immune system disease	0.281862731126412	851
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	immune system disease	0.281862731126412	851
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	cancer or benign tumor	0.281887028684843	476
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	cancer or benign tumor	0.281887028684843	476
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	cancer or benign tumor	0.281887028684843	476
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	cancer or benign tumor	0.281887028684843	476
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	genetic, familial or congenital disease	0.281963823820655	548
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	genetic, familial or congenital disease	0.281963823820655	548
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	psychiatric disorder	0.282063698282122	33
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	musculoskeletal or connective tissue disease	0.282068427007135	808
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	musculoskeletal or connective tissue disease	0.282068427007135	808
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	targetBased	356517	1139	endocrine system disease	0.282118595092748	5184
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	integumentary system disease	0.282291162301668	331
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	genetic, familial or congenital disease	0.282600203969975	221
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	genetic, familial or congenital disease	0.282600203969975	221
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	targetBased	324747	2221	genetic, familial or congenital disease	0.282850073089782	382
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	phenotype	0.282933484229465	1083
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	phenotype	0.282933484229465	1083
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	nervous system disease	0.282973301051172	183
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	CFTR	targetBased	343786	1253	endocrine system disease	0.283223717329647	626
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	CFTR	targetBased	296501	2737	endocrine system disease	0.283223717329647	626
Nrf2 qHTS screen for inhibitors	NFE2L2	targetBased	360873	7438	gastrointestinal disease	0.283252811812483	688
qHTS of Nrf2 Activators	NFE2L2	pathwayBased	403871	1243	gastrointestinal disease	0.283252811812483	688
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	targetBased	306502	2634	disorder of visual system	0.283476587843887	454
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	targetBased	306502	1509	disorder of visual system	0.283476587843887	454
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	targetBased	306502	2634	musculoskeletal or connective tissue disease	0.283643683298956	438
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	targetBased	306502	1509	musculoskeletal or connective tissue disease	0.283643683298956	438
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H	targetBased	104728	4230	nervous system disease	0.284015269874954	1920
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	nervous system disease	0.284053409993613	143
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	nutritional or metabolic disease	0.284087609563328	1322
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	genetic, familial or congenital disease	0.284097813405646	1098
USP8 deubiquitinase inhibition: Primary qHTS	USP8	targetBased	47480	2010	endocrine system disease	0.284193972253571	88
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	immune system disease	0.284282062775898	113
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	genetic, familial or congenital disease	0.284607759531048	47
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	genetic, familial or congenital disease	0.284607759531048	47
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	hematologic disease	0.284612218012725	110
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	gastrointestinal disease	0.284615917758805	58
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	targetBased	205582	727	psychiatric disorder	0.284707690065011	102
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	CFTR	targetBased	343786	1253	pancreas disease	0.284735446573053	471
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	CFTR	targetBased	296501	2737	pancreas disease	0.284735446573053	471
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	cardiovascular disease	0.284814573037216	113
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	cardiovascular disease	0.284814573037216	113
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	gastrointestinal disease	0.284832737223483	30
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	gastrointestinal disease	0.284832737223483	30
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	cardiovascular disease	0.284926104347463	230
E3 Ligase HTS_1536	MDM2	targetBased	207811	220	cancer or benign tumor	0.285079455361369	5355
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	gastrointestinal disease	0.285204436351899	532
HTS for BAP1 Enzyme inhibitors	BAP1	targetBased	71016	346	respiratory or thoracic disease	0.285387508742238	105
Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2)	GPT2	targetBased	98912	236	nervous system disease	0.285577708323194	31
Dicer-mediated maturation of pre-microRNA	DICER1	targetBased	46715	2829	nervous system disease	0.285613583129234	180
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	nervous system disease	0.285753718869332	196
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	gastrointestinal disease	0.285951021888019	730
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	nervous system disease	0.286275044173807	287
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	urinary system disease	0.286459320563299	174
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	infectious disease	0.286526502989479	753
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	gastrointestinal disease	0.286693450126032	377
HTS for BAP1 Enzyme inhibitors	BAP1	targetBased	71016	346	gastrointestinal disease	0.287120827849473	163
qHTS for Inhibitors of Polymerase Eta	POLH	targetBased	388717	4730	nutritional or metabolic disease	0.287276116746772	165
qHTS of D3 Dopamine Receptor Agonist: qHTS	DRD3	targetBased	407539	2380	nervous system disease	0.287286097920552	1016
qHTS of D3 Dopamine Receptor Antagonist: qHTS	DRD3	targetBased	364051	9106	nervous system disease	0.287286097920552	1016
qHTS of D3 Dopamine Receptor Potentiators: qHTS	DRD3	targetBased	407539	2380	nervous system disease	0.287286097920552	1016
HTS for BAP1 Enzyme inhibitors	BAP1	targetBased	71016	346	disorder of visual system	0.287305442430176	29
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	genetic, familial or congenital disease	0.287308094053503	269
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	targetBased	369953	1241	nervous system disease	0.287462009112558	35
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	targetBased	189882	6790	genetic, familial or congenital disease	0.287937611463864	2694
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	targetBased	48068	449	genetic, familial or congenital disease	0.287937611463864	2694
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	targetBased	220571	2380	genetic, familial or congenital disease	0.287937611463864	2694
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	targetBased	223611	305	genetic, familial or congenital disease	0.287937611463864	2694
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	genetic, familial or congenital disease	0.288057921692239	137
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	psychiatric disorder	0.288130632936073	1663
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	targetBased	309684	1662	genetic, familial or congenital disease	0.288202054680083	344
qHTS assay for inhibitors of human lactate dehydrogenase	LDHA	targetBased	476056	732	nutritional or metabolic disease	0.288371282870323	230
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	psychiatric disorder	0.288517720653819	252
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	musculoskeletal or connective tissue disease	0.288547350930345	28
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	musculoskeletal or connective tissue disease	0.288547350930345	28
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	cancer or benign tumor	0.288816367525507	19367
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	cancer or benign tumor	0.288816367525507	19367
qHTS assay for inhibitors of human lactate dehydrogenase	LDHA	targetBased	476056	732	genetic, familial or congenital disease	0.288856876451472	516
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS	targetBased	385746	932	genetic, familial or congenital disease	0.288895131202157	850
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	MEN1	targetBased	263421	615	gastrointestinal disease	0.288926026114239	411
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	endocrine system disease	0.289050597913055	390
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	endocrine system disease	0.289050597913055	390
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	hematologic disease	0.289149117260233	2557
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	hematologic disease	0.289149117260233	2557
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	infectious disease	0.289489523209689	1767
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	infectious disease	0.289489523209689	1767
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	infectious disease	0.289489523209689	1767
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	infectious disease	0.289489523209689	1767
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	infectious disease	0.289489523209689	1767
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	psychiatric disorder	0.289870409309081	2285
qHTS for Inhibitors of Polymerase Eta	POLH	targetBased	388717	4730	integumentary system disease	0.290001196342719	175
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	reproductive system or breast disease	0.290015482100919	190
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	reproductive system or breast disease	0.290015482100919	190
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	targetBased	639428	9218	genetic, familial or congenital disease	0.290556320577233	351
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B	targetBased	292323	567	genetic, familial or congenital disease	0.290571352374007	66
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	nutritional or metabolic disease	0.290584455498939	105
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	nutritional or metabolic disease	0.290584455498939	105
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	targetBased	338328	2501	genetic, familial or congenital disease	0.290701743155285	305
qHTS Assay for Activators of ClpP	CLPP	targetBased	338378	6439	nutritional or metabolic disease	0.290816927937545	43
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	targetBased	338328	2501	musculoskeletal or connective tissue disease	0.290913851935723	198
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	psychiatric disorder	0.291074121713901	136
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	psychiatric disorder	0.291074121713901	136
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	nutritional or metabolic disease	0.291299448115663	33
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	nutritional or metabolic disease	0.291299448115663	33
qHTS Assay for Activators of ClpP	CLPP	targetBased	338378	6439	endocrine system disease	0.291406615046282	55
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	targetBased	205582	727	nervous system disease	0.291418763493011	120
qHTS Assay for Activators of ClpP	CLPP	targetBased	338378	6439	genetic, familial or congenital disease	0.291464054195396	86
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	cancer or benign tumor	0.291585178082874	3284
Primary cell-based high-throughput screening assay to measure PERK inhibition	EIF2AK3	targetBased	217959	370	musculoskeletal or connective tissue disease	0.291590622292809	266
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	nervous system disease	0.291714746160251	151
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	genetic, familial or congenital disease	0.291763546772344	64
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	GFER	targetBased	288728	10857	genetic, familial or congenital disease	0.291763546772344	64
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	psychiatric disorder	0.291805484474816	95
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B	targetBased	292323	567	nervous system disease	0.291847392792435	184
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	nervous system disease	0.292054607859825	57
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A	targetBased	310014	1321	genetic, familial or congenital disease	0.292466606700016	834
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	nervous system disease	0.292746178703482	794
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	nervous system disease	0.292746178703482	794
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	psychiatric disorder	0.292801027392692	221
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	gastrointestinal disease	0.292809800146558	674
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	cancer or benign tumor	0.293526863571609	3019
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	cancer or benign tumor	0.293526863571609	3019
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	cancer or benign tumor	0.293526863571609	3019
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	cancer or benign tumor	0.293526863571609	3019
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	cancer or benign tumor	0.293526863571609	3019
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	cancer or benign tumor	0.293526863571609	3019
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	disorder of visual system	0.293659325627087	89
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	disorder of visual system	0.293659325627087	89
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	DRD2	targetBased	359518	300	nervous system disease	0.293865287003299	3680
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	DRD2	targetBased	335652	1779	nervous system disease	0.293865287003299	3680
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	DRD2	targetBased	362274	1056	nervous system disease	0.293865287003299	3680
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	DRD2	targetBased	336308	6862	nervous system disease	0.293865287003299	3680
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	DRD2	targetBased	357537	806	nervous system disease	0.293865287003299	3680
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	DRD2	targetBased	339887	1178	nervous system disease	0.293865287003299	3680
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	targetBased	306502	2634	genetic, familial or congenital disease	0.293867865504868	711
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	targetBased	306502	1509	genetic, familial or congenital disease	0.293867865504868	711
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA	targetBased	90878	289	genetic, familial or congenital disease	0.293969986349411	781
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	phenotype	0.293999070189601	1660
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	phenotype	0.293999070189601	1660
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	phenotype	0.293999070189601	1660
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	disorder of visual system	0.294018067583688	1006
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF	targetBased	642362	5830	disorder of visual system	0.294018067583688	1006
Primary cell-based high-throughput screening assay to measure PERK inhibition	EIF2AK3	targetBased	217959	370	genetic, familial or congenital disease	0.294222604585371	426
Glucocerebrosidase	GBA1	targetBased	48118	549	cardiovascular disease	0.294235203169089	213
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	genetic, familial or congenital disease	0.294544690363571	7028
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	genetic, familial or congenital disease	0.294544690363571	7028
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	targetBased	72072	2464	psychiatric disorder	0.294545088176652	23
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	targetBased	73912	5649	psychiatric disorder	0.294545088176652	23
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	urinary system disease	0.294899242780575	164
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	targetBased	356517	1139	musculoskeletal or connective tissue disease	0.295623036025768	2125
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	musculoskeletal or connective tissue disease	0.295634932995792	77
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	musculoskeletal or connective tissue disease	0.295634932995792	77
Nrf2 qHTS screen for inhibitors	NFE2L2	targetBased	360873	7438	genetic, familial or congenital disease	0.295683760766397	592
qHTS of Nrf2 Activators	NFE2L2	pathwayBased	403871	1243	genetic, familial or congenital disease	0.295683760766397	592
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	cardiovascular disease	0.295772002661356	69
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	cardiovascular disease	0.295772002661356	69
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP	pathwayBased	193400	1987	nutritional or metabolic disease	0.296400576493995	911
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP	pathwayBased	193714	1590	nutritional or metabolic disease	0.296400576493995	911
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP	targetBased	404343	257	nutritional or metabolic disease	0.296400576493995	911
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	integumentary system disease	0.296573564076537	512
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	integumentary system disease	0.296573564076537	512
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	integumentary system disease	0.296573564076537	512
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	integumentary system disease	0.296573564076537	512
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	integumentary system disease	0.296573564076537	512
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	integumentary system disease	0.296573564076537	512
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	DCLRE1C	targetBased	30104	235	nutritional or metabolic disease	0.296838018663434	512
Nrf2 qHTS screen for inhibitors	NFE2L2	targetBased	360873	7438	cancer or benign tumor	0.297091142324639	1926
qHTS of Nrf2 Activators	NFE2L2	pathwayBased	403871	1243	cancer or benign tumor	0.297091142324639	1926
Colorimetric Assay for Inhibitors for NALP1	NLRP1	targetBased	280024	1717	genetic, familial or congenital disease	0.297214512705533	382
Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter	FXN	targetBased	356160	1985	genetic, familial or congenital disease	0.297539511667236	767
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A	targetBased	310014	1321	nervous system disease	0.297683593025544	655
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	targetBased	369953	3123	cancer or benign tumor	0.297706338045056	422
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	hematologic disease	0.297796297319023	657
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	musculoskeletal or connective tissue disease	0.298056523073168	2885
Factor XIIa 1536 HTS	F12	targetBased	217430	649	integumentary system disease	0.298134545120243	59
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2	targetBased	57013	201	immune system disease	0.298478087771959	898
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	gastrointestinal disease	0.298709473653827	203
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	gastrointestinal disease	0.298709473653827	203
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	musculoskeletal or connective tissue disease	0.298747387517632	1565
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	musculoskeletal or connective tissue disease	0.298747387517632	1565
Factor XIIa 1536 HTS	F12	targetBased	217430	649	cardiovascular disease	0.299406783643809	71
Dicer-mediated maturation of pre-microRNA	DICER1	targetBased	46715	2829	endocrine system disease	0.299576761531126	372
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	endocrine system disease	0.299660796271136	1656
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	endocrine system disease	0.299660796271136	1656
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	targetBased	148480	6428	genetic, familial or congenital disease	0.300098214320156	175
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	cancer or benign tumor	0.300234000855061	201
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	cancer or benign tumor	0.300234000855061	201
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	nutritional or metabolic disease	0.300415352416651	246
Glucocerebrosidase	GBA1	targetBased	48118	549	psychiatric disorder	0.300528345396805	291
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	genetic, familial or congenital disease	0.301794123555221	75
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	musculoskeletal or connective tissue disease	0.301915430925714	206
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	nervous system disease	0.301939506919505	151
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	hematologic disease	0.302107789202345	654
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	disorder of visual system	0.302178509416749	589
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	disorder of visual system	0.302178509416749	589
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	disorder of visual system	0.302178509416749	589
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	genetic, familial or congenital disease	0.302240130189785	1995
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	genetic, familial or congenital disease	0.302240130189785	1995
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	musculoskeletal or connective tissue disease	0.302390832862623	341
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	targetBased	189132	4127	nervous system disease	0.302587836741825	1123
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1	pathwayBased	195980	5134	integumentary system disease	0.302981769888463	524
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	integumentary system disease	0.302981769888463	524
uHTS identification of HIF-2a Inhibitors in a luminesence assay	EPAS1	targetBased	363840	2624	cancer or benign tumor	0.303886858588741	1991
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	cardiovascular disease	0.304049714920847	42
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	cardiovascular disease	0.304049714920847	42
HTS for BAP1 Enzyme inhibitors	BAP1	targetBased	71016	346	genetic, familial or congenital disease	0.304074234034137	2924
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	nervous system disease	0.304101687726101	121
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	cancer or benign tumor	0.304328070362583	19000
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	targetBased	189882	6790	nervous system disease	0.304379846446857	2822
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	targetBased	48068	449	nervous system disease	0.304379846446857	2822
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	targetBased	220571	2380	nervous system disease	0.304379846446857	2822
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	targetBased	223611	305	nervous system disease	0.304379846446857	2822
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	genetic, familial or congenital disease	0.304953246121065	1687
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6	targetBased	362098	692	genetic, familial or congenital disease	0.304955066284085	179
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	psychiatric disorder	0.305113985759858	765
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	immune system disease	0.305400688801944	146
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	cardiovascular disease	0.305622477329174	123
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	integumentary system disease	0.305701219195517	1397
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF	targetBased	642362	5830	integumentary system disease	0.305701219195517	1397
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	760	genetic, familial or congenital disease	0.305805520492826	79
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	498	genetic, familial or congenital disease	0.305805520492826	79
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	targetBased	356517	1139	nervous system disease	0.305852566777921	3546
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	hematologic disease	0.305859664489525	1323
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	nutritional or metabolic disease	0.305920737129524	460
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	nutritional or metabolic disease	0.305920737129524	460
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	genetic, familial or congenital disease	0.306087169507468	2285
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	immune system disease	0.306160749009508	1337
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	musculoskeletal or connective tissue disease	0.306307822234368	382
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	genetic, familial or congenital disease	0.306316093907558	5740
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	targetBased	353950	4145	endocrine system disease	0.306363187381098	572
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	musculoskeletal or connective tissue disease	0.306498655699844	700
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	nervous system disease	0.306915232134702	276
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	nervous system disease	0.306915232134702	276
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	endocrine system disease	0.306927361297911	422
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	immune system disease	0.307243363520542	5393
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	immune system disease	0.307243363520542	5393
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	cardiovascular disease	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	cardiovascular disease	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	cardiovascular disease	0.307418870150215	258
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	hematologic disease	0.307443154517656	259
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	hematologic disease	0.307443154517656	259
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	hematologic disease	0.307443154517656	259
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	immune system disease	0.307579170037309	259
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	immune system disease	0.307579170037309	259
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	immune system disease	0.307579170037309	259
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	immune system disease	0.307710567268856	1811
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	immune system disease	0.307710567268856	1811
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2	targetBased	57013	201	hematologic disease	0.307822983381966	1120
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	nutritional or metabolic disease	0.307868755968155	1470
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	targetBased	368927	3838	psychiatric disorder	0.308411337144409	57
Glucocerebrosidase	GBA1	targetBased	48118	549	musculoskeletal or connective tissue disease	0.308468228399704	434
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	cancer or benign tumor	0.308577451220937	1614
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	DCLRE1C	targetBased	30104	235	immune system disease	0.308706207097983	885
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	targetBased	400814	482	disorder of visual system	0.308753278727696	525
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	targetBased	400814	482	nutritional or metabolic disease	0.308888657919539	574
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	targetBased	400814	482	genetic, familial or congenital disease	0.308940117014018	632
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	DCLRE1C	targetBased	30104	235	genetic, familial or congenital disease	0.308988106740828	938
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	nervous system disease	0.309396142305143	256
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	genetic, familial or congenital disease	0.309417667520199	285
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	cancer or benign tumor	0.309783393357057	2076
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF	targetBased	642362	5830	cancer or benign tumor	0.309783393357057	2076
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	cancer or benign tumor	0.310041153278111	1427
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	cancer or benign tumor	0.310041153278111	1427
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	immune system disease	0.310196861625257	344
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	hematologic disease	0.310265658070919	347
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	psychiatric disorder	0.310652093826764	700
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM	targetBased	347933	673	cancer or benign tumor	0.310830895559193	1608
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	disorder of visual system	0.311024837839567	373
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	disorder of visual system	0.311024837839567	373
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	pregnancy or perinatal disease	0.311058927279803	174
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	pregnancy or perinatal disease	0.311058927279803	174
Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter	FXN	targetBased	356160	1985	nervous system disease	0.311156174964267	702
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	musculoskeletal or connective tissue disease	0.311265938920477	3390
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	musculoskeletal or connective tissue disease	0.311265938920477	3390
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	musculoskeletal or connective tissue disease	0.311265938920477	3390
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	musculoskeletal or connective tissue disease	0.311265938920477	3390
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	musculoskeletal or connective tissue disease	0.311265938920477	3390
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	genetic, familial or congenital disease	0.311532799464242	1149
qHTS for Inhibitors of Polymerase Eta	POLH	targetBased	388717	4730	genetic, familial or congenital disease	0.311575977657708	215
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	genetic, familial or congenital disease	0.311756450856284	690
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	cancer or benign tumor	0.311759333158674	952
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	cancer or benign tumor	0.311759333158674	952
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1	pathwayBased	195980	5134	gastrointestinal disease	0.311829263265792	836
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	gastrointestinal disease	0.311829263265792	836
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	cancer or benign tumor	0.311935903234522	414
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	genetic, familial or congenital disease	0.311973089003439	519
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	genetic, familial or congenital disease	0.311973089003439	519
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	genetic, familial or congenital disease	0.311973089003439	519
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	genetic, familial or congenital disease	0.311973089003439	519
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	genetic, familial or congenital disease	0.312217324474024	1127
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	genetic, familial or congenital disease	0.312302387477963	1699
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	genetic, familial or congenital disease	0.312302387477963	1699
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	targetBased	356517	1139	genetic, familial or congenital disease	0.312340139538638	4651
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	genetic, familial or congenital disease	0.312512628680813	397
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	genetic, familial or congenital disease	0.312512628680813	397
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	nutritional or metabolic disease	0.312528108587847	379
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	reproductive system or breast disease	0.312629923411077	521
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	nutritional or metabolic disease	0.312673954860042	515
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	nutritional or metabolic disease	0.312673954860042	515
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	nutritional or metabolic disease	0.312673954860042	515
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	nervous system disease	0.312698553448821	391
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	nervous system disease	0.312698553448821	391
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	genetic, familial or congenital disease	0.312731197417235	4921
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	genetic, familial or congenital disease	0.312783918956298	479
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	genetic, familial or congenital disease	0.312783918956298	479
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	integumentary system disease	0.312803637004698	1187
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	genetic, familial or congenital disease	0.312804989074029	524
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	genetic, familial or congenital disease	0.312804989074029	524
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	genetic, familial or congenital disease	0.312804989074029	524
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	endocrine system disease	0.313324052611862	482
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	endocrine system disease	0.313324052611862	482
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	integumentary system disease	0.313361782505648	292
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	genetic, familial or congenital disease	0.313416589838099	387
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	nervous system disease	0.313604323093212	354
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	nervous system disease	0.313604323093212	354
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	nervous system disease	0.313604323093212	354
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DLD	targetBased	194152	1342	nutritional or metabolic disease	0.313610445442402	672
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	gastrointestinal disease	0.313769186613035	558
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	genetic, familial or congenital disease	0.314076059171278	3551
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	genetic, familial or congenital disease	0.314076059171278	3551
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DLD	targetBased	194152	1342	nervous system disease	0.314206732963241	394
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	reproductive system or breast disease	0.314361866626238	500
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	reproductive system or breast disease	0.314361866626238	500
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	pancreas disease	0.314591148011711	1944
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	pancreas disease	0.314591148011711	1944
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	pancreas disease	0.314591148011711	1944
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	pancreas disease	0.314591148011711	1944
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	pancreas disease	0.314591148011711	1944
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	pancreas disease	0.314591148011711	1944
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	nervous system disease	0.314794193796945	423
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	reproductive system or breast disease	0.314805936282202	566
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	reproductive system or breast disease	0.314805936282202	566
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	CFTR	targetBased	343786	1253	reproductive system or breast disease	0.315041861934939	610
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	CFTR	targetBased	296501	2737	reproductive system or breast disease	0.315041861934939	610
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	genetic, familial or congenital disease	0.315091238427186	595
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	genetic, familial or congenital disease	0.315091238427186	595
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	cardiovascular disease	0.315523573282344	42
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	genetic, familial or congenital disease	0.315554571893296	3318
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	genetic, familial or congenital disease	0.315554571893296	3318
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	genetic, familial or congenital disease	0.315554571893296	3318
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	genetic, familial or congenital disease	0.315596442679615	3254
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	genetic, familial or congenital disease	0.315596442679615	3254
Factor XIIa 1536 HTS	F12	targetBased	217430	649	genetic, familial or congenital disease	0.315607023876376	135
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	genetic, familial or congenital disease	0.315815933451571	911
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	pancreas disease	0.315846831046733	987
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	pancreas disease	0.315846831046733	987
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	pancreas disease	0.315846831046733	987
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	pancreas disease	0.315846831046733	987
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	pancreas disease	0.315846831046733	987
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	endocrine system disease	0.315868340882225	451
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2	targetBased	57013	201	musculoskeletal or connective tissue disease	0.315962014443753	783
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL	targetBased	195560	517	musculoskeletal or connective tissue disease	0.316075291888129	352
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	cancer or benign tumor	0.316163085082115	15605
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	cancer or benign tumor	0.316163085082115	15605
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	nervous system disease	0.316487469058231	1147
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	nervous system disease	0.316487469058231	1147
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	musculoskeletal or connective tissue disease	0.316688810157075	649
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP	pathwayBased	193400	1987	genetic, familial or congenital disease	0.316837720004613	1339
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP	pathwayBased	193714	1590	genetic, familial or congenital disease	0.316837720004613	1339
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP	targetBased	404343	257	genetic, familial or congenital disease	0.316837720004613	1339
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DLD	targetBased	194152	1342	genetic, familial or congenital disease	0.316851447573788	707
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL	targetBased	195560	517	nutritional or metabolic disease	0.317182635727507	604
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	endocrine system disease	0.317186740601109	123
Factor XIa 1536 HTS	F11	targetBased	218707	302	genetic, familial or congenital disease	0.317669102902295	348
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	immune system disease	0.317811608195027	953
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	targetBased	72072	2464	nutritional or metabolic disease	0.317828798923755	59
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	targetBased	73912	5649	nutritional or metabolic disease	0.317828798923755	59
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	targetBased	72072	2464	genetic, familial or congenital disease	0.317886419060715	73
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	targetBased	73912	5649	genetic, familial or congenital disease	0.317886419060715	73
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM	targetBased	347933	673	hematologic disease	0.318045691512211	2060
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	musculoskeletal or connective tissue disease	0.318262049798229	861
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1	targetBased	359207	1432	musculoskeletal or connective tissue disease	0.318507585483694	3071
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	integumentary system disease	0.318572746917791	417
Dicer-mediated maturation of pre-microRNA	DICER1	targetBased	46715	2829	cancer or benign tumor	0.318609849391891	3208
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	immune system disease	0.318611816475064	863
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	immune system disease	0.318611816475064	863
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	genetic, familial or congenital disease	0.318890286197477	275
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	cardiovascular disease	0.318983536953805	1026
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM	targetBased	347933	673	integumentary system disease	0.319022293003942	2074
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	genetic, familial or congenital disease	0.319181639876614	1666
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	genetic, familial or congenital disease	0.319240200010273	904
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	immune system disease	0.319384600162143	4345
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	immune system disease	0.319384600162143	4345
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	immune system disease	0.319384600162143	4345
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	immune system disease	0.319384600162143	4345
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	immune system disease	0.319384600162143	4345
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1	pathwayBased	195980	5134	genetic, familial or congenital disease	0.319456917577182	1894
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	genetic, familial or congenital disease	0.319456917577182	1894
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	cancer or benign tumor	0.319543644436173	569
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	genetic, familial or congenital disease	0.319695193814414	1286
Glucocerebrosidase	GBA1	targetBased	48118	549	nervous system disease	0.320008781072992	867
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	targetBased	368927	3838	nervous system disease	0.320293794315348	78
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	integumentary system disease	0.320294779178675	6985
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	integumentary system disease	0.320294779178675	6985
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	targetBased	356517	1139	reproductive system or breast disease	0.320391454803785	2999
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	genetic, familial or congenital disease	0.320430237609648	1334
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	genetic, familial or congenital disease	0.320430237609648	1334
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	genetic, familial or congenital disease	0.320664311024958	2005
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	musculoskeletal or connective tissue disease	0.320805436377577	2042
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	gastrointestinal disease	0.320960159387738	2595
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	gastrointestinal disease	0.320960159387738	2595
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	nutritional or metabolic disease	0.320961777769247	658
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1	targetBased	359207	1432	cancer or benign tumor	0.321006698817602	5922
Thrombin 1536 HTS	F2	targetBased	217233	557	hematologic disease	0.321108383014022	1138
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	760	hematologic disease	0.321312955977006	137
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	498	hematologic disease	0.321312955977006	137
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	genetic, familial or congenital disease	0.321450076564814	1085
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hematologic disease	0.321643309276836	5102
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	hematologic disease	0.321643309276836	5102
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	hematologic disease	0.321643309276836	5102
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	hematologic disease	0.321643309276836	5102
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	hematologic disease	0.321643309276836	5102
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	integumentary system disease	0.321725988748087	177
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	integumentary system disease	0.321725988748087	177
Glucocerebrosidase	GBA1	targetBased	48118	549	disorder of visual system	0.322305630477413	1353
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	musculoskeletal or connective tissue disease	0.322579835574433	908
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	musculoskeletal or connective tissue disease	0.322579835574433	908
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	targetBased	356517	1139	integumentary system disease	0.322665894064112	2421
Dicer-mediated maturation of pre-microRNA	DICER1	targetBased	46715	2829	genetic, familial or congenital disease	0.322745041093415	6515
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	pancreas disease	0.322844923608494	2516
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	pancreas disease	0.322844923608494	2516
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	targetBased	368927	3838	genetic, familial or congenital disease	0.323139590723859	375
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	genetic, familial or congenital disease	0.323144976628818	1701
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	disorder of visual system	0.323339146766986	6920
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	nutritional or metabolic disease	0.323362189361219	2650
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	nutritional or metabolic disease	0.323362189361219	2650
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	genetic, familial or congenital disease	0.323610111977805	1136
Glucocerebrosidase	GBA1	targetBased	48118	549	nutritional or metabolic disease	0.323635269819001	1703
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	genetic, familial or congenital disease	0.323698969576175	1678
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	genetic, familial or congenital disease	0.323698969576175	1678
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	genetic, familial or congenital disease	0.323698969576175	1678
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	genetic, familial or congenital disease	0.323698969576175	1678
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	genetic, familial or congenital disease	0.323698969576175	1678
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	genetic, familial or congenital disease	0.323698969576175	1678
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	targetBased	72072	2464	nervous system disease	0.323819126188099	70
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	targetBased	73912	5649	nervous system disease	0.323819126188099	70
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	reproductive system or breast disease	0.324145529515924	6113
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	reproductive system or breast disease	0.324145529515924	6113
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	reproductive system or breast disease	0.324145529515924	6113
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	reproductive system or breast disease	0.324145529515924	6113
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	reproductive system or breast disease	0.324145529515924	6113
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	hematologic disease	0.324185774456495	1884
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	hematologic disease	0.324185774456495	1884
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS	targetBased	385746	932	nervous system disease	0.324308151895714	1226
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	genetic, familial or congenital disease	0.324584241119767	1125
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	genetic, familial or congenital disease	0.324880250919624	3286
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	musculoskeletal or connective tissue disease	0.325063801846501	711
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	cancer or benign tumor	0.325152956365848	20807
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	cancer or benign tumor	0.325152956365848	20807
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	nutritional or metabolic disease	0.325382439172619	563
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	nutritional or metabolic disease	0.325382439172619	563
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	endocrine system disease	0.325400153642913	1030
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	urinary system disease	0.325552885614388	2093
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	urinary system disease	0.325552885614388	2093
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	urinary system disease	0.325552885614388	2093
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	urinary system disease	0.325552885614388	2093
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	urinary system disease	0.325552885614388	2093
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	nervous system disease	0.325723804319424	1687
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	reproductive system or breast disease	0.325862177682374	8730
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	reproductive system or breast disease	0.325862177682374	8730
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP	pathwayBased	193400	1987	cardiovascular disease	0.325927232973664	368
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP	pathwayBased	193714	1590	cardiovascular disease	0.325927232973664	368
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP	targetBased	404343	257	cardiovascular disease	0.325927232973664	368
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	endocrine system disease	0.326169613024321	2734
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	endocrine system disease	0.326169613024321	2734
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1	targetBased	359207	1432	hematologic disease	0.327033266899264	4591
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	musculoskeletal or connective tissue disease	0.327079035837153	296
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	genetic, familial or congenital disease	0.327229908314915	353
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	nutritional or metabolic disease	0.327455969323508	2716
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	nutritional or metabolic disease	0.327455969323508	2716
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	nutritional or metabolic disease	0.327455969323508	2716
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	nutritional or metabolic disease	0.327455969323508	2716
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	nutritional or metabolic disease	0.327455969323508	2716
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	nutritional or metabolic disease	0.327455969323508	2716
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	cancer or benign tumor	0.327470894007758	4874
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	cancer or benign tumor	0.327470894007758	4874
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	nervous system disease	0.327609598995878	408
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	psychiatric disorder	0.327630879518947	2403
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	psychiatric disorder	0.327630879518947	2403
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	psychiatric disorder	0.327630879518947	2403
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	musculoskeletal or connective tissue disease	0.327665498967558	3382
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA	targetBased	302297	1165	musculoskeletal or connective tissue disease	0.327665498967558	3382
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	genetic, familial or congenital disease	0.327681149865223	3528
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA	targetBased	302297	1165	genetic, familial or congenital disease	0.327681149865223	3528
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	endocrine system disease	0.327684307976301	600
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	endocrine system disease	0.327684307976301	600
Glucocerebrosidase	GBA1	targetBased	48118	549	genetic, familial or congenital disease	0.327699938775025	2385
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	genetic, familial or congenital disease	0.327836127376136	1019
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	genetic, familial or congenital disease	0.327836127376136	1019
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	genetic, familial or congenital disease	0.327836127376136	1019
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	musculoskeletal or connective tissue disease	0.328351146857462	3592
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL	targetBased	195560	517	genetic, familial or congenital disease	0.328402603232135	990
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP	pathwayBased	193400	1987	psychiatric disorder	0.328602472567388	986
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP	pathwayBased	193714	1590	psychiatric disorder	0.328602472567388	986
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP	targetBased	404343	257	psychiatric disorder	0.328602472567388	986
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	MEN1	targetBased	263421	615	genetic, familial or congenital disease	0.328606941270685	3191
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	cardiovascular disease	0.328745754442431	3161
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA	targetBased	302297	1165	cardiovascular disease	0.328745754442431	3161
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gastrointestinal disease	0.329006687360773	8564
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	gastrointestinal disease	0.329006687360773	8564
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	gastrointestinal disease	0.329006687360773	8564
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	gastrointestinal disease	0.329006687360773	8564
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	gastrointestinal disease	0.329006687360773	8564
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	genetic, familial or congenital disease	0.329254383686021	3555
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1	targetBased	356517	1139	cancer or benign tumor	0.329352820693522	33956
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	genetic, familial or congenital disease	0.329380894200514	3881
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	genetic, familial or congenital disease	0.329380894200514	3881
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	genetic, familial or congenital disease	0.329506330194391	4038
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	infectious disease	0.329652055331171	2444
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	urinary system disease	0.330058650266577	556
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	urinary system disease	0.330058650266577	556
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	musculoskeletal or connective tissue disease	0.330507964529131	556
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	endocrine system disease	0.330597241370765	7736
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1	targetBased	359207	1432	genetic, familial or congenital disease	0.330625021919238	4269
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	genetic, familial or congenital disease	0.330723341207283	2107
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	cardiovascular disease	0.330813909047144	480
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	musculoskeletal or connective tissue disease	0.331512512112977	721
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	musculoskeletal or connective tissue disease	0.331512512112977	721
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	genetic, familial or congenital disease	0.331720690682477	1876
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	genetic, familial or congenital disease	0.331720690682477	1876
HTS for BAP1 Enzyme inhibitors	BAP1	targetBased	71016	346	cancer or benign tumor	0.331855481416617	2714
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	cardiovascular disease	0.332487878427688	1173
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	immune system disease	0.332610568987967	2650
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	RXFP1	targetBased	350177	2058	cardiovascular disease	0.332674497659342	15
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	RXFP1	targetBased	350177	2058	cardiovascular disease	0.332674497659342	15
qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	targetBased	362198	1084	cardiovascular disease	0.332674497659342	15
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	CFTR	targetBased	343786	1253	respiratory or thoracic disease	0.332808758011083	6518
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	CFTR	targetBased	296501	2737	respiratory or thoracic disease	0.332808758011083	6518
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	nervous system disease	0.332822358352271	3924
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	nervous system disease	0.332822358352271	3924
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	endocrine system disease	0.332888972071445	7392
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	endocrine system disease	0.332888972071445	7392
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	endocrine system disease	0.332888972071445	7392
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	endocrine system disease	0.332888972071445	7392
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	endocrine system disease	0.332888972071445	7392
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	gastrointestinal disease	0.333536313063467	1311
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	nervous system disease	0.333678467927107	2541
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	nervous system disease	0.333705759587628	2482
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	nervous system disease	0.333705759587628	2482
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	cancer or benign tumor	0.333773777774185	6971
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	genetic, familial or congenital disease	0.334027307351841	737
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	genetic, familial or congenital disease	0.334216508501578	995
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	genetic, familial or congenital disease	0.334216508501578	995
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	integumentary system disease	0.334727150574033	9183
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	760	cardiovascular disease	0.334871188391366	112
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB	targetBased	369953	498	cardiovascular disease	0.334871188391366	112
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	CFTR	targetBased	343786	1253	genetic, familial or congenital disease	0.335065100353641	7294
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	CFTR	targetBased	296501	2737	genetic, familial or congenital disease	0.335065100353641	7294
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	cancer or benign tumor	0.335339717787305	2988
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	endocrine system disease	0.335395716076541	13929
High Throughput Imaging Assay for Beta-Catenin	CTNNB1	targetBased	193542	587	cancer or benign tumor	0.335544368847756	5488
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	genetic, familial or congenital disease	0.337001191331503	22157
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	cancer or benign tumor	0.337341831464507	10920
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	nervous system disease	0.337994237995216	1245
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	integumentary system disease	0.338275470558646	10246
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	MEN1	targetBased	263421	615	cancer or benign tumor	0.338367437685307	4485
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	nervous system disease	0.338448947202366	3256
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	immune system disease	0.338643550414287	3366
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	immune system disease	0.338643550414287	3366
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	CFTR	targetBased	343786	1253	gastrointestinal disease	0.338673280198078	752
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	CFTR	targetBased	296501	2737	gastrointestinal disease	0.338673280198078	752
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	reproductive system or breast disease	0.339512616804793	15595
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	reproductive system or breast disease	0.339868813175177	11058
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1	targetBased	335777	499	cardiovascular disease	0.340167126270028	45
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	genetic, familial or congenital disease	0.340400832091816	25729
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	genetic, familial or congenital disease	0.340458431891269	11870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	genetic, familial or congenital disease	0.340458431891269	11870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	genetic, familial or congenital disease	0.340458431891269	11870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	genetic, familial or congenital disease	0.340458431891269	11870
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	genetic, familial or congenital disease	0.340458431891269	11870
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	hematologic disease	0.340847332310171	4451
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	hematologic disease	0.340847332310171	4451
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	nervous system disease	0.340904817235426	13599
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	cardiovascular disease	0.340989394320578	25
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	cardiovascular disease	0.341432478862547	33
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	cardiovascular disease	0.341432478862547	33
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM	targetBased	322361	619	immune system disease	0.341769682133615	13933
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15	targetBased	73174	1034	immune system disease	0.342419908337337	101
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	nervous system disease	0.343334268432742	2990
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1	pathwayBased	376029	3978	cancer or benign tumor	0.343443036880484	28897
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	endocrine system disease	0.343737730561135	1002
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	endocrine system disease	0.343737730561135	1002
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	nervous system disease	0.344095492220634	8473
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	nervous system disease	0.344095492220634	8473
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	nervous system disease	0.344095492220634	8473
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	nervous system disease	0.347539116824133	6861
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	TP53	targetBased	54509	528	nervous system disease	0.347539116824133	6861
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	TP53	targetBased	54513	338	nervous system disease	0.347539116824133	6861
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	TP53	targetBased	125394	1890	nervous system disease	0.347539116824133	6861
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	TP53	targetBased	124022	1156	nervous system disease	0.347539116824133	6861
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	MEN1	targetBased	263421	615	pancreas disease	0.351592162701471	293
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	endocrine system disease	0.357384975935039	282
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	endocrine system disease	0.357384975935039	282
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	cardiovascular disease	0.360131954081304	2016
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	cardiovascular disease	0.360131954081304	2016
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	endocrine system disease	0.363979898702827	72
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1	pathwayBased	195980	5134	immune system disease	0.366490339703082	1895
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	immune system disease	0.366490339703082	1895
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1	pathwayBased	195980	5134	endocrine system disease	0.371706445481081	642
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	endocrine system disease	0.371706445481081	642
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9	targetBased	305610	3794	psychiatric disorder	0.374136471588455	18
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	gastrointestinal disease	0.375465575819017	3259
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	gastrointestinal disease	0.375465575819017	3259
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	gastrointestinal disease	0.375465575819017	3259
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	gastrointestinal disease	0.375465575819017	3259
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	gastrointestinal disease	0.375465575819017	3259
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	gastrointestinal disease	0.375465575819017	3259
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B	targetBased	292323	567	gastrointestinal disease	0.406070807924668	7
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	cardiovascular disease	0.410382330244059	57
Factor XIa 1536 HTS	F11	targetBased	218707	302	hematologic disease	0.416941715352259	284
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	cardiovascular disease	0.422480278299169	1148
qHTS of GLP-1 Receptor Agonists	GLP1R	targetBased	373462	23	cardiovascular disease	0.422480278299169	1148
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R	targetBased	405130	6428	cardiovascular disease	0.422480278299169	1148
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	cardiovascular disease	0.422629473144974	77
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	DRD2	targetBased	359518	300	psychiatric disorder	0.436731495881783	2989
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	DRD2	targetBased	335652	1779	psychiatric disorder	0.436731495881783	2989
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	DRD2	targetBased	362274	1056	psychiatric disorder	0.436731495881783	2989
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	DRD2	targetBased	336308	6862	psychiatric disorder	0.436731495881783	2989
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	DRD2	targetBased	357537	806	psychiatric disorder	0.436731495881783	2989
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	DRD2	targetBased	339887	1178	psychiatric disorder	0.436731495881783	2989
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	endocrine system disease	0.448525999180786	3471
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	endocrine system disease	0.448525999180786	3471
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H	targetBased	104728	4230	gastrointestinal disease	0.449925211715772	23
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	immune system disease	0.472874199959455	238
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	cardiovascular disease	0.474126404865489	764
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	cardiovascular disease	0.480347418477022	57
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	cardiovascular disease	0.480347418477022	57
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A	targetBased	324747	813	cardiovascular disease	0.486479509434325	26
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	698	gastrointestinal disease	0.490885862309666	7
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	2133	gastrointestinal disease	0.490885862309666	7
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	1081	gastrointestinal disease	0.490885862309666	7
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	targetBased	250190	1304	cardiovascular disease	0.491731756591956	16
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	targetBased	255537	2141	cardiovascular disease	0.491731756591956	16
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	immune system disease	0.492607079113499	62
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4	targetBased	363803	502	gastrointestinal disease	0.492691737550043	9
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4	targetBased	363803	2629	gastrointestinal disease	0.492691737550043	9
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4	targetBased	363803	1450	gastrointestinal disease	0.492691737550043	9
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	immune system disease	0.494874296988137	67
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	immune system disease	0.494874296988137	67
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	cardiovascular disease	0.496212594590731	87
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	cardiovascular disease	0.497521079265452	24
Primary HTS Assay for S1P3 Antagonists	S1PR3	targetBased	169141	462	immune system disease	0.498318865242747	72
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	immune system disease	0.500615323516007	118
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	immune system disease	0.500615323516007	118
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2	targetBased	86095	1114	cardiovascular disease	0.506169890816898	958
HTS for developing T Cell Immune Modulators	ITGAL	targetBased	326271	221	immune system disease	0.522929901011049	341
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B	targetBased	292323	567	cardiovascular disease	0.524872087847244	13
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	immune system disease	0.533722345866493	54
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	immune system disease	0.533722345866493	54
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	endocrine system disease	0.534743396323204	3025
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	endocrine system disease	0.534743396323204	3025
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	endocrine system disease	0.534743396323204	3025
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	endocrine system disease	0.534743396323204	3025
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	endocrine system disease	0.534743396323204	3025
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	endocrine system disease	0.534743396323204	3025
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	cardiovascular disease	0.535520127802918	249
Factor XIa 1536 HTS	F11	targetBased	218707	302	cardiovascular disease	0.537372937091695	124
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	immune system disease	0.549017525637101	6397
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	gastrointestinal disease	0.549751654009714	39
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D	targetBased	335531	328	gastrointestinal disease	0.552312264766224	68
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	cardiovascular disease	0.565377921266872	1016
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	cardiovascular disease	0.565377921266872	1016
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	cardiovascular disease	0.565377921266872	1016
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	cardiovascular disease	0.565377921266872	1016
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	cardiovascular disease	0.565377921266872	1016
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	cardiovascular disease	0.565377921266872	1016
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	targetBased	76168	1231	cardiovascular disease	0.572262314692425	199
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	endocrine system disease	0.572992644318413	2052
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	endocrine system disease	0.572992644318413	2052
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	endocrine system disease	0.572992644318413	2052
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	endocrine system disease	0.572992644318413	2052
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	cardiovascular disease	0.580314423500688	225
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	cardiovascular disease	0.586768348902106	37
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	cardiovascular disease	0.586768348902106	37
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H	targetBased	104728	4230	cardiovascular disease	0.588584606815859	17
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	MEN1	targetBased	263421	615	endocrine system disease	0.592161424189356	3093
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	immune system disease	0.595121158095572	560
qHTS of D3 Dopamine Receptor Agonist: qHTS	DRD3	targetBased	407539	2380	cardiovascular disease	0.598320696606389	23
qHTS of D3 Dopamine Receptor Antagonist: qHTS	DRD3	targetBased	364051	9106	cardiovascular disease	0.598320696606389	23
qHTS of D3 Dopamine Receptor Potentiators: qHTS	DRD3	targetBased	407539	2380	cardiovascular disease	0.598320696606389	23
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	immune system disease	0.602704752929704	145
Allosteric Modulators of D1 Receptors: Primary Screen	DRD1	targetBased	57705	3413	cardiovascular disease	0.607297737405928	29
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	DRD1	targetBased	361330	3713	cardiovascular disease	0.607297737405928	29
Antagonist of Human D 1 Dopamine Receptor: qHTS	DRD1	targetBased	355805	11440	cardiovascular disease	0.607297737405928	29
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	cardiovascular disease	0.607544555155389	1625
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	cardiovascular disease	0.607544555155389	1625
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	cardiovascular disease	0.607544555155389	1625
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	DRD2	targetBased	359518	300	cardiovascular disease	0.613837191033568	102
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	DRD2	targetBased	335652	1779	cardiovascular disease	0.613837191033568	102
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	DRD2	targetBased	362274	1056	cardiovascular disease	0.613837191033568	102
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	DRD2	targetBased	336308	6862	cardiovascular disease	0.613837191033568	102
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	DRD2	targetBased	357537	806	cardiovascular disease	0.613837191033568	102
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	DRD2	targetBased	339887	1178	cardiovascular disease	0.613837191033568	102
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL1B	pathwayBased	362051	17187	immune system disease	0.614841884541934	4323
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	immune system disease	0.619818346569292	589
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	gastrointestinal disease	0.626780891642088	146
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	gastrointestinal disease	0.626780891642088	146
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	DRD2	targetBased	359518	300	gastrointestinal disease	0.630154237489178	108
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	DRD2	targetBased	335652	1779	gastrointestinal disease	0.630154237489178	108
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	DRD2	targetBased	362274	1056	gastrointestinal disease	0.630154237489178	108
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	DRD2	targetBased	336308	6862	gastrointestinal disease	0.630154237489178	108
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	DRD2	targetBased	357537	806	gastrointestinal disease	0.630154237489178	108
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	DRD2	targetBased	339887	1178	gastrointestinal disease	0.630154237489178	108
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1	targetBased	86095	1442	cardiovascular disease	0.634011670214364	698
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1	targetBased	86095	1151	cardiovascular disease	0.634011670214364	698
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1	targetBased	359207	1189	gastrointestinal disease	0.647353283120319	44
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1	targetBased	63676	1938	gastrointestinal disease	0.647353283120319	44
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1	targetBased	359207	316	gastrointestinal disease	0.647353283120319	44
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1	targetBased	63656	2179	gastrointestinal disease	0.647353283120319	44
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1	targetBased	359207	4555	gastrointestinal disease	0.647353283120319	44
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	cardiovascular disease	0.663210251287628	2757
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	cardiovascular disease	0.663210251287628	2757
HTS for Beta-2AR agonists via FAP method	ADRB2	targetBased	339297	1446	cardiovascular disease	0.665572696941909	629
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	immune system disease	0.749586470205582	4012
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	hematologic disease	0.756268849901468	5543

Check best scored target-disease associations in table:

PubChemAssay	program	assayType	testedComopunds	activeCompounds	diseaseName	associationScore	numberOfEvidences	therapeuticArea
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	cystic fibrosis	0.996125989381412	17187	respiratory
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	cystic fibrosis	0.996125989381412	17187	respiratory
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	Costello syndrome	0.971682105449753	1184	muculoEskeletalConnective
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast neoplasm	0.969800044375086	10492	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Ataxia-telangiectasia	0.965192627517889	20484	visualSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Li-Fraumeni syndrome	0.961183981598178	6950	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Li-Fraumeni syndrome	0.961183981598178	6950	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Li-Fraumeni syndrome	0.961183981598178	6950	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Li-Fraumeni syndrome	0.961183981598178	6950	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Li-Fraumeni syndrome	0.961183981598178	6950	cancer
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	glycogen storage disease II	0.960121004133098	4311	muculoEskeletalConnective
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	glycogen storage disease II	0.960121004133098	4311	muculoEskeletalConnective
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	multiple endocrine neoplasia type 1	0.955651497731723	4107	cancer
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	Blau syndrome	0.939286992074845	1956	muculoEskeletalConnective
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	adult hypophosphatasia	0.939215261483421	551	muculoEskeletalConnective
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast carcinoma	0.938370121037582	9141	cancer
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	Bloom syndrome	0.937191544742725	5934	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Benign familial neonatal seizures	0.933986431041984	515	pregnancyPerinatal
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Benign familial neonatal seizures	0.933986431041984	515	pregnancyPerinatal
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pseudohypoparathyroidism type 1A	0.931191434735326	489	muculoEskeletalConnective
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pseudohypoparathyroidism type 1A	0.931191434735326	489	muculoEskeletalConnective
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	ataxia telangiectasia	0.929721108758776	19098	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	Andersen-Tawil syndrome	0.928674186301643	1100	muculoEskeletalConnective
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	congenital factor XI deficiency	0.928341461537528	543	hematologic
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	targetBased	400814	482	mucolipidosis type IV	0.926582257823166	1539	metabolicEndocrine
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	hypertrophic cardiomyopathy	0.926253064265713	1241	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	hypertrophic cardiomyopathy	0.926253064265713	1241	muculoEskeletalConnective
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	CINCA syndrome	0.925563914784182	621	muculoEskeletalConnective
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	Hypocalcemic vitamin D-resistant rickets	0.924912744974669	399	muculoEskeletalConnective
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	Crohn's disease	0.923073177649278	1414	immune
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	chronic myelogenous leukemia	0.920783141818354	6490	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast-ovarian cancer, familial, susceptibility to, 1	0.920613213950633	8442	geneticDisorder
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	type 2 diabetes mellitus	0.920445028915377	3693	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	type 2 diabetes mellitus	0.920445028915377	3693	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	type 2 diabetes mellitus	0.920445028915377	3693	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	type 2 diabetes mellitus	0.920445028915377	3693	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	type 2 diabetes mellitus	0.920445028915377	3693	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	type 2 diabetes mellitus	0.920445028915377	3693	metabolicEndocrine
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	DICER1-related tumor predisposition	0.918516861565067	7946	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Romano-Ward syndrome	0.917575767779804	689	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Romano-Ward syndrome	0.917575767779804	689	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	long QT syndrome 1	0.916478812281366	1359	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	long QT syndrome 1	0.916478812281366	1359	geneticDisorder
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	Glycogen storage disease due to acid maltase deficiency	0.916238536169051	4712	muculoEskeletalConnective
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	Glycogen storage disease due to acid maltase deficiency	0.916238536169051	4712	muculoEskeletalConnective
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	targetBased	194152	1342	pyruvate dehydrogenase E3 deficiency	0.909058118974501	882	metabolicEndocrine
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	Weaver syndrome	0.907269836964628	782	muculoEskeletalConnective
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	Werner syndrome	0.907108387719303	6225	visualSystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian neoplasm	0.906277040676126	7663	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Hereditary breast and ovarian cancer syndrome	0.905263436460505	20171	cancer
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease type 1	0.904732450777115	509	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	targetBased	368927	3838	intellectual disability-sparse hair-brachydactyly syndrome	0.903276780005793	93	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian cancer	0.902464031304924	7268	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	isolated focal cortical dysplasia type II	0.901441338803717	153	nervousSystem
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	Charcot-Marie-Tooth disease type 1A	0.900951611526078	408	nervousSystem
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pseudohypoparathyroidism type 1C	0.900125093342387	147	muculoEskeletalConnective
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pseudohypoparathyroidism type 1C	0.900125093342387	147	muculoEskeletalConnective
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome	0.899428613297051	174	geneticDisorder
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Chronic mucocutaneous candidosis	0.898378085302774	825	immune
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Chronic mucocutaneous candidosis	0.898378085302774	825	immune
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	autoimmune disease	0.897704362357904	1295	immune
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	autoimmune disease	0.897704362357904	1295	immune
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	hypophosphatasia	0.896956238684656	1435	metabolicEndocrine
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	Cardiodysrhythmic potassium-sensitive periodic paralysis	0.896801261242644	914	muculoEskeletalConnective
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	McCune-Albright syndrome	0.895970037054108	329	muculoEskeletalConnective
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	McCune-Albright syndrome	0.895970037054108	329	muculoEskeletalConnective
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	BAP1-related tumor predisposition syndrome	0.895619429083368	3174	cancer
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	X-linked adrenal hypoplasia congenita	0.895131822908991	639	nervousSystem
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	X-linked adrenal hypoplasia congenita	0.895131822908991	639	nervousSystem
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	Muckle-Wells syndrome	0.894883848273049	515	muculoEskeletalConnective
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome	0.894516532057074	815	immune
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome	0.894516532057074	815	immune
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	Gerstmann-Straussler-Scheinker syndrome	0.893488295726227	213	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Jervell and Lange-Nielsen syndrome 1	0.893302073115444	366	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Jervell and Lange-Nielsen syndrome 1	0.893302073115444	366	geneticDisorder
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	Waardenburg syndrome type 2A	0.892192747843683	1002	geneticDisorder
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	Waardenburg syndrome type 2A	0.892192747843683	1002	geneticDisorder
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	targetBased	385746	932	sporadic amyotrophic lateral sclerosis	0.892054957027048	663	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	obesity	0.891868554414912	272	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	obesity	0.891868554414912	272	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hepatocellular carcinoma	0.891165571922842	7068	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	hepatocellular carcinoma	0.891165571922842	7068	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	hepatocellular carcinoma	0.891165571922842	7068	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	hepatocellular carcinoma	0.891165571922842	7068	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	hepatocellular carcinoma	0.891165571922842	7068	cancer
Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter	FXN	targetBased	356160	1985	Friedreich ataxia	0.890999212816761	1874	muculoEskeletalConnective
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	Branchio-otic syndrome	0.890802361045508	257	nervousSystem
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	severe combined immunodeficiency due to DCLRE1C deficiency	0.890628296247178	1470	metabolicEndocrine
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	Dejerine-Sottas syndrome	0.890154648768819	101	nervousSystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	cancer	0.889745401546417	20752	cancer
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	enhanced S-cone syndrome	0.889625053819804	461	geneticDisorder
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	enhanced S-cone syndrome	0.889625053819804	461	geneticDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	cancer	0.887742187650375	6406	cancer
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	inflammatory bowel disease 1	0.886077108068074	365	geneticDisorder
Factor XIIa 1536 HTS	F12_modulation	targetBased	217430	649	congenital factor XII deficiency	0.885973348043109	105	hematologic
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	hypertrophic cardiomyopathy 7	0.885049175732636	144	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	hypertrophic cardiomyopathy 7	0.885049175732636	144	muculoEskeletalConnective
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pseudohypoparathyroidism type 1B	0.884574613045788	245	metabolicEndocrine
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pseudohypoparathyroidism type 1B	0.884574613045788	245	metabolicEndocrine
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	ACTH-independent macronodular adrenal hyperplasia 1	0.883349328229437	104	geneticDisorder
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	ACTH-independent macronodular adrenal hyperplasia 1	0.883349328229437	104	geneticDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Fanconi anemia, complementation group S	0.882895059808289	251	muculoEskeletalConnective
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	Autosomal dominant hyper-IgE syndrome	0.882882834629081	1250	immune
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	Autosomal dominant hyper-IgE syndrome	0.882882834629081	1250	immune
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1	0.882670337369514	2060	cancer
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1	0.882670337369514	2060	cancer
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	hyper-IgE recurrent infection syndrome 1, autosomal dominant	0.882249492479488	959	immune
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	hyper-IgE recurrent infection syndrome 1, autosomal dominant	0.882249492479488	959	immune
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	Camurati-Engelmann disease	0.882045406274388	110	muculoEskeletalConnective
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease type 2	0.881332474439115	207	metabolicEndocrine
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	hyper-IgM syndrome type 2	0.879623212791959	387	immune
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1	0.879401901695586	138	muculoEskeletalConnective
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease type I	0.878031247240919	443	psychiatricDisorder
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	neurodevelopmental disorder with involuntary movements	0.877979009956465	90	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	neurodevelopmental disorder with involuntary movements	0.877979009956465	90	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	neurodevelopmental disorder with involuntary movements	0.877979009956465	90	nervousSystem
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	congenital prothrombin deficiency	0.877708103951809	440	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	congenital afibrinogenemia	0.876312075943651	206	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	congenital afibrinogenemia	0.876312075943651	206	hematologic
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	hypothyroidism due to TSH receptor mutations	0.876175090766287	206	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	hypothyroidism due to TSH receptor mutations	0.876175090766287	206	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	hypothyroidism due to TSH receptor mutations	0.876175090766287	206	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	hypothyroidism due to TSH receptor mutations	0.876175090766287	206	metabolicEndocrine
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	hepatocellular carcinoma	0.875521957433293	1848	cancer
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	Niemann-Pick disease type C	0.875385794852707	3870	metabolicEndocrine
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	382	focal segmental glomerulosclerosis	0.875186084052801	548	urinarySystem
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	3253	focal segmental glomerulosclerosis	0.875186084052801	548	urinarySystem
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	familial rhabdoid tumor	0.874158218818574	6884	cancer
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	familial cold autoinflammatory syndrome 1	0.873832417903922	297	muculoEskeletalConnective
Primary cell-based high-throughput screening assay to measure PERK inhibition	PERK_inhibitors	targetBased	217959	370	Wolcott-Rallison syndrome	0.873386417124152	435	muculoEskeletalConnective
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	head and neck squamous cell carcinoma	0.872621428237112	3127	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	head and neck squamous cell carcinoma	0.872621428237112	3127	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	head and neck squamous cell carcinoma	0.872621428237112	3127	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	head and neck squamous cell carcinoma	0.872621428237112	3127	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	head and neck squamous cell carcinoma	0.872621428237112	3127	cancer
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	metaphyseal chondrodysplasia, Jansen type	0.870699161633779	171	muculoEskeletalConnective
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	congenital heart defects and skeletal malformations syndrome	0.870462387860388	74	geneticDisorder
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	Hereditary late-onset Parkinson disease	0.870085087181022	125	metabolicEndocrine
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	Hereditary late-onset Parkinson disease	0.870085087181022	125	metabolicEndocrine
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	congenital bilateral aplasia of vas deferens from CFTR mutation	0.869751101269822	953	reproductiveSystem
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	congenital bilateral aplasia of vas deferens from CFTR mutation	0.869751101269822	953	reproductiveSystem
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease type 3	0.869364153583014	180	muculoEskeletalConnective
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	severe intellectual disability-progressive spastic diplegia syndrome	0.869266163504584	149	psychiatricDisorder
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	Proteus syndrome	0.869235310377157	179	muculoEskeletalConnective
qHTS for Inhibitors of Polymerase Eta	POLH	targetBased	388717	4730	Xeroderma pigmentosum variant	0.867864105199451	51	geneticDisorder
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	Albright hereditary osteodystrophy	0.866673808957289	189	muculoEskeletalConnective
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	Albright hereditary osteodystrophy	0.866673808957289	189	muculoEskeletalConnective
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	Tietz syndrome	0.865119071324702	993	visualSystem
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	Tietz syndrome	0.865119071324702	993	visualSystem
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	targetBased	72072	2464	HSD10 disease	0.865073065613424	59	psychiatricDisorder
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	targetBased	73912	5649	HSD10 disease	0.865073065613424	59	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast cancer	0.864119807394064	12264	cancer
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Alzheimer disease type 1	0.863489229240414	90	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Alzheimer disease type 1	0.863489229240414	90	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Alzheimer disease type 1	0.863489229240414	90	nervousSystem
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	Carney complex, type 1	0.862585949626369	1275	geneticDisorder
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	myeloproliferative disorder	0.861829240204984	5324	cancer
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Alzheimer disease	0.861771076336328	1120	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Alzheimer disease	0.861771076336328	1120	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Alzheimer disease	0.861771076336328	1120	nervousSystem
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	Charcot-Marie-Tooth disease type 1E	0.861079375757666	69	nervousSystem
qHTS for Inhibitors of Polymerase Eta	POLH	targetBased	388717	4730	xeroderma pigmentosum variant type	0.860919268933285	369	metabolicEndocrine
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	hereditary neuropathy with liability to pressure palsies	0.858608783470146	360	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	familial long QT syndrome	0.858261017924304	1652	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	familial long QT syndrome	0.858261017924304	1652	cardioVascular
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pseudopseudohypoparathyroidism	0.857715919055999	266	muculoEskeletalConnective
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pseudopseudohypoparathyroidism	0.857715919055999	266	muculoEskeletalConnective
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease type II	0.855638338257464	192	psychiatricDisorder
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	factor XI deficiency	0.855157966549838	264	hematologic
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	PPARG-related familial partial lipodystrophy	0.853828081057315	135	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	PPARG-related familial partial lipodystrophy	0.853828081057315	135	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	PPARG-related familial partial lipodystrophy	0.853828081057315	135	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	PPARG-related familial partial lipodystrophy	0.853828081057315	135	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	PPARG-related familial partial lipodystrophy	0.853828081057315	135	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	PPARG-related familial partial lipodystrophy	0.853828081057315	135	metabolicEndocrine
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast carcinoma	0.852709036989038	5420	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast carcinoma	0.852709036989038	5420	cancer
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	hypothyroidism	0.852391824258962	546	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	hypothyroidism	0.852391824258962	546	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	hypothyroidism	0.852391824258962	546	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	hypothyroidism	0.852391824258962	546	metabolicEndocrine
qHTS Assay for Activators of ClpP	Bacillus subtilis (strain 168)	targetBased	338378	6439	Perrault syndrome	0.851666345145291	107	metabolicEndocrine
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	Charcot-Marie-Tooth disease type 3	0.851523859619184	102	nervousSystem
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	Familial afibrinogenemia	0.849937604123244	24	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	Familial afibrinogenemia	0.849937604123244	24	hematologic
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Susceptibility to viral and mycobacterial infections	0.849381507517208	756	immune
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Susceptibility to viral and mycobacterial infections	0.849381507517208	756	immune
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	Congenital factor II deficiency	0.848343511620626	104	hematologic
Factor XIIa 1536 HTS	F12_modulation	targetBased	217430	649	hereditary angioedema type 3	0.848320324519467	99	dermatology
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	Cytomegalic congenital adrenal hypoplasia	0.848222789812202	44	reproductiveSystem
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	Cytomegalic congenital adrenal hypoplasia	0.848222789812202	44	reproductiveSystem
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	semantic dementia	0.847634887281404	330	psychiatricDisorder
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	semantic dementia	0.847634887281404	330	psychiatricDisorder
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	semantic dementia	0.847634887281404	330	psychiatricDisorder
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	immunodeficiency, developmental delay, and hypohomocysteinemia	0.847171548352911	36	immune
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	immunodeficiency, developmental delay, and hypohomocysteinemia	0.847171548352911	36	immune
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	leukocyte adhesion deficiency 1	0.846366489681156	1155	immune
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	hereditary sensory neuropathy-deafness-dementia syndrome	0.846132579723701	1868	geneticDisorder
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease type III	0.843925331047856	164	muculoEskeletalConnective
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	Huntington disease-like 1	0.843396184087878	176	psychiatricDisorder
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Uveal Melanoma	0.842672768448216	66	cancer
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	Leukocyte adhesion deficiency type I	0.840099916485533	65	immune
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	cardiomyopathy, familial restrictive, 1	0.839628176662135	108	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	cardiomyopathy, familial restrictive, 1	0.839628176662135	108	muculoEskeletalConnective
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	neoplasm	0.838869652727156	24991	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	polycythemia vera	0.838231550055395	1434	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast cancer	0.837897580570166	12265	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast cancer	0.837897580570166	12265	cancer
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	inherited Creutzfeldt-Jakob disease	0.837038041259018	132	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Hereditary breast cancer	0.836992105233513	7631	cancer
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	immunodeficiency 31B	0.836677178211477	767	geneticDisorder
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	immunodeficiency 31B	0.836677178211477	767	geneticDisorder
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	cancer	0.835992187469882	39501	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast neoplasm	0.835522351213338	6847	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast neoplasm	0.835522351213338	6847	cancer
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	neuroferritinopathy	0.835274341530147	296	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	breast adenocarcinoma	0.835161405915504	527	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	breast adenocarcinoma	0.835161405915504	527	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	breast adenocarcinoma	0.835161405915504	527	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	breast adenocarcinoma	0.835161405915504	527	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	breast adenocarcinoma	0.835161405915504	527	cancer
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	common variable immunodeficiency	0.834779616196932	290	cancer
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	common variable immunodeficiency	0.834779616196932	290	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lung adenocarcinoma	0.834485116926117	1395	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lung adenocarcinoma	0.834485116926117	1395	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lung adenocarcinoma	0.834485116926117	1395	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lung adenocarcinoma	0.834485116926117	1395	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lung adenocarcinoma	0.834485116926117	1395	cancer
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid disease	0.834278902759498	1999	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid disease	0.834278902759498	1999	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	thyroid disease	0.834278902759498	1999	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	thyroid disease	0.834278902759498	1999	metabolicEndocrine
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	retinitis pigmentosa 37	0.832806550013503	123	visualSystem
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	retinitis pigmentosa 37	0.832806550013503	123	visualSystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	neoplasm	0.832471458207819	8077	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	diabetes mellitus	0.832249916636913	3050	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	diabetes mellitus	0.832249916636913	3050	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	diabetes mellitus	0.832249916636913	3050	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	diabetes mellitus	0.832249916636913	3050	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	diabetes mellitus	0.832249916636913	3050	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	diabetes mellitus	0.832249916636913	3050	metabolicEndocrine
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	hyperparathyroidism	0.832240869271689	1881	metabolicEndocrine
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	hyperproinsulinemia	0.832222133425273	153	geneticDisorder
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	hyperproinsulinemia	0.832222133425273	153	geneticDisorder
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	intellectual disability, autosomal dominant 48	0.831351009514037	54	geneticDisorder
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	intellectual disability, autosomal dominant 48	0.831351009514037	54	geneticDisorder
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	premature ovarian failure 7	0.830926945955708	29	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	premature ovarian failure 7	0.830926945955708	29	reproductiveSystem
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	acute myeloid leukemia	0.830898626678178	3529	cancer
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	acute myeloid leukemia	0.830898626678178	3529	cancer
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	dilated cardiomyopathy 1FF	0.830166550514321	63	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	dilated cardiomyopathy 1FF	0.830166550514321	63	muculoEskeletalConnective
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	dyschromatosis universalis hereditaria 3	0.830129534525025	30	geneticDisorder
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	prion disease	0.829860821013757	4242	infective
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Jervell and Lange-Nielsen syndrome	0.829758025318848	193	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Jervell and Lange-Nielsen syndrome	0.829758025318848	193	cardioVascular
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	progressive osseous heteroplasia	0.829331087202839	191	dermatology
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	progressive osseous heteroplasia	0.829331087202839	191	dermatology
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	Acrodysostosis 1 with or without hormone resistance	0.829085639795519	192	muculoEskeletalConnective
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	primary myelofibrosis	0.828570613464231	590	cancer
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	Familial short QT syndrome	0.828402105198518	351	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	Familial short QT syndrome	0.828402105198518	351	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	Familial short QT syndrome	0.828402105198518	351	cardioVascular
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	Parkinson disease	0.828171049197643	6136	nervousSystem
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	Parkinson disease	0.828171049197643	6136	nervousSystem
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	diabetes mellitus, permanent neonatal 4	0.827937679728068	86	metabolicEndocrine
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	diabetes mellitus, permanent neonatal 4	0.827937679728068	86	metabolicEndocrine
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	amyotrophic lateral sclerosis	0.827061532998182	1066	nervousSystem
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	cerebral amyloid angiopathy, APP-related	0.826810281381391	53	psychiatricDisorder
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	cerebral amyloid angiopathy, APP-related	0.826810281381391	53	psychiatricDisorder
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	cerebral amyloid angiopathy, APP-related	0.826810281381391	53	psychiatricDisorder
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness	0.826650178195704	47	geneticDisorder
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness	0.826650178195704	47	geneticDisorder
qHTS assay for inhibitors of human lactate dehydrogenase	lactateDehydrogenaseInhibitors	targetBased	476056	732	glycogen storage disease due to lactate dehydrogenase M-subunit deficiency	0.825949553451582	236	muculoEskeletalConnective
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	amyotrophic lateral sclerosis	0.824971871393985	552	nervousSystem
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	amyotrophic lateral sclerosis	0.824971871393985	552	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colorectal cancer	0.824947173642699	1104	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colorectal cancer	0.824947173642699	1104	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colorectal cancer	0.824947173642699	1104	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colorectal cancer	0.824947173642699	1104	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colorectal cancer	0.824947173642699	1104	cancer
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	aldosterone-producing adenoma with seizures and neurological abnormalities	0.824148217889939	128	metabolicEndocrine
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	chondrodysplasia Blomstrand type	0.824076159020484	170	muculoEskeletalConnective
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease	0.823552732111791	2711	metabolicEndocrine
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	frontotemporal dementia and/or amyotrophic lateral sclerosis 6	0.823020002027243	783	nervousSystem
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	targetBased	306502	2634	Presynaptic congenital myasthenic syndromes	0.822381801512511	639	muculoEskeletalConnective
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	targetBased	306502	1509	Presynaptic congenital myasthenic syndromes	0.822381801512511	639	muculoEskeletalConnective
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	type 2 diabetes mellitus	0.822214179786226	8610	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	type 2 diabetes mellitus	0.822214179786226	8610	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	type 2 diabetes mellitus	0.822214179786226	8610	metabolicEndocrine
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	acute lymphoblastic leukemia	0.821223780852646	2618	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	acute myeloid leukemia	0.820990723759405	3172	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	acute myeloid leukemia	0.820990723759405	3172	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	acute myeloid leukemia	0.820990723759405	3172	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	acute myeloid leukemia	0.820990723759405	3172	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	acute myeloid leukemia	0.820990723759405	3172	cancer
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	targetBased	385746	932	amyotrophic lateral sclerosis	0.820983415810258	893	nervousSystem
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	selective pituitary resistance to thyroid hormone	0.819781482042683	48	metabolicEndocrine
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	Aneurysm - osteoarthritis syndrome	0.818691129384453	60	muculoEskeletalConnective
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	primary failure of tooth eruption	0.818655159347425	134	geneticDisorder
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	inclusion body myopathy with Paget disease of bone and frontotemporal dementia	0.817906305372197	1060	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	familial dysfibrinogenemia	0.817497971692264	115	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	familial dysfibrinogenemia	0.817497971692264	115	hematologic
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	Jawad syndrome	0.817102677603061	47	geneticDisorder
Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2)	GPT2	targetBased	98912	236	glutamate pyruvate transaminase 2 deficiency	0.816256444320932	56	geneticDisorder
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	spermatogenic failure 8	0.816032599202828	24	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	spermatogenic failure 8	0.816032599202828	24	reproductiveSystem
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	cardiac arrhythmia	0.815852504474459	1310	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	cardiac arrhythmia	0.815852504474459	1310	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	cardiac arrhythmia	0.815852504474459	1310	cardioVascular
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	intellectual developmental disorder with or without epilepsy or cerebellar ataxia	0.815362549629963	102	nervousSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	intellectual developmental disorder with or without epilepsy or cerebellar ataxia	0.815362549629963	102	nervousSystem
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	endocrine neoplasm	0.814230692322863	2441	cancer
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	medulloblastoma	0.814044525642904	108	cancer
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	Carney complex	0.813899511484162	764	geneticDisorder
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	Pick disease	0.813029001015443	2286	psychiatricDisorder
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	Pick disease	0.813029001015443	2286	psychiatricDisorder
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	Pick disease	0.813029001015443	2286	psychiatricDisorder
Glucocerebrosidase	GBA1	targetBased	48118	549	Parkinson disease	0.812818197273596	1199	nervousSystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian carcinoma	0.811014153936412	630	cancer
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	Niemann-Pick disease	0.810720962981773	1356	metabolicEndocrine
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	familial long QT syndrome	0.810413609236612	888	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	familial long QT syndrome	0.810413609236612	888	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	familial long QT syndrome	0.810413609236612	888	cardioVascular
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	parkinsonism-dystonia, infantile	0.809677753063431	616	nervousSystem
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	Seizure	0.809233289945136	281	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	pancreatic neoplasm	0.808830166678429	1045	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	pancreatic neoplasm	0.808830166678429	1045	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	pancreatic neoplasm	0.808830166678429	1045	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	pancreatic neoplasm	0.808830166678429	1045	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	pancreatic neoplasm	0.808830166678429	1045	cancer
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	DYRK1A-related intellectual disability syndrome	0.808262884097842	1089	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	pulmonary hypertension, primary, 4	0.806230597298378	260	geneticDisorder
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	thrombophilia due to thrombin defect	0.805005841741523	84	hematologic
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	prostate adenocarcinoma	0.804334708461005	352	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	prostate adenocarcinoma	0.804334708461005	352	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	prostate adenocarcinoma	0.804334708461005	352	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	prostate adenocarcinoma	0.804334708461005	352	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	prostate adenocarcinoma	0.804334708461005	352	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	linear nevus sebaceous syndrome	0.803862671575397	54	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	schizophrenia	0.803689936994135	4030	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	schizophrenia	0.803689936994135	4030	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	schizophrenia	0.803689936994135	4030	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	schizophrenia	0.803689936994135	4030	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	schizophrenia	0.803689936994135	4030	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	schizophrenia	0.803689936994135	4030	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	short QT syndrome type 3	0.803575814937152	741	geneticDisorder
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	supranuclear palsy, progressive, 1	0.803558269928458	35	visualSystem
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	supranuclear palsy, progressive, 1	0.803558269928458	35	visualSystem
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	supranuclear palsy, progressive, 1	0.803558269928458	35	visualSystem
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	atrial fibrillation	0.802439563669594	261	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	atrial fibrillation	0.802439563669594	261	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	atrial fibrillation	0.802439563669594	261	cardioVascular
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	ulcerative colitis	0.802339118184399	318	immune
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	Lewy body dementia	0.801708456086421	1304	psychiatricDisorder
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	Lewy body dementia	0.801708456086421	1304	psychiatricDisorder
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	MODY	0.801268492989806	168	metabolicEndocrine
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	MODY	0.801268492989806	168	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ovarian neoplasm	0.800787973060319	1661	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ovarian neoplasm	0.800787973060319	1661	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ovarian neoplasm	0.800787973060319	1661	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ovarian neoplasm	0.800787973060319	1661	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ovarian neoplasm	0.800787973060319	1661	cancer
Factor XIIa 1536 HTS	F12_modulation	targetBased	217430	649	hereditary angioedema	0.800372299981284	87	dermatology
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	targetBased	369953	2602	congenital heart disease	0.798914888419431	147	cardioVascular
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	targetBased	309684	1662	Rauch-Steindl syndrome	0.798894331176793	60	geneticDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gastric adenocarcinoma	0.798791596621054	633	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gastric adenocarcinoma	0.798791596621054	633	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gastric adenocarcinoma	0.798791596621054	633	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gastric adenocarcinoma	0.798791596621054	633	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gastric adenocarcinoma	0.798791596621054	633	cancer
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	Familial cold urticaria	0.798662521910481	38	immune
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cancer	0.798462583624305	70480	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cancer	0.798462583624305	70480	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cancer	0.798462583624305	70480	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cancer	0.798462583624305	70480	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cancer	0.798462583624305	70480	cancer
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	sinoatrial node dysfunction and deafness	0.798234352836398	89	cardioVascular
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	targetBased	148480	6428	hypertrophic osteoarthropathy, primary, autosomal recessive, 1	0.798213557362017	135	muculoEskeletalConnective
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	neoplasm	0.797175874096195	36242	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	neoplasm	0.797175874096195	36242	cancer
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	lean body mass	0.797055288021613	210	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	lean body mass	0.797055288021613	210	metabolicEndocrine
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	0.796724875126738	3169	cancer
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	hereditary thrombocytopenia and hematologic cancer predisposition syndrome	0.796724875126738	3169	cancer
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	Seckel syndrome 2	0.795909043926353	35	muculoEskeletalConnective
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	Creutzfeldt Jacob Disease	0.794969944120682	206	infective
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	retinitis pigmentosa	0.794921236355417	203	metabolicEndocrine
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	retinitis pigmentosa	0.794921236355417	203	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	osteosarcoma	0.793475959159254	405	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	osteosarcoma	0.793475959159254	405	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	osteosarcoma	0.793475959159254	405	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	osteosarcoma	0.793475959159254	405	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	osteosarcoma	0.793475959159254	405	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	breast cancer	0.793469661384171	4260	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	breast cancer	0.793469661384171	4260	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	breast cancer	0.793469661384171	4260	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	breast cancer	0.793469661384171	4260	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	breast cancer	0.793469661384171	4260	cancer
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	body mass index	0.793103015324844	185	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	body mass index	0.793103015324844	185	metabolicEndocrine
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	atrial fibrillation, familial, 3	0.792880726749446	315	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	atrial fibrillation, familial, 3	0.792880726749446	315	geneticDisorder
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	familial gestational hyperthyroidism	0.792500474621163	45	pregnancyPerinatal
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	familial gestational hyperthyroidism	0.792500474621163	45	pregnancyPerinatal
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	familial gestational hyperthyroidism	0.792500474621163	45	pregnancyPerinatal
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	familial gestational hyperthyroidism	0.792500474621163	45	pregnancyPerinatal
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	fat body mass	0.792334309492539	188	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	fat body mass	0.792334309492539	188	metabolicEndocrine
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	hyper-IgE syndrome	0.791517184926309	530	immune
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	hyper-IgE syndrome	0.791517184926309	530	immune
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	alkaline phosphatase measurement	0.791261379108031	93	otherPhenotypes
High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits	GNAI3	targetBased	204125	876	auriculocondylar syndrome	0.791157912368328	41	muculoEskeletalConnective
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	chronic lymphocytic leukemia	0.791053421387467	1441	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	chronic lymphocytic leukemia	0.791053421387467	1441	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	chronic lymphocytic leukemia	0.791053421387467	1441	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	chronic lymphocytic leukemia	0.791053421387467	1441	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	chronic lymphocytic leukemia	0.791053421387467	1441	cancer
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	body fat percentage	0.790829523756632	128	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	body fat percentage	0.790829523756632	128	metabolicEndocrine
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	Yao syndrome	0.788711803511674	96	geneticDisorder
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	maturity-onset diabetes of the young type 10	0.788516298768167	69	geneticDisorder
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	maturity-onset diabetes of the young type 10	0.788516298768167	69	geneticDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	pancreatic adenocarcinoma	0.787429982948732	847	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	pancreatic adenocarcinoma	0.787429982948732	847	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	pancreatic adenocarcinoma	0.787429982948732	847	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	pancreatic adenocarcinoma	0.787429982948732	847	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	pancreatic adenocarcinoma	0.787429982948732	847	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes	0.786905869129326	133	nervousSystem
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	goiter, multinodular 1, with or without Sertoli-Leydig cell tumors	0.786101469175161	83	cancer
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	neurodevelopmental disorder with seizures and non-epileptic hyperkinetic movements	0.785713138394098	92	nervousSystem
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	CARASIL syndrome	0.784936074971295	51	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	bipolar disorder	0.784698432000525	1317	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	bipolar disorder	0.784698432000525	1317	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	bipolar disorder	0.784698432000525	1317	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	bipolar disorder	0.784698432000525	1317	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	bipolar disorder	0.784698432000525	1317	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	bipolar disorder	0.784698432000525	1317	psychiatricDisorder
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	hypertension	0.784665512239552	1291	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	atrial fibrillation	0.783777345668684	234	cardioVascular
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ovarian cancer	0.783276111831291	1196	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ovarian cancer	0.783276111831291	1196	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ovarian cancer	0.783276111831291	1196	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ovarian cancer	0.783276111831291	1196	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ovarian cancer	0.783276111831291	1196	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	multiple benign circumferential skin creases on limbs 1	0.783227863087577	24	geneticDisorder
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	cutaneous melanoma	0.783010945534478	722	cancer
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	cutaneous melanoma	0.783010945534478	722	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	squamous cell lung carcinoma	0.782904796477414	523	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	squamous cell lung carcinoma	0.782904796477414	523	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	squamous cell lung carcinoma	0.782904796477414	523	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	squamous cell lung carcinoma	0.782904796477414	523	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	squamous cell lung carcinoma	0.782904796477414	523	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	Linear nevus sebaceus syndrome	0.782821035564354	47	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	Loeys-Dietz syndrome	0.782631949327588	824	muculoEskeletalConnective
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	Genetic central nervous system malformation	0.782164853414173	15	geneticDisorder
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	acrodysostosis	0.781959384313481	152	muculoEskeletalConnective
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	CARASIL	0.781674677671435	134	geneticDisorder
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	platelet count	0.781132669160644	77	hematologic
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Familial exudative vitreoretinopathy	0.780174169924281	54	visualSystem
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	Pleuropulmonary blastoma	0.780118945779228	395	cancer
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	body weight	0.779946115907984	80	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	body weight	0.779946115907984	80	metabolicEndocrine
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	erythrocytosis, familial, 4	0.779929786051706	233	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex	PRKACB	targetBased	343468	273	cardioacrofacial dysplasia 2	0.779521288627592	24	geneticDisorder
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome	0.779415318502638	122	metabolicEndocrine
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	nicotine dependence	0.779304545775545	138	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	unipolar depression	0.778810435779702	148	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	unipolar depression	0.778810435779702	148	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	unipolar depression	0.778810435779702	148	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	unipolar depression	0.778810435779702	148	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	unipolar depression	0.778810435779702	148	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	unipolar depression	0.778810435779702	148	psychiatricDisorder
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	permanent neonatal diabetes mellitus	0.777959509145123	63	metabolicEndocrine
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	permanent neonatal diabetes mellitus	0.777959509145123	63	metabolicEndocrine
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	familial thoracic aortic aneurysm and aortic dissection	0.777860473513668	1211	cardioVascular
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	intellectual disability, autosomal recessive 65	0.777855262897303	78	psychiatricDisorder
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	hereditary chronic pancreatitis	0.777489202209142	461	metabolicEndocrine
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	hereditary chronic pancreatitis	0.777489202209142	461	metabolicEndocrine
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	targetBased	306502	2634	Congenital myasthenic syndromes	0.774715316348506	860	muculoEskeletalConnective
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	targetBased	306502	1509	Congenital myasthenic syndromes	0.774715316348506	860	muculoEskeletalConnective
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	high density lipoprotein cholesterol measurement	0.774346264551129	83	metabolicEndocrine
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	high density lipoprotein cholesterol measurement	0.774346264551129	83	metabolicEndocrine
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	global developmental delay - lung cysts - overgrowth - Wilms tumor syndrome	0.773844445367218	506	cancer
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	schizophrenia	0.773518981697282	911	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	schizophrenia	0.773518981697282	911	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	schizophrenia	0.773518981697282	911	psychiatricDisorder
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	congenital bilateral absence of vas deferens	0.773298478345554	346	reproductiveSystem
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	congenital bilateral absence of vas deferens	0.773298478345554	346	reproductiveSystem
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	Omenn syndrome	0.773255884585553	42	immune
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	neoplasm	0.773198977841017	6645	cancer
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	developmental and epileptic encephalopathy	0.773169282096942	596	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	developmental and epileptic encephalopathy	0.773169282096942	596	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	developmental and epileptic encephalopathy	0.773169282096942	596	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	pancreatic carcinoma	0.772563433295667	611	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	pancreatic carcinoma	0.772563433295667	611	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	pancreatic carcinoma	0.772563433295667	611	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	pancreatic carcinoma	0.772563433295667	611	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	pancreatic carcinoma	0.772563433295667	611	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adrenal cortex carcinoma	0.772501421851151	549	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adrenal cortex carcinoma	0.772501421851151	549	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adrenal cortex carcinoma	0.772501421851151	549	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adrenal cortex carcinoma	0.772501421851151	549	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adrenal cortex carcinoma	0.772501421851151	549	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	breast cancer	0.771774175297562	2611	cancer
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	Birk-Barel syndrome	0.771166979421912	51	psychiatricDisorder
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	generalized resistance to thyroid hormone	0.770774380396017	44	metabolicEndocrine
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	targetBased	288728	10857	congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome	0.770329660937942	30	muculoEskeletalConnective
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	targetBased	288728	10857	congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome	0.770329660937942	30	muculoEskeletalConnective
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	frontotemporal dementia with motor neuron disease	0.769549611350366	329	psychiatricDisorder
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	frontotemporal dementia with motor neuron disease	0.769549611350366	329	psychiatricDisorder
Colorimetric Assay for Inhibitors for NALP1	NLRP1	targetBased	280024	1717	corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome	0.769399353712043	54	visualSystem
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	Young adult-onset Parkinsonism	0.769243896644589	113	metabolicEndocrine
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	Young adult-onset Parkinsonism	0.769243896644589	113	metabolicEndocrine
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	embryonal rhabdomyosarcoma	0.769159310314872	123	cancer
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	primary ovarian insufficiency	0.768831049962756	66	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	primary ovarian insufficiency	0.768831049962756	66	reproductiveSystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	platelet crit	0.768707774378392	50	hematologic
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	multiple endocrine neoplasia	0.767584741814198	1559	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	nevus, epidermal	0.765990926960034	47	cancer
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	Eiken syndrome	0.765164840016023	86	muculoEskeletalConnective
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Familial short QT syndrome	0.764568393200508	60	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Familial short QT syndrome	0.764568393200508	60	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	hip circumference	0.764439035227678	48	otherPhenotypes
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	hip circumference	0.764439035227678	48	otherPhenotypes
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	prothrombin deficiency	0.764218597299019	588	hematologic
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	Familial multinodular goiter	0.763909243189879	84	metabolicEndocrine
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	Cowden syndrome 6	0.763828042183345	722	geneticDisorder
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	cancer	0.762437302926748	1581	cancer
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	cancer	0.762437302926748	1581	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	urinary bladder cancer	0.761976143434719	875	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	urinary bladder cancer	0.761976143434719	875	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	urinary bladder cancer	0.761976143434719	875	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	urinary bladder cancer	0.761976143434719	875	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	urinary bladder cancer	0.761976143434719	875	cancer
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Hereditary cerebral hemorrhage with amyloidosis	0.761314869524214	39	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Hereditary cerebral hemorrhage with amyloidosis	0.761314869524214	39	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Hereditary cerebral hemorrhage with amyloidosis	0.761314869524214	39	nervousSystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	ulcerative colitis	0.760994816046525	161	immune
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	bronchiectasis with or without elevated sweat chloride 1	0.760900509374716	894	respiratory
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	bronchiectasis with or without elevated sweat chloride 1	0.760900509374716	894	respiratory
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	classic dopamine transporter deficiency syndrome	0.760444706064359	66	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	ventricular fibrillation	0.760259527871274	51	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	ventricular fibrillation	0.760259527871274	51	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	ventricular fibrillation	0.760259527871274	51	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	waist circumference	0.758230714129653	50	otherPhenotypes
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	waist circumference	0.758230714129653	50	otherPhenotypes
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	glycogen storage disease due to glycogen branching enzyme deficiency	0.758107361832069	338	muculoEskeletalConnective
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	breast neoplasm	0.757177438416621	2227	cancer
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	type 1 diabetes mellitus	0.756980358905614	1970	metabolicEndocrine
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	type 1 diabetes mellitus	0.756980358905614	1970	metabolicEndocrine
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	urinary bladder cancer	0.756664701286372	130	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Choroid Plexus Papilloma	0.756303928580139	80	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Choroid Plexus Papilloma	0.756303928580139	80	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Choroid Plexus Papilloma	0.756303928580139	80	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Choroid Plexus Papilloma	0.756303928580139	80	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Choroid Plexus Papilloma	0.756303928580139	80	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Genital neoplasm, female	0.756154198723462	7331	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	esophageal cancer	0.755733859976898	808	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	esophageal cancer	0.755733859976898	808	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	esophageal cancer	0.755733859976898	808	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	esophageal cancer	0.755733859976898	808	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	esophageal cancer	0.755733859976898	808	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	follicular thyroid carcinoma	0.755392732456168	65	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	breast neoplasm	0.755353716652497	2799	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	breast neoplasm	0.755353716652497	2799	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	breast neoplasm	0.755353716652497	2799	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	breast neoplasm	0.755353716652497	2799	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	breast neoplasm	0.755353716652497	2799	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	pancreatic cancer, susceptibility to, 4	0.754570439851074	213	geneticDisorder
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	cancer	0.753722443923473	6564	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	essential thrombocythemia	0.753090144400383	1853	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	developmental and epileptic encephalopathy	0.752819952083254	2611	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	developmental and epileptic encephalopathy	0.752819952083254	2611	nervousSystem
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	inflammatory bowel disease, immunodeficiency, and encephalopathy	0.752376428542243	30	immune
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	familial pseudohyperkalemia	0.751304181752444	20	hematologic
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	Infantile dystonia-parkinsonism	0.751026462125741	122	nervousSystem
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	leukocyte adhesion deficiency	0.750707304739755	536	immune
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	Noonan syndrome	0.750196204718814	41	muculoEskeletalConnective
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	targetBased	385746	932	essential tremor	0.749984466437818	387	otherPhenotypes
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hereditary breast carcinoma	0.746971472284402	108	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	hereditary breast carcinoma	0.746971472284402	108	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	hereditary breast carcinoma	0.746971472284402	108	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	hereditary breast carcinoma	0.746971472284402	108	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	hereditary breast carcinoma	0.746971472284402	108	cancer
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	targetBased	148480	6428	cranio-osteoarthropathy	0.746918073560792	12	geneticDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	opioid use disorder	0.746624149297985	278	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	opioid use disorder	0.746624149297985	278	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colorectal adenocarcinoma	0.746609442237671	429	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colorectal adenocarcinoma	0.746609442237671	429	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colorectal adenocarcinoma	0.746609442237671	429	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colorectal adenocarcinoma	0.746609442237671	429	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colorectal adenocarcinoma	0.746609442237671	429	cancer
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	base metabolic rate measurement	0.746509529530886	33	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	base metabolic rate measurement	0.746509529530886	33	metabolicEndocrine
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Benign Skin Appendage Neoplasm	0.746464058544635	29	cancer
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	diabetes mellitus	0.746078951984027	6203	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	diabetes mellitus	0.746078951984027	6203	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	diabetes mellitus	0.746078951984027	6203	metabolicEndocrine
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	stroke	0.745819195337535	29	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hereditary neoplastic syndrome	0.745817539826029	5525	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	hereditary neoplastic syndrome	0.745817539826029	5525	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	hereditary neoplastic syndrome	0.745817539826029	5525	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	hereditary neoplastic syndrome	0.745817539826029	5525	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	hereditary neoplastic syndrome	0.745817539826029	5525	cancer
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	dilated cardiomyopathy 2A	0.744453709686017	86	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	dilated cardiomyopathy 2A	0.744453709686017	86	muculoEskeletalConnective
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Inherited cancer-predisposing syndrome	0.744246331522584	20897	geneticDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	small cell lung carcinoma	0.743850543799876	1614	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	small cell lung carcinoma	0.743850543799876	1614	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	small cell lung carcinoma	0.743850543799876	1614	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	small cell lung carcinoma	0.743850543799876	1614	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	small cell lung carcinoma	0.743850543799876	1614	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	short QT syndrome type 2	0.743607842397551	320	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	short QT syndrome type 2	0.743607842397551	320	geneticDisorder
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	schizophrenia	0.743395452086089	48	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	diffuse large B-cell lymphoma	0.743259744045603	845	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	diffuse large B-cell lymphoma	0.743259744045603	845	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	diffuse large B-cell lymphoma	0.743259744045603	845	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	diffuse large B-cell lymphoma	0.743259744045603	845	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	diffuse large B-cell lymphoma	0.743259744045603	845	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	breast carcinoma	0.742846429132578	2349	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	breast carcinoma	0.742846429132578	2349	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	breast carcinoma	0.742846429132578	2349	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	breast carcinoma	0.742846429132578	2349	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	breast carcinoma	0.742846429132578	2349	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	IGF-1 measurement	0.742703261668942	36	otherPhenotypes
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	targetBased	63696	220	cancer	0.742522421363885	1330	cancer
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	targetBased	290726	2649	cancer	0.742522421363885	1330	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Seizure	0.742012328791577	104	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Seizure	0.742012328791577	104	nervousSystem
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	odontohypophosphatasia	0.741759323098823	20	metabolicEndocrine
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	osteoporosis	0.740989460833532	72	muculoEskeletalConnective
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	osteoporosis	0.740989460833532	72	muculoEskeletalConnective
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	parathyroid adenoma	0.740465619640904	206	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	basal cell carcinoma, susceptibility to, 7	0.740214576533468	50	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	basal cell carcinoma, susceptibility to, 7	0.740214576533468	50	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	basal cell carcinoma, susceptibility to, 7	0.740214576533468	50	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	basal cell carcinoma, susceptibility to, 7	0.740214576533468	50	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	basal cell carcinoma, susceptibility to, 7	0.740214576533468	50	geneticDisorder
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	cerebral amyloid angiopathy	0.739822242551998	67	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	obesity due to melanocortin 4 receptor deficiency	0.739222725453875	152	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	obesity due to melanocortin 4 receptor deficiency	0.739222725453875	152	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	multiple myeloma	0.739052515476112	726	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	multiple myeloma	0.739052515476112	726	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	multiple myeloma	0.739052515476112	726	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	multiple myeloma	0.739052515476112	726	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	multiple myeloma	0.739052515476112	726	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	hereditary breast ovarian cancer syndrome	0.738790451491213	11288	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	hereditary neoplastic syndrome	0.738658920587182	17319	cancer
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	targetBased	639428	9218	uveal coloboma-cleft lip and palate-intellectual disability	0.738514274092363	21	psychiatricDisorder
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	cardiomyopathy	0.738160697713462	1141	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	cardiomyopathy	0.738160697713462	1141	muculoEskeletalConnective
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	targetBased	362274	1085	deafness	0.737707430803668	111	nervousSystem
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	Crohn's disease	0.737705438254737	75	immune
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	lipoprotein measurement	0.737641092943203	90	metabolicEndocrine
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	lipoprotein measurement	0.737641092943203	90	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	bone marrow failure syndrome	0.737460111393103	73	muculoEskeletalConnective
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	bone marrow failure syndrome	0.737460111393103	73	muculoEskeletalConnective
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	bone marrow failure syndrome	0.737460111393103	73	muculoEskeletalConnective
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	bone marrow failure syndrome	0.737460111393103	73	muculoEskeletalConnective
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	bone marrow failure syndrome	0.737460111393103	73	muculoEskeletalConnective
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	autosomal dominant nonsyndromic hearing loss	0.737234129322474	225	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	nasopharyngeal carcinoma	0.737012287640562	68	infective
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	nasopharyngeal carcinoma	0.737012287640562	68	infective
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	nasopharyngeal carcinoma	0.737012287640562	68	infective
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	nasopharyngeal carcinoma	0.737012287640562	68	infective
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	nasopharyngeal carcinoma	0.737012287640562	68	infective
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	targetBased	639428	9218	Uveal coloboma - cleft lip and palate - intellectual disability	0.736353370947332	11	geneticDisorder
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	Noonan syndrome	0.735833813629442	26	muculoEskeletalConnective
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	Noonan syndrome	0.735833813629442	26	muculoEskeletalConnective
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Pleural Mesothelioma	0.735350430677337	70	cancer
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	congenital disorder of glycosylation	0.735305299331021	997	metabolicEndocrine
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	congenital disorder of glycosylation	0.735305299331021	997	metabolicEndocrine
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	congenital disorder of glycosylation	0.735305299331021	997	metabolicEndocrine
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pseudohypoparathyroidism	0.734855055294246	573	metabolicEndocrine
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pseudohypoparathyroidism	0.734855055294246	573	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	neoplasm	0.734763617551086	117109	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	neoplasm	0.734763617551086	117109	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	neoplasm	0.734763617551086	117109	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	neoplasm	0.734763617551086	117109	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	neoplasm	0.734763617551086	117109	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Prolonged QT interval	0.734109946020632	2070	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Prolonged QT interval	0.734109946020632	2070	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	Prolonged QT interval	0.734041769977036	3500	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	Prolonged QT interval	0.734041769977036	3500	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	Prolonged QT interval	0.734041769977036	3500	cardioVascular
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	complex cortical dysplasia with other brain malformations 6	0.733669508945977	42	geneticDisorder
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	urinary bladder carcinoma	0.733331528757895	307	cancer
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	hereditary neoplastic syndrome	0.733240953654702	3378	cancer
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	targetBased	338328	2501	polydactyly, postaxial, type A8	0.732801265040584	21	muculoEskeletalConnective
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	ovarian cancer	0.732513052579539	72	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adrenocortical carcinoma, hereditary	0.732277820907482	320	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adrenocortical carcinoma, hereditary	0.732277820907482	320	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adrenocortical carcinoma, hereditary	0.732277820907482	320	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adrenocortical carcinoma, hereditary	0.732277820907482	320	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adrenocortical carcinoma, hereditary	0.732277820907482	320	cancer
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	progressive supranuclear palsy	0.732176008180037	68	visualSystem
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	progressive supranuclear palsy	0.732176008180037	68	visualSystem
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	progressive supranuclear palsy	0.732176008180037	68	visualSystem
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	urinary bladder carcinoma	0.732157805652173	127	cancer
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	primary hyperparathyroidism	0.731336275407759	1712	metabolicEndocrine
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	targetBased	358434	2554	spinocerebellar ataxia type 2	0.731331827352406	473	psychiatricDisorder
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	prostate adenocarcinoma	0.731249965361392	63	cancer
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	targetBased	189882	6790	Huntington disease	0.731024441538217	7266	nervousSystem
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	targetBased	48068	449	Huntington disease	0.731024441538217	7266	nervousSystem
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	targetBased	220571	2380	Huntington disease	0.731024441538217	7266	nervousSystem
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	targetBased	223611	305	Huntington disease	0.731024441538217	7266	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Parkinson disease	0.730757536945714	165	nervousSystem
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Parkinson disease	0.730757536945714	165	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Parkinson disease	0.730757536945714	165	nervousSystem
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Parkinson disease	0.730757536945714	165	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Parkinson disease	0.730757536945714	165	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	atrial fibrillation, familial, 9	0.730580053077848	210	geneticDisorder
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	targetBased	369953	3123	cancer	0.730312854683163	391	cancer
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	frontotemporal dementia	0.729976188098486	1347	psychiatricDisorder
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	frontotemporal dementia	0.729976188098486	1347	psychiatricDisorder
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	frontotemporal dementia	0.729976188098486	1347	psychiatricDisorder
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	cancer	0.729137686870591	4215	cancer
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	cancer	0.728959503512403	614	cancer
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	cancer	0.728900443873601	3505	cancer
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	genetic disorder	0.728291041288442	1024	geneticDisorder
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	genetic disorder	0.728291041288442	1024	geneticDisorder
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	targetBased	324747	2221	Congenital myasthenic syndromes	0.727310482862168	891	muculoEskeletalConnective
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	melanoma	0.727160629242358	2492	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	melanoma	0.727160629242358	2492	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	melanoma	0.727160629242358	2492	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	melanoma	0.727160629242358	2492	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	melanoma	0.727160629242358	2492	cancer
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	targetBased	189132	4127	generalised epilepsy	0.726615041643907	463	nervousSystem
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	targetBased	194152	1342	maple syrup urine disease	0.726575680343748	1132	metabolicEndocrine
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	Pituitary Gland Adenoma	0.726268004475537	170	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	Pituitary Gland Adenoma	0.726268004475537	170	cancer
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	targetBased	369953	2294	reticulate acropigmentation of Kitamura	0.725807307099538	20	dermatology
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	whole body water mass	0.724805104839169	30	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	whole body water mass	0.724805104839169	30	metabolicEndocrine
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	Classical progressive supranuclear palsy	0.724714707725161	50	psychiatricDisorder
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	Classical progressive supranuclear palsy	0.724714707725161	50	psychiatricDisorder
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	Classical progressive supranuclear palsy	0.724714707725161	50	psychiatricDisorder
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	targetBased	73174	1034	eosinophil count	0.724336231239081	52	hematologic
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	monogenic diabetes	0.723854062699688	131	immune
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	monogenic diabetes	0.723854062699688	131	immune
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	multiple benign circumferential skin creases on limbs	0.723505147515324	25	dermatology
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	hypertrophic cardiomyopathy	0.723494176407128	465	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	targetBased	368927	3838	blepharophimosis-impaired intellectual development syndrome	0.722425494125991	45	geneticDisorder
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	targetBased	353950	4145	congenital hypothyroidism	0.722405177821548	288	metabolicEndocrine
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	keratitis fugax hereditaria	0.722048024803848	129	geneticDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	attention deficit hyperactivity disorder	0.721501946320093	203	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	attention deficit hyperactivity disorder	0.721501946320093	203	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	attention deficit hyperactivity disorder	0.721501946320093	203	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	attention deficit hyperactivity disorder	0.721501946320093	203	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	attention deficit hyperactivity disorder	0.721501946320093	203	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	attention deficit hyperactivity disorder	0.721501946320093	203	psychiatricDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	chronic lymphocytic leukemia	0.721306850470058	362	cancer
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	Charcot-Marie-Tooth disease type 1	0.721305340964187	609	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	Epileptic encephalopathy	0.721014842095344	71	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	Epileptic encephalopathy	0.721014842095344	71	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	Epileptic encephalopathy	0.721014842095344	71	nervousSystem
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	leukocyte count	0.720998711707685	68	hematologic
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	leukocyte count	0.720998711707685	68	hematologic
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	hereditary neoplastic syndrome	0.720820341742928	3689	cancer
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	targetBased	325247	1021	Quebec platelet disorder	0.720412492694258	131	hematologic
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	chronic pancreatitis	0.720305011735222	173	metabolicEndocrine
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	chronic pancreatitis	0.720305011735222	173	metabolicEndocrine
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	targetBased	385746	932	frontotemporal dementia with motor neuron disease	0.720114897719733	614	psychiatricDisorder
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	total cholesterol measurement	0.720081380330332	28	metabolicEndocrine
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	total cholesterol measurement	0.720081380330332	28	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	endometrial cancer	0.719716014087321	348	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	endometrial cancer	0.719716014087321	348	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	endometrial cancer	0.719716014087321	348	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	endometrial cancer	0.719716014087321	348	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	endometrial cancer	0.719716014087321	348	cancer
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	targetBased	189132	4127	malignant migrating partial seizures of infancy	0.719347083244386	1206	nervousSystem
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	targetBased	369953	1241	spinocerebellar ataxia, autosomal recessive 23	0.719126736741118	27	psychiatricDisorder
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	targetBased	125268	2463	Bartter syndrome	0.719032633702922	260	urinarySystem
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	Thrombocytopenia	0.718968650475424	230	hematologic
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	Thrombocytopenia	0.718968650475424	230	hematologic
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	adenocarcinoma	0.718867795822544	302	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	susceptibility to breast cancer	0.718849250077404	32	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	pancreatic carcinoma	0.718784932807895	97	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	leukemia	0.718194542732695	3745	cancer
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	acute myeloid leukemia	0.718076005186988	918	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	thyroid neoplasm	0.717923499573761	177	cancer
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	hepatocellular carcinoma	0.717676555746485	407	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	hepatocellular carcinoma	0.717676555746485	407	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	psychosis	0.717504452857608	1775	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	psychosis	0.717504452857608	1775	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	psychosis	0.717504452857608	1775	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	psychosis	0.717504452857608	1775	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	psychosis	0.717504452857608	1775	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	psychosis	0.717504452857608	1775	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	cardiac arrhythmia	0.717418405216669	970	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	cardiac arrhythmia	0.717418405216669	970	cardioVascular
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	pancreatic carcinoma	0.717108809180929	280	cancer
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	targetBased	369953	1241	Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency	0.716707964739166	14	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	urinary bladder carcinoma	0.715943490770942	1968	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	urinary bladder carcinoma	0.715943490770942	1968	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	urinary bladder carcinoma	0.715943490770942	1968	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	urinary bladder carcinoma	0.715943490770942	1968	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	urinary bladder carcinoma	0.715943490770942	1968	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	digestive system cancer	0.715610156304212	337	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	myeloid leukemia	0.715357066963333	2551	cancer
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	Charcot-Marie-Tooth disease	0.714642276410934	828	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	sarcoma	0.714640176905728	2314	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	sarcoma	0.714640176905728	2314	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	sarcoma	0.714640176905728	2314	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	sarcoma	0.714640176905728	2314	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	sarcoma	0.714640176905728	2314	cancer
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	46,XY complete gonadal dysgenesis	0.714510258851383	372	muculoEskeletalConnective
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	46,XY complete gonadal dysgenesis	0.714510258851383	372	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	pigmented nodular adrenocortical disease, primary, 1	0.714082948468669	30	geneticDisorder
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	Rare disease with thoracic aortic aneurysm and aortic dissection	0.713819263156603	1211	geneticDisorder
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	progressive supranuclear palsy-parkinsonism syndrome	0.713727143151145	27	visualSystem
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	progressive supranuclear palsy-parkinsonism syndrome	0.713727143151145	27	visualSystem
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	progressive supranuclear palsy-parkinsonism syndrome	0.713727143151145	27	visualSystem
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	cancer	0.713286180158294	565	cancer
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	Abnormality of the cardiovascular system	0.711592736821994	2381	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	Abnormality of the cardiovascular system	0.711592736821994	2381	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	Abnormality of the cardiovascular system	0.711592736821994	2381	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	mental or behavioural disorder	0.710887433093737	2921	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	mental or behavioural disorder	0.710887433093737	2921	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	mental or behavioural disorder	0.710887433093737	2921	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	mental or behavioural disorder	0.710887433093737	2921	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	mental or behavioural disorder	0.710887433093737	2921	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	mental or behavioural disorder	0.710887433093737	2921	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Tourette syndrome	0.710541683908988	86	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Tourette syndrome	0.710541683908988	86	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Tourette syndrome	0.710541683908988	86	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Tourette syndrome	0.710541683908988	86	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Tourette syndrome	0.710541683908988	86	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Tourette syndrome	0.710541683908988	86	psychiatricDisorder
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	genetic disorder	0.710261598890103	693	geneticDisorder
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	targetBased	148480	6428	isolated congenital digital clubbing	0.710106043082438	116	muculoEskeletalConnective
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	Waardenburg syndrome	0.710068003690276	557	visualSystem
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	Waardenburg syndrome	0.710068003690276	557	visualSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	non-small cell lung carcinoma	0.709956252910777	4899	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	non-small cell lung carcinoma	0.709956252910777	4899	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	non-small cell lung carcinoma	0.709956252910777	4899	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	non-small cell lung carcinoma	0.709956252910777	4899	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	non-small cell lung carcinoma	0.709956252910777	4899	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	glioblastoma multiforme	0.709913256686522	2001	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	glioblastoma multiforme	0.709913256686522	2001	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	glioblastoma multiforme	0.709913256686522	2001	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	glioblastoma multiforme	0.709913256686522	2001	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	glioblastoma multiforme	0.709913256686522	2001	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	attention deficit hyperactivity disorder	0.709461505766322	1824	psychiatricDisorder
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	high density lipoprotein cholesterol measurement	0.709062972457657	42	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	high density lipoprotein cholesterol measurement	0.709062972457657	42	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	high density lipoprotein cholesterol measurement	0.709062972457657	42	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	high density lipoprotein cholesterol measurement	0.709062972457657	42	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	high density lipoprotein cholesterol measurement	0.709062972457657	42	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	high density lipoprotein cholesterol measurement	0.709062972457657	42	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	anthropometric measurement	0.708890420062797	443	otherPhenotypes
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	anthropometric measurement	0.708890420062797	443	otherPhenotypes
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	head and neck squamous cell carcinoma	0.708595202152874	261	cancer
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	targetBased	104728	4230	epilepsy	0.708489341786052	1893	nervousSystem
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	382	familial idiopathic steroid-resistant nephrotic syndrome	0.707847255095907	233	urinarySystem
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	3253	familial idiopathic steroid-resistant nephrotic syndrome	0.707847255095907	233	urinarySystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	myelofibrosis	0.707709957175985	1089	muculoEskeletalConnective
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	renal cell carcinoma	0.707437226974782	676	cancer
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	melanoma	0.707371985908243	295	cancer
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	targetBased	217454	1142	chronic granulomatous disease	0.707233849788776	336	immune
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	targetBased	73174	1034	eosinophil percentage of leukocytes	0.706952569843882	27	hematologic
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	hereditary neoplastic syndrome	0.706743784625669	6520	cancer
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	targetBased	338328	2501	polydactyly of a biphalangeal thumb	0.706647047561123	14	muculoEskeletalConnective
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	genetic disorder	0.706313571733555	1011	geneticDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	cancer	0.705430116689074	449	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	cancer	0.705430116689074	449	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	glioma susceptibility 1	0.705073058362988	80	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	glioma susceptibility 1	0.705073058362988	80	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	glioma susceptibility 1	0.705073058362988	80	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	glioma susceptibility 1	0.705073058362988	80	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	glioma susceptibility 1	0.705073058362988	80	geneticDisorder
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	Noonan syndrome and Noonan-related syndrome	0.704710908817553	459	muculoEskeletalConnective
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	targetBased	362274	1085	hearing loss, autosomal recessive	0.704448220309956	103	nervousSystem
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	venous thromboembolism	0.704341553035662	518	cardioVascular
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	inflammatory bowel disease	0.703692814590368	1872	immune
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	rasopathy	0.703145113650579	518	geneticDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	depressive disorder	0.702767776105905	257	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	depressive disorder	0.702767776105905	257	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	depressive disorder	0.702767776105905	257	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	depressive disorder	0.702767776105905	257	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	depressive disorder	0.702767776105905	257	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	depressive disorder	0.702767776105905	257	psychiatricDisorder
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	targetBased	194152	1342	Leigh syndrome	0.702759335081669	123	metabolicEndocrine
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	Angiofibroma	0.702187728399871	38	cancer
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	autoinflammatory syndrome	0.702039458685415	1491	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter	FXN	targetBased	356160	1985	neurodegenerative disease	0.701945822331272	694	nervousSystem
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	Waardenburg syndrome type 2	0.701605857510609	495	visualSystem
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	Waardenburg syndrome type 2	0.701605857510609	495	visualSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	autism spectrum disorder	0.701153255351398	112	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	autism spectrum disorder	0.701153255351398	112	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	autism spectrum disorder	0.701153255351398	112	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	autism spectrum disorder	0.701153255351398	112	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	autism spectrum disorder	0.701153255351398	112	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	autism spectrum disorder	0.701153255351398	112	psychiatricDisorder
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	severe combined immunodeficiency	0.700962625675913	816	immune
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	squamous cell lung carcinoma	0.700426818850629	89	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	squamous cell lung carcinoma	0.700426818850629	89	cancer
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	epilepsy	0.700209149187544	307	nervousSystem
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	familial amyotrophic lateral sclerosis	0.699636907731946	319	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	Familial short QT syndrome	0.699555539533156	30	cardioVascular
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	nasopharyngeal neoplasm	0.699511170028026	49	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	nasopharyngeal neoplasm	0.699511170028026	49	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	nasopharyngeal neoplasm	0.699511170028026	49	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	nasopharyngeal neoplasm	0.699511170028026	49	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	nasopharyngeal neoplasm	0.699511170028026	49	cancer
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	46,XY disorder of sex development	0.697883070713665	226	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	46,XY disorder of sex development	0.697883070713665	226	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast adenocarcinoma	0.696683621141791	918	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast adenocarcinoma	0.696683621141791	918	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	gastric cancer	0.696672156439903	159	cancer
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	complex neurodevelopmental disorder	0.696313309749674	190	nervousSystem
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	dilated cardiomyopathy	0.696018079292442	92	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	dilated cardiomyopathy	0.696018079292442	92	muculoEskeletalConnective
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	major depressive disorder	0.695750938597305	389	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	major depressive disorder	0.695750938597305	389	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	non-Hodgkins lymphoma	0.695708969907574	1850	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	non-Hodgkins lymphoma	0.695708969907574	1850	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	non-Hodgkins lymphoma	0.695708969907574	1850	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	non-Hodgkins lymphoma	0.695708969907574	1850	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	non-Hodgkins lymphoma	0.695708969907574	1850	cancer
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	cancer	0.695643178729002	130	cancer
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	cancer	0.695643178729002	130	cancer
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	body weights and measures	0.694882527663013	216	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	body weights and measures	0.694882527663013	216	metabolicEndocrine
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	hereditary neoplastic syndrome	0.694777963492794	4859	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	epilepsy	0.694388489028926	1078	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	epilepsy	0.694388489028926	1078	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	genetic disorder	0.694188075467308	429	geneticDisorder
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	genetic disorder	0.694188075467308	429	geneticDisorder
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	genetic disorder	0.694188075467308	429	geneticDisorder
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	obesity	0.693615894867754	71	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	obesity	0.693615894867754	71	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	obesity	0.693615894867754	71	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	obesity	0.693615894867754	71	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	obesity	0.693615894867754	71	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	obesity	0.693615894867754	71	metabolicEndocrine
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	chronic obstructive pulmonary disease	0.693504127735036	1633	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	major depressive disorder	0.693202281364196	303	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	basal cell carcinoma	0.693049628473067	401	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	basal cell carcinoma	0.693049628473067	401	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	basal cell carcinoma	0.693049628473067	401	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	basal cell carcinoma	0.693049628473067	401	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	basal cell carcinoma	0.693049628473067	401	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	ulcerative colitis	0.692888906416013	432	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	ulcerative colitis	0.692888906416013	432	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	ulcerative colitis	0.692888906416013	432	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	ulcerative colitis	0.692888906416013	432	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	ulcerative colitis	0.692888906416013	432	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	ulcerative colitis	0.692888906416013	432	immune
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	disorder of glycogen metabolism	0.692888266555033	1495	metabolicEndocrine
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	disorder of glycogen metabolism	0.692888266555033	1495	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lymphoma	0.692516703724469	2300	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lymphoma	0.692516703724469	2300	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lymphoma	0.692516703724469	2300	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lymphoma	0.692516703724469	2300	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lymphoma	0.692516703724469	2300	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	colorectal cancer	0.692377036344037	58	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	squamous cell carcinoma	0.691147782991076	5273	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	squamous cell carcinoma	0.691147782991076	5273	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	squamous cell carcinoma	0.691147782991076	5273	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	squamous cell carcinoma	0.691147782991076	5273	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	squamous cell carcinoma	0.691147782991076	5273	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	polycystic ovary syndrome	0.691019361968048	297	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	polycystic ovary syndrome	0.691019361968048	297	reproductiveSystem
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	targetBased	368927	3838	genetic disorder	0.690909342585011	550	geneticDisorder
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	psychosis	0.690741306707689	392	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	psychosis	0.690741306707689	392	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	psychosis	0.690741306707689	392	psychiatricDisorder
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	neurodegenerative disease	0.690582730159146	1125	nervousSystem
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	multiple sclerosis	0.690530836424373	76	immune
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	familial pancreatic carcinoma	0.690429985228812	80	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	familial pancreatic carcinoma	0.690429985228812	80	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	familial pancreatic carcinoma	0.690429985228812	80	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	familial pancreatic carcinoma	0.690429985228812	80	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	familial pancreatic carcinoma	0.690429985228812	80	cancer
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	breast cancer	0.690361420729005	871	cancer
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	Atypical progressive supranuclear palsy	0.689294807696597	33	psychiatricDisorder
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	Atypical progressive supranuclear palsy	0.689294807696597	33	psychiatricDisorder
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	Atypical progressive supranuclear palsy	0.689294807696597	33	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	rhabdomyosarcoma	0.688273946449154	275	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	rhabdomyosarcoma	0.688273946449154	275	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	rhabdomyosarcoma	0.688273946449154	275	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	rhabdomyosarcoma	0.688273946449154	275	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	rhabdomyosarcoma	0.688273946449154	275	cancer
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	clear cell renal carcinoma	0.687745221766357	15	cancer
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	targetBased	324747	7988	psoriasis	0.687648482714935	222	immune
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	targetBased	326022	1334	rheumatoid arthritis	0.687131196796391	53	immune
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	migraine disorder	0.687070847503308	335	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	breast cancer	0.686684940581599	2847	cancer
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	Inherited cancer-predisposing syndrome	0.685854292102405	4835	geneticDisorder
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	liver disease	0.685650937463137	671	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	liver disease	0.685650937463137	671	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	liver disease	0.685650937463137	671	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	liver disease	0.685650937463137	671	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	liver disease	0.685650937463137	671	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	liver disease	0.685650937463137	671	metabolicEndocrine
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	neoplasm	0.685425205092243	6252	cancer
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	targetBased	400814	482	genetic disorder	0.685251079386375	703	geneticDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Parkinson disease	0.685174950061005	842	nervousSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Parkinson disease	0.685174950061005	842	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Parkinson disease	0.685174950061005	842	nervousSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Parkinson disease	0.685174950061005	842	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Parkinson disease	0.685174950061005	842	nervousSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Parkinson disease	0.685174950061005	842	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	schizophrenia	0.684251885809616	2878	psychiatricDisorder
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	major depressive disorder	0.684232928654062	180	psychiatricDisorder
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	osteoporosis	0.683681888899659	113	muculoEskeletalConnective
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	schizophrenia	0.683528594348945	696	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	schizophrenia	0.683528594348945	696	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	Ventricular arrhythmia	0.683101878753051	162	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	Ventricular arrhythmia	0.683101878753051	162	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	Ventricular arrhythmia	0.683101878753051	162	cardioVascular
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	genetic disorder	0.682760822197724	7473	geneticDisorder
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	genetic disorder	0.682760822197724	7473	geneticDisorder
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	diabetes mellitus	0.682345221976707	3901	metabolicEndocrine
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	diabetes mellitus	0.682345221976707	3901	metabolicEndocrine
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	psoriasis	0.682247545111168	296	immune
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	colorectal cancer	0.682157692026859	193	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	breast carcinoma	0.682065381231255	257	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	COVID-19	0.681978936473465	329	infective
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	schizophrenia	0.681178593375036	351	psychiatricDisorder
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	lymphoid neoplasm	0.681165036449891	1079	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	chronic kidney disease	0.680879493325072	458	urinarySystem
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	reticulocyte measurement	0.680245557576501	30	hematologic
qHTS Assay for Inhibitors of GCN5L2	KAT2A	targetBased	381571	792	cancer	0.679538557997074	140	cancer
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Hereditary cerebral hemorrhage with amyloidosis, Dutch type	0.678931554588663	12	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Hereditary cerebral hemorrhage with amyloidosis, Dutch type	0.678931554588663	12	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Hereditary cerebral hemorrhage with amyloidosis, Dutch type	0.678931554588663	12	nervousSystem
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pancreatic adenocarcinoma	0.678833343678363	36	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pancreatic adenocarcinoma	0.678833343678363	36	cancer
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Hereditary cerebral hemorrhage with amyloidosis, Piedmont type	0.678595966853222	8	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Hereditary cerebral hemorrhage with amyloidosis, Piedmont type	0.678595966853222	8	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Hereditary cerebral hemorrhage with amyloidosis, Piedmont type	0.678595966853222	8	nervousSystem
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Hereditary cerebral hemorrhage with amyloidosis, Iowa type	0.678595966853222	8	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Hereditary cerebral hemorrhage with amyloidosis, Iowa type	0.678595966853222	8	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Hereditary cerebral hemorrhage with amyloidosis, Iowa type	0.678595966853222	8	nervousSystem
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Hereditary cerebral hemorrhage with amyloidosis, Italian type	0.678595966853222	8	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Hereditary cerebral hemorrhage with amyloidosis, Italian type	0.678595966853222	8	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Hereditary cerebral hemorrhage with amyloidosis, Italian type	0.678595966853222	8	nervousSystem
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Hereditary cerebral hemorrhage with amyloidosis, Flemish type	0.678595966853222	8	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Hereditary cerebral hemorrhage with amyloidosis, Flemish type	0.678595966853222	8	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Hereditary cerebral hemorrhage with amyloidosis, Flemish type	0.678595966853222	8	nervousSystem
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Hereditary cerebral hemorrhage with amyloidosis, Arctic type	0.678595966853222	8	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Hereditary cerebral hemorrhage with amyloidosis, Arctic type	0.678595966853222	8	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Hereditary cerebral hemorrhage with amyloidosis, Arctic type	0.678595966853222	8	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	breast neoplasm	0.678524544348591	1359	cancer
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	hereditary sensory and autonomic neuropathy type 1	0.678383562696946	2457	metabolicEndocrine
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	mental or behavioural disorder	0.678096812690304	635	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	mental or behavioural disorder	0.678096812690304	635	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	mental or behavioural disorder	0.678096812690304	635	psychiatricDisorder
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	diffuse large B-cell lymphoma	0.677996101121258	565	cancer
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	familial hypertrophic cardiomyopathy	0.677983200454697	73	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	familial hypertrophic cardiomyopathy	0.677983200454697	73	muculoEskeletalConnective
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	myelodysplastic syndrome	0.677763361237735	571	cancer
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	microphthalmia, isolated, with coloboma 7	0.677759312474563	21	geneticDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	anxiety disorder	0.677507356279003	380	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	anxiety disorder	0.677507356279003	380	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	bone osteosarcoma	0.677273520190282	56	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	bone osteosarcoma	0.677273520190282	56	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	bone osteosarcoma	0.677273520190282	56	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	bone osteosarcoma	0.677273520190282	56	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	bone osteosarcoma	0.677273520190282	56	cancer
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	cancer	0.677194877664189	166	cancer
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	multiple myeloma	0.676525185755556	1089	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	drug dependence	0.676418660162289	657	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	drug dependence	0.676418660162289	657	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	psychosis	0.676238391345276	1279	psychiatricDisorder
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	hypothyroidism	0.676224852086246	502	metabolicEndocrine
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Intellectual disability	0.675838335815259	63	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	autism	0.675593943440856	261	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	autism	0.675593943440856	261	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	autism	0.675593943440856	261	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	autism	0.675593943440856	261	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	autism	0.675593943440856	261	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	autism	0.675593943440856	261	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Abnormality of the cardiovascular system	0.675190267140752	1550	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Abnormality of the cardiovascular system	0.675190267140752	1550	cardioVascular
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	pain	0.675089080796179	1370	nervousSystem
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	neurodegenerative disease	0.674892905265714	1044	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	mental or behavioural disorder	0.674689655936239	2309	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	hypertension	0.674429375550638	181	cardioVascular
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	endometrial cancer	0.674111345989311	123	cancer
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	disorder of sexual differentiation	0.673726545644413	377	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	disorder of sexual differentiation	0.673726545644413	377	reproductiveSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	non-small cell lung carcinoma	0.673534018217188	1970	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	infertility	0.673498662347584	318	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	infertility	0.673498662347584	318	reproductiveSystem
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	genetic disorder	0.673477919010773	546	geneticDisorder
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	genetic disorder	0.673477919010773	546	geneticDisorder
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	genetic disorder	0.673477919010773	546	geneticDisorder
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	genetic disorder	0.673477919010773	546	geneticDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	unipolar depression	0.673413511389257	303	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	bipolar disorder	0.673380276889437	1227	psychiatricDisorder
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	ankylosing spondylitis	0.673282147689306	33	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	alcohol dependence	0.673240401913081	285	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	alcohol dependence	0.673240401913081	285	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lymphoid neoplasm	0.673172901271881	2270	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lymphoid neoplasm	0.673172901271881	2270	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lymphoid neoplasm	0.673172901271881	2270	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lymphoid neoplasm	0.673172901271881	2270	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lymphoid neoplasm	0.673172901271881	2270	cancer
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	atrial fibrillation	0.673166313522287	170	cardioVascular
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	Progressive supranuclear palsy - parkinsonism	0.673064875545468	26	psychiatricDisorder
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	Progressive supranuclear palsy - parkinsonism	0.673064875545468	26	psychiatricDisorder
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	Progressive supranuclear palsy - parkinsonism	0.673064875545468	26	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	obsessive-compulsive disorder	0.672861113899014	39	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	obsessive-compulsive disorder	0.672861113899014	39	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	obsessive-compulsive disorder	0.672861113899014	39	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	obsessive-compulsive disorder	0.672861113899014	39	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	obsessive-compulsive disorder	0.672861113899014	39	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	obsessive-compulsive disorder	0.672861113899014	39	psychiatricDisorder
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	reticulocyte count	0.672855333065367	30	hematologic
qHTS for Inhibitors of Glutaminase (GLS)	GLS	targetBased	405291	844	global developmental delay, progressive ataxia, and elevated glutamine	0.672693441898238	14	geneticDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	colorectal adenocarcinoma	0.672688746591176	19	cancer
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	parathyroid disease	0.672577744708436	1855	metabolicEndocrine
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	asthma	0.672561601153222	1631	respiratory
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	restrictive cardiomyopathy	0.672321932673797	120	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	restrictive cardiomyopathy	0.672321932673797	120	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	depressive disorder	0.671961291843088	359	psychiatricDisorder
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	acute lymphoblastic leukemia	0.671778593539966	457	cancer
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	targetBased	369953	1241	neurodegenerative disease	0.671502953160591	26	nervousSystem
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	Goldmann-Favre syndrome	0.671491858896114	78	visualSystem
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	Goldmann-Favre syndrome	0.671491858896114	78	visualSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Uterine Carcinosarcoma	0.671124202650939	228	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Uterine Carcinosarcoma	0.671124202650939	228	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Uterine Carcinosarcoma	0.671124202650939	228	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Uterine Carcinosarcoma	0.671124202650939	228	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Uterine Carcinosarcoma	0.671124202650939	228	cancer
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	Parkinson disease	0.670877516160389	746	nervousSystem
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	Parkinson disease	0.670877516160389	746	nervousSystem
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	Parkinson disease	0.670877516160389	746	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	myocardial infarction	0.670611093215975	227	cardioVascular
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	alcohol dependence	0.670607044489001	198	psychiatricDisorder
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	atrial fibrillation	0.670494073297023	97	cardioVascular
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	neutrophil count	0.670237943777037	29	hematologic
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	neutrophil count	0.670237943777037	29	hematologic
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	Sleep Disorder	0.670129565809086	83	psychiatricDisorder
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	familial atrial myxoma	0.669881265397799	39	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	cancer	0.669757231333485	16724	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	cancer	0.669757231333485	16724	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	hypogonadism	0.669694218698102	233	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	hypogonadism	0.669694218698102	233	reproductiveSystem
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	neoplasm	0.669681742135009	1140	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	pain	0.669376737588158	4676	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	pain	0.669376737588158	4676	nervousSystem
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	bipolar disorder	0.669375228835304	280	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	bipolar disorder	0.669375228835304	280	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	bipolar disorder	0.669375228835304	280	psychiatricDisorder
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	eosinophil count	0.669089535404003	25	hematologic
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	eosinophil count	0.669089535404003	25	hematologic
Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity	FGF22_inhibitors	targetBased	339650	5128	cancer	0.668938724864321	38	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	hypertension	0.668853049947844	367	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	neoplasm	0.668792435509745	475	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	neoplasm	0.668792435509745	475	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	genetic disorder	0.668213927029209	911	geneticDisorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	open-angle glaucoma	0.668093484041488	190	visualSystem
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid neoplasm	0.667632909500217	246	cancer
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid neoplasm	0.667632909500217	246	cancer
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	thyroid neoplasm	0.667632909500217	246	cancer
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	thyroid neoplasm	0.667632909500217	246	cancer
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	opioid dependence	0.667574265772021	380	psychiatricDisorder
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	0.667521194648004	21	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	malignant glioma	0.667419094877046	1888	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	malignant glioma	0.667419094877046	1888	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	malignant glioma	0.667419094877046	1888	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	malignant glioma	0.667419094877046	1888	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	malignant glioma	0.667419094877046	1888	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	glaucoma	0.667126406812208	214	visualSystem
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	type 1 diabetes mellitus	0.667118677384461	374	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	type 1 diabetes mellitus	0.667118677384461	374	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	type 1 diabetes mellitus	0.667118677384461	374	metabolicEndocrine
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	Microcephaly	0.667110376709887	110	otherPhenotypes
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	drug dependence	0.667078041570145	390	psychiatricDisorder
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	depressive disorder	0.667053686218244	313	psychiatricDisorder
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	genetic disorder	0.666818759871887	924	geneticDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	autism	0.666809464893294	263	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	rheumatoid arthritis	0.666736202498445	133	immune
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	Headache	0.666642011690004	210	otherPhenotypes
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	gastrointestinal stromal tumor	0.666559986194665	320	cancer
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	appendicular lean mass	0.666466888144041	17	otherPhenotypes
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	appendicular lean mass	0.666466888144041	17	otherPhenotypes
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	coronary artery disease	0.666430352142117	442	cardioVascular
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	Fever	0.666308468235629	115	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Chronic pain	0.666248934967793	527	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Chronic pain	0.666248934967793	527	nervousSystem
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	targetBased	205582	727	bipolar disorder	0.666223962413413	179	psychiatricDisorder
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	Atypical behavior	0.666103237753127	22	psychiatricDisorder
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	Atypical behavior	0.666103237753127	22	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian epithelial tumor	0.665791319751206	7078	cancer
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	obesity	0.665388121938735	202	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	obesity	0.665388121938735	202	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	obesity	0.665388121938735	202	metabolicEndocrine
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	monocyte count	0.665324642173597	28	hematologic
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	monocyte count	0.665324642173597	28	hematologic
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	schizoaffective disorder	0.665187702963058	315	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	schizoaffective disorder	0.665187702963058	315	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	schizoaffective disorder	0.665187702963058	315	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	schizoaffective disorder	0.665187702963058	315	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	schizoaffective disorder	0.665187702963058	315	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	schizoaffective disorder	0.665187702963058	315	psychiatricDisorder
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	Prinzmetal's angina	0.664977476876164	306	cardioVascular
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	multiple sclerosis	0.664837114041353	511	immune
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	alcohol dependence	0.664778854425383	200	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	alcohol dependence	0.664778854425383	200	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	alcohol dependence	0.664778854425383	200	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	alcohol dependence	0.664778854425383	200	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	alcohol dependence	0.664778854425383	200	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	alcohol dependence	0.664778854425383	200	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	schizoaffective disorder	0.664704658955117	297	psychiatricDisorder
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	genetic disorder	0.664619035583931	175	geneticDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	bipolar disorder	0.664540949556231	143	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	bipolar disorder	0.664540949556231	143	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	migraine disorder	0.664498935640487	95	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	migraine disorder	0.664498935640487	95	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Diarrhea	0.664483849517651	134	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Diarrhea	0.664483849517651	134	gastroIntestinal
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	pancreatic neoplasm	0.664254622474054	127	cancer
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	targetBased	361330	651	hypothyroidism, congenital, nongoitrous, 7	0.664140119751598	12	geneticDisorder
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	targetBased	361330	2424	hypothyroidism, congenital, nongoitrous, 7	0.664140119751598	12	geneticDisorder
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	targetBased	315412	318	bipolar disorder	0.664011412408151	167	psychiatricDisorder
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	genetic disorder	0.663829323589053	5730	geneticDisorder
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	HIV infection	0.663611509897898	18	infective
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	depressive disorder	0.663494633120395	264	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	depressive disorder	0.663494633120395	264	psychiatricDisorder
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	cancer	0.663322592053893	1001	cancer
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	unipolar depression	0.663206489836322	246	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	unipolar depression	0.663206489836322	246	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	bipolar I disorder	0.663161506636499	119	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	bipolar I disorder	0.663161506636499	119	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	bipolar I disorder	0.663161506636499	119	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	bipolar I disorder	0.663161506636499	119	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	bipolar I disorder	0.663161506636499	119	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	bipolar I disorder	0.663161506636499	119	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	urinary bladder carcinoma	0.663159024758506	62	cancer
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	migraine disorder	0.662916077246258	83	nervousSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	pain	0.662857415411265	216	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	chronic obstructive pulmonary disease	0.662832074953336	287	respiratory
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	chronic obstructive pulmonary disease	0.662832074953336	287	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	chronic obstructive pulmonary disease	0.662832074953336	287	respiratory
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	chronic obstructive pulmonary disease	0.662832074953336	287	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	chronic obstructive pulmonary disease	0.662832074953336	287	respiratory
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Malignant Pancreatic Neoplasm	0.662742907080579	519	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Malignant Pancreatic Neoplasm	0.662742907080579	519	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Malignant Pancreatic Neoplasm	0.662742907080579	519	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Malignant Pancreatic Neoplasm	0.662742907080579	519	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Malignant Pancreatic Neoplasm	0.662742907080579	519	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	menopause	0.662677082846212	180	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	menopause	0.662677082846212	180	reproductiveSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Constipation	0.662629221068349	183	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Constipation	0.662629221068349	183	otherPhenotypes
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	Back pain	0.662533243340019	73	nervousSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	Parkinson disease	0.662457377099708	142	nervousSystem
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	angina pectoris	0.662387380315676	134	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	bipolar I disorder	0.662096838691452	110	psychiatricDisorder
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	Bilateral tonic-clonic seizure	0.662025642890829	123	otherPhenotypes
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	osteoporosis	0.661909666301374	61	muculoEskeletalConnective
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	COVID-19	0.661807962739989	108	infective
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lip and oral cavity carcinoma	0.661600167112357	634	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lip and oral cavity carcinoma	0.661600167112357	634	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lip and oral cavity carcinoma	0.661600167112357	634	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lip and oral cavity carcinoma	0.661600167112357	634	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lip and oral cavity carcinoma	0.661600167112357	634	cancer
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	ovarian carcinoma	0.661454282948221	250	cancer
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	lymphoma	0.661365156411374	554	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colon carcinoma	0.661335987264173	950	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colon carcinoma	0.661335987264173	950	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colon carcinoma	0.661335987264173	950	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colon carcinoma	0.661335987264173	950	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colon carcinoma	0.661335987264173	950	cancer
Glucocerebrosidase	GBA1	targetBased	48118	549	Lewy body dementia	0.661047543540739	344	psychiatricDisorder
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	genetic disorder	0.660992694667135	3455	geneticDisorder
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	cancer	0.660773367238811	1157	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	influenza	0.660725338872141	104	infective
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	primary ovarian insufficiency	0.660662625776492	198	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	primary ovarian insufficiency	0.660662625776492	198	reproductiveSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	emphysema	0.660629027927607	50	respiratory
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	heart failure	0.660625331502392	81	cardioVascular
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	common cold	0.660607902407363	99	respiratory
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	depressive disorder	0.660408365269154	68	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	depressive disorder	0.660408365269154	68	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	depressive disorder	0.660408365269154	68	psychiatricDisorder
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	venous thromboembolism	0.660405165989325	101	cardioVascular
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	infection	0.660276964107463	81	infective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Agitation	0.660174078598244	98	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Agitation	0.660145911506038	99	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Agitation	0.660145911506038	99	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Agitation	0.660145911506038	99	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Agitation	0.660145911506038	99	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Agitation	0.660145911506038	99	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Agitation	0.660145911506038	99	psychiatricDisorder
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	schizoaffective disorder	0.659694094276201	74	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	schizoaffective disorder	0.659694094276201	74	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	schizoaffective disorder	0.659694094276201	74	psychiatricDisorder
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	myocardial infarction	0.659633610265158	76	cardioVascular
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	opioid use disorder	0.659567124251188	153	psychiatricDisorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	pain	0.659538183102147	110	nervousSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	depressive disorder	0.659245989128873	186	psychiatricDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	acne	0.659027038178219	60	dermatology
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	acne	0.659027038178219	60	dermatology
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Low back pain	0.658909432708107	138	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Low back pain	0.658909432708107	138	nervousSystem
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	osteoporosis	0.658783124032757	133	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	endocrine neoplasm	0.658688749369898	83	cancer
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	targetBased	194152	1342	genetic disorder	0.658402703233372	730	geneticDisorder
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	colorectal adenocarcinoma	0.658346544341343	17	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	obesity	0.658323474596516	83	metabolicEndocrine
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	restless legs syndrome	0.658301784622236	117	nervousSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	restless legs syndrome	0.658301784622236	117	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	restless legs syndrome	0.658301784622236	117	nervousSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	restless legs syndrome	0.658301784622236	117	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	restless legs syndrome	0.658301784622236	117	nervousSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	restless legs syndrome	0.658301784622236	117	nervousSystem
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	Intellectual disability	0.658125365429922	17	nervousSystem
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	Intellectual disability	0.658125365429922	17	nervousSystem
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	restless legs syndrome	0.658022198908649	108	nervousSystem
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	restless legs syndrome	0.658022198908649	108	nervousSystem
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	restless legs syndrome	0.658022198908649	108	nervousSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	Alzheimer disease	0.657913251023908	81	nervousSystem
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	neoplasm	0.657839573780106	4779	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	male breast carcinoma	0.657373889939552	47	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	male breast carcinoma	0.657373889939552	47	cancer
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	multiple sclerosis	0.657352493094362	83	immune
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	multiple sclerosis	0.657352493094362	83	immune
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	osteoarthritis	0.657280791256667	97	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	osteoarthritis	0.657280791256667	97	muculoEskeletalConnective
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	hereditary neoplastic syndrome	0.657217545791875	14264	cancer
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	drug use measurement	0.656828814690532	9	psychiatricDisorder
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	drug use measurement	0.656828814690532	9	psychiatricDisorder
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	drug use measurement	0.656828814690532	9	psychiatricDisorder
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	drug use measurement	0.656828814690532	9	psychiatricDisorder
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	postpartum hemorrhage	0.656394447196096	89	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	migraine disorder	0.656348969587944	101	nervousSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	migraine disorder	0.656348969587944	101	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	migraine disorder	0.656348969587944	101	nervousSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	migraine disorder	0.656348969587944	101	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	migraine disorder	0.656348969587944	101	nervousSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	migraine disorder	0.656348969587944	101	nervousSystem
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	Venous thrombosis	0.656248273264026	522	hematologic
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	atrial fibrillation	0.656155319809075	74	cardioVascular
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	relapsing-remitting multiple sclerosis	0.655930591244198	144	immune
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	ulcerative colitis	0.655877863539481	66	immune
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	Agitation	0.655849552139749	60	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	Agitation	0.655849552139749	60	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	Agitation	0.655849552139749	60	psychiatricDisorder
Allosteric Modulators of D1 Receptors: Primary Screen	D1	targetBased	57705	3413	hemorrhage	0.655846725244634	54	hematologic
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	targetBased	361330	3713	hemorrhage	0.655846725244634	54	hematologic
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	targetBased	355805	11440	hemorrhage	0.655846725244634	54	hematologic
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	lymphoid leukemia	0.655837105084316	996	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Premature ovarian insufficiency	0.655812081846905	56	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Premature ovarian insufficiency	0.655812081846905	56	reproductiveSystem
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	non-small cell lung carcinoma	0.655334675854879	718	cancer
Primary HTS Assay for S1P3 Antagonists	S1PR3	targetBased	169141	462	multiple sclerosis	0.655299992173261	82	immune
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	psoriasis vulgaris	0.655284149899379	86	immune
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	neoplasm	0.655184857451428	8177	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	acute lymphoblastic leukemia	0.655164699314168	219	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	acute lymphoblastic leukemia	0.655097189866326	1529	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	acute lymphoblastic leukemia	0.655097189866326	1529	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	acute lymphoblastic leukemia	0.655097189866326	1529	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	acute lymphoblastic leukemia	0.655097189866326	1529	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	acute lymphoblastic leukemia	0.655097189866326	1529	cancer
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	genetic disorder	0.655049959767248	1196	geneticDisorder
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	essential hypertension	0.655030426761749	86	cardioVascular
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	large congenital melanocytic nevus	0.654965888031878	32	cancer
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	autism	0.654787051710058	59	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	autism	0.654787051710058	59	psychiatricDisorder
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	major depressive disorder	0.654704899119961	125	psychiatricDisorder
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	apolipoprotein A 1 measurement	0.654585106434475	18	otherPhenotypes
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	apolipoprotein A 1 measurement	0.654585106434475	18	otherPhenotypes
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lymphoma	0.654474277762646	1237	cancer
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	Abnormality of the skeletal system	0.654264744820366	73	muculoEskeletalConnective
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	Abnormality of the skeletal system	0.654264744820366	73	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	neuropathic pain	0.654073840918953	89	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	neuropathic pain	0.654073840918953	89	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Myopia	0.653717988912803	71	visualSystem
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Myopia	0.653717988912803	71	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Myopia	0.653717988912803	71	visualSystem
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Myopia	0.653717988912803	71	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Myopia	0.653717988912803	71	visualSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	movement disorder	0.653671582289342	258	nervousSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	movement disorder	0.653671582289342	258	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	movement disorder	0.653671582289342	258	nervousSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	movement disorder	0.653671582289342	258	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	movement disorder	0.653671582289342	258	nervousSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	movement disorder	0.653671582289342	258	nervousSystem
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	Thrombocytopenia	0.653647579537218	492	hematologic
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	multiple sclerosis	0.653518109271019	73	immune
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	multiple sclerosis	0.653518109271019	73	immune
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	cancer	0.653448141858887	163	cancer
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	adrenal cortex carcinoma	0.653106561534341	90	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	prophylactic surgery	0.652727389691613	42	otherPhenotypes
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	neurodegenerative disease	0.652444219623287	429	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	neurodegenerative disease	0.652444219623287	429	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	neurodegenerative disease	0.652444219623287	429	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	neurodegenerative disease	0.652444219623287	429	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	neurodegenerative disease	0.652444219623287	429	nervousSystem
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	unipolar depression	0.652139811175138	47	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	unipolar depression	0.652139811175138	47	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	unipolar depression	0.652139811175138	47	psychiatricDisorder
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	Hypocalcemia	0.652037636559681	45	otherPhenotypes
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	diffuse large B-cell lymphoma	0.651733669028007	342	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	congestive heart failure	0.651600017001438	50	cardioVascular
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	postmenopausal osteoporosis	0.651434014354781	44	muculoEskeletalConnective
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	Hodgkins lymphoma	0.651414538506129	246	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	arthritis	0.651046057163841	78	muculoEskeletalConnective
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	chronic bronchitis	0.650991429284571	41	respiratory
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	metabolic disease	0.650932856407589	2914	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	metabolic disease	0.650932856407589	2914	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	metabolic disease	0.650932856407589	2914	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	metabolic disease	0.650932856407589	2914	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	metabolic disease	0.650932856407589	2914	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	metabolic disease	0.650932856407589	2914	metabolicEndocrine
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	genetic disorder	0.650930856963825	1140	geneticDisorder
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	prostate cancer	0.650787355768156	872	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	gout	0.650695824149268	48	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Tourette syndrome	0.650624549944278	33	psychiatricDisorder
qHTS assay for inhibitors of human lactate dehydrogenase	lactateDehydrogenaseInhibitors	targetBased	476056	732	disorder of glycogen metabolism	0.650586578528587	90	metabolicEndocrine
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	postmenopausal osteoporosis	0.650220587016059	56	muculoEskeletalConnective
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	telomere length	0.650168587201349	33	otherPhenotypes
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	genetic disorder	0.649725346159822	348	geneticDisorder
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	narcolepsy-cataplexy syndrome	0.649086161600151	35	psychiatricDisorder
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	coronary artery disease	0.649046640119132	118	cardioVascular
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	neoplasm	0.649002328313517	9186	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	targetBased	369953	2353	HIV infection	0.648992922909193	91	infective
HTS for developing T Cell Immune Modulators	ITGAL	targetBased	326271	221	dry eye syndrome	0.648755531974305	36	visualSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	alcohol dependence	0.648735442562118	57	psychiatricDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	prostate carcinoma	0.648714094744205	50	cancer
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	targetBased	326024	5748	insomnia	0.648644519344265	89	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	targetBased	326024	1387	insomnia	0.648644519344265	89	psychiatricDisorder
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	genetic disorder	0.648602087011644	3850	geneticDisorder
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	genetic disorder	0.648602087011644	3850	geneticDisorder
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	non-small cell lung carcinoma	0.648573088621513	308	cancer
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	hemorrhage	0.648280443805337	36	hematologic
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	Chronic pain	0.648225361607717	53	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	cancer pain	0.647690739119118	54	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	cancer pain	0.647690739119118	54	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	sudden cardiac arrest	0.647528186233432	36	cardioVascular
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	schizoaffective disorder	0.647495263851435	45	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	schizoaffective disorder	0.647495263851435	45	psychiatricDisorder
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	combined immunodeficiency	0.647259809976761	700	immune
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	myxedema	0.647247201046324	83	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	myxedema	0.647247201046324	83	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	myxedema	0.647247201046324	83	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	myxedema	0.647247201046324	83	metabolicEndocrine
HTS for developing T Cell Immune Modulators	ITGAL	targetBased	326271	221	psoriasis	0.647172633973302	119	immune
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	movement disorder	0.647165212846683	81	nervousSystem
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	movement disorder	0.647165212846683	81	nervousSystem
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	movement disorder	0.647165212846683	81	nervousSystem
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	menopause	0.647144623444855	81	reproductiveSystem
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	Low back pain	0.647073385018578	35	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	low grade glioma	0.647024924444588	163	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	low grade glioma	0.647024924444588	163	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	low grade glioma	0.647024924444588	163	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	low grade glioma	0.647024924444588	163	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	low grade glioma	0.647024924444588	163	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Back pain	0.646964767679243	78	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Back pain	0.646964767679243	78	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	brain neoplasm	0.646414536804601	648	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	brain neoplasm	0.646414536804601	648	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	brain neoplasm	0.646414536804601	648	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	brain neoplasm	0.646414536804601	648	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	brain neoplasm	0.646414536804601	648	cancer
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	targetBased	64908	446	schizophrenia	0.646240142990496	35	psychiatricDisorder
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	targetBased	64908	641	schizophrenia	0.646240142990496	35	psychiatricDisorder
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	stroke	0.646209969421255	32	nervousSystem
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	T-B- severe combined immunodeficiency	0.646206966714383	547	immune
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	osteoarthritis	0.645932652943565	116	muculoEskeletalConnective
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	post-traumatic stress disorder	0.645823745379977	110	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	post-traumatic stress disorder	0.645823745379977	110	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	post-traumatic stress disorder	0.645823745379977	110	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	post-traumatic stress disorder	0.645823745379977	110	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	post-traumatic stress disorder	0.645823745379977	110	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	post-traumatic stress disorder	0.645823745379977	110	psychiatricDisorder
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	multiple sclerosis	0.645671851693653	110	immune
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	Dementia	0.645650315796052	30	psychiatricDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Ataxia-telangiectasia variant	0.645586906054851	11	nervousSystem
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	neoplasm	0.645516132179648	4509	cancer
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	congenital hypothyroidism	0.645401662748241	232	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	congenital hypothyroidism	0.645401662748241	232	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	congenital hypothyroidism	0.645401662748241	232	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	congenital hypothyroidism	0.645401662748241	232	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	delirium	0.645294220123001	50	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	multiple sclerosis	0.645235750885557	44	immune
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	multiple sclerosis	0.645235750885557	44	immune
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	multiple sclerosis	0.645235750885557	44	immune
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	multiple sclerosis	0.645235750885557	44	immune
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	multiple sclerosis	0.645235750885557	44	immune
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	multiple sclerosis	0.645235750885557	44	immune
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	multiple sclerosis	0.645235750885557	44	immune
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	heart failure	0.645161667574849	44	cardioVascular
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	genetic disorder	0.645081328212271	121	geneticDisorder
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	toothache	0.644988505060209	38	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	osteoarthritis, knee	0.644836374558565	48	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	osteoarthritis, knee	0.644836374558565	48	muculoEskeletalConnective
Allosteric Modulators of D1 Receptors: Primary Screen	D1	targetBased	57705	3413	Parkinson disease	0.644792569331339	158	nervousSystem
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	targetBased	361330	3713	Parkinson disease	0.644792569331339	158	nervousSystem
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	targetBased	355805	11440	Parkinson disease	0.644792569331339	158	nervousSystem
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	major depressive disorder	0.644790053219678	33	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	major depressive disorder	0.644790053219678	33	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	major depressive disorder	0.644790053219678	33	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	gastric cancer	0.644706663355619	76	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Nausea and vomiting	0.644439340477792	58	otherPhenotypes
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Nausea and vomiting	0.644439340477792	58	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Nausea and vomiting	0.644439340477792	58	otherPhenotypes
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Nausea and vomiting	0.644439340477792	58	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Nausea and vomiting	0.644439340477792	58	otherPhenotypes
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Nausea and vomiting	0.644439340477792	58	otherPhenotypes
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	phosphate measurement	0.644251002036827	30	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	post operative nausea and vomiting	0.644129386558569	38	otherPhenotypes
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	post operative nausea and vomiting	0.644129386558569	38	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	post operative nausea and vomiting	0.644129386558569	38	otherPhenotypes
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	post operative nausea and vomiting	0.644129386558569	38	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	post operative nausea and vomiting	0.644129386558569	38	otherPhenotypes
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	post operative nausea and vomiting	0.644129386558569	38	otherPhenotypes
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	ulcerative colitis	0.644099885304213	123	immune
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	delirium	0.643827981382046	48	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	delirium	0.643827981382046	48	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	delirium	0.643827981382046	48	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	delirium	0.643827981382046	48	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	delirium	0.643827981382046	48	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	delirium	0.643827981382046	48	psychiatricDisorder
Primary HTS Assay for S1P3 Antagonists	S1PR3	targetBased	169141	462	relapsing-remitting multiple sclerosis	0.643752814149123	48	immune
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	drug dependence	0.643739922579374	259	psychiatricDisorder
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	non-Hodgkins lymphoma	0.643640984649825	451	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	secondary Parkinson disease	0.643570744246353	28	metabolicEndocrine
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	postmenopausal osteoporosis	0.643509974124573	30	muculoEskeletalConnective
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	postmenopausal osteoporosis	0.643509974124573	30	muculoEskeletalConnective
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Hepatoblastoma	0.643412414649967	21	cancer
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	hyperlipidemia	0.643396782824324	27	metabolicEndocrine
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	Ocular albinism with congenital sensorineural deafness	0.643378037527545	8	metabolicEndocrine
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	Ocular albinism with congenital sensorineural deafness	0.643378037527545	8	metabolicEndocrine
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	relapsing-remitting multiple sclerosis	0.643347103603292	47	immune
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	relapsing-remitting multiple sclerosis	0.643347103603292	47	immune
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	enuresis	0.643223221917796	27	psychiatricDisorder
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	glycogen storage disease due to acid maltase deficiency, infantile onset	0.642982582442733	17	muculoEskeletalConnective
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	glycogen storage disease due to acid maltase deficiency, infantile onset	0.642982582442733	17	muculoEskeletalConnective
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	Coronary Vasospasm	0.642829168666001	119	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	malaria	0.642740677354967	196	infective
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Pleural Mesothelioma	0.642612657221498	75	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Pleural Mesothelioma	0.642612657221498	75	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Pleural Mesothelioma	0.642612657221498	75	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Pleural Mesothelioma	0.642612657221498	75	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Pleural Mesothelioma	0.642612657221498	75	cancer
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	psychosis	0.642439139861967	296	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	psychosis	0.642439139861967	296	psychiatricDisorder
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	neurodegenerative disease	0.642288414311277	2279	nervousSystem
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	neurodegenerative disease	0.642288414311277	2279	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	post-traumatic stress disorder	0.642088916127175	81	psychiatricDisorder
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	hypoparathyroidism	0.641977609633434	58	metabolicEndocrine
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	coronary artery disease	0.641765925028877	28	cardioVascular
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	targetBased	315412	318	depressive disorder	0.641528774775255	33	psychiatricDisorder
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	targetBased	205582	727	depressive disorder	0.641258301078033	33	psychiatricDisorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	hemangioma	0.641219378530656	62	cancer
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	chronic myelomonocytic leukemia	0.641149353645763	58	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Ventricular arrhythmia	0.641084137971574	32	cardioVascular
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	targetBased	369953	2294	Alzheimer disease 18	0.640966313727322	12	nervousSystem
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	postmenopausal osteoporosis	0.640838273592233	36	muculoEskeletalConnective
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	deep vein thrombosis	0.640640436953824	362	hematologic
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	bipolar I disorder	0.640639481752904	29	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	bipolar I disorder	0.640639481752904	29	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	bipolar I disorder	0.640639481752904	29	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Inherited cancer-predisposing syndrome	0.640609428471365	2785	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Inherited cancer-predisposing syndrome	0.640609428471365	2785	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Inherited cancer-predisposing syndrome	0.640609428471365	2785	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Inherited cancer-predisposing syndrome	0.640609428471365	2785	geneticDisorder
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Inherited cancer-predisposing syndrome	0.640609428471365	2785	geneticDisorder
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	smoking cessation	0.640378804205756	36	nervousSystem
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	breast carcinoma	0.639892659510695	224	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	type 2 diabetes mellitus	0.639626764279892	80	metabolicEndocrine
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	type 2 diabetes mellitus	0.639626764279892	80	metabolicEndocrine
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	type 2 diabetes mellitus	0.639626764279892	80	metabolicEndocrine
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	type 2 diabetes mellitus	0.639626764279892	80	metabolicEndocrine
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	type 2 diabetes mellitus	0.639626764279892	80	metabolicEndocrine
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	type 2 diabetes mellitus	0.639626764279892	80	metabolicEndocrine
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	injury	0.639553777527006	41	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	neonatal abstinence syndrome	0.639503808879902	57	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	neonatal abstinence syndrome	0.639503808879902	57	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	attention deficit hyperactivity disorder	0.639130063012709	60	psychiatricDisorder
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	cerebral atherosclerosis	0.638992421523723	21	cardioVascular
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	postencephalitic Parkinson disease	0.638992421523723	21	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	heroin dependence	0.638960310809911	104	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	heroin dependence	0.638960310809911	104	psychiatricDisorder
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	head and neck squamous cell carcinoma	0.638949556374262	113	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	head and neck squamous cell carcinoma	0.638949556374262	113	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	septic shock	0.638939480030344	42	infective
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	hypertrophic cardiomyopathy	0.638631820518866	20	muculoEskeletalConnective
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	hypertrophic cardiomyopathy	0.638631820518866	20	muculoEskeletalConnective
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	non-Hodgkins lymphoma	0.638504676439922	510	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	obesity	0.638477857428487	43	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	obesity	0.638477857428487	43	metabolicEndocrine
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	hemorrhage	0.638135094889748	55	hematologic
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Inherited cancer-predisposing syndrome	0.637998636890931	10414	geneticDisorder
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	targetBased	189882	6790	neurodegenerative disease	0.637927127163836	2712	nervousSystem
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	targetBased	48068	449	neurodegenerative disease	0.637927127163836	2712	nervousSystem
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	targetBased	220571	2380	neurodegenerative disease	0.637927127163836	2712	nervousSystem
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	targetBased	223611	305	neurodegenerative disease	0.637927127163836	2712	nervousSystem
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	preeclampsia	0.637771450291283	22	pregnancyPerinatal
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	dry eye syndrome	0.637763988057418	32	visualSystem
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	alternating hemiplegia of childhood	0.637739119574785	216	nervousSystem
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	alternating hemiplegia of childhood	0.637739119574785	216	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	cardiac arrhythmia	0.637646823165619	67	cardioVascular
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	familial Mediterranean fever	0.637516775910312	23	muculoEskeletalConnective
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	sinusitis	0.637275760427135	26	muculoEskeletalConnective
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Inherited cancer-predisposing syndrome	0.636957765238631	2586	geneticDisorder
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	delirium	0.636915792851204	35	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	delirium	0.636915792851204	35	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	delirium	0.636915792851204	35	psychiatricDisorder
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Myelofibrosis	0.636911227177659	1019	otherPhenotypes
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	medulloblastoma	0.636851805368641	16	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	bipolar disorder	0.636690276883609	44	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	mental or behavioural disorder	0.636562574634408	918	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	mental or behavioural disorder	0.636562574634408	918	psychiatricDisorder
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	lung adenocarcinoma	0.636562053600706	51	cancer
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	diabetes insipidus	0.636202273524071	20	urinarySystem
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	Inherited cancer-predisposing syndrome	0.636201142184717	3272	geneticDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Parkinson disease	0.636198525212416	78	nervousSystem
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	targetBased	315412	318	bipolar I disorder	0.636160747136378	23	psychiatricDisorder
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	targetBased	205582	727	bipolar I disorder	0.636160747136378	23	psychiatricDisorder
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	motor neuron disease	0.636159681085823	613	nervousSystem
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	motor neuron disease	0.636159681085823	613	nervousSystem
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	hereditary neoplastic syndrome	0.635838473701773	3305	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	targetBased	369953	2602	46,xx sex reversal 5	0.635489221358593	9	geneticDisorder
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	lymphoid neoplasm	0.635028303815862	555	cancer
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	refractory anemia with excess blasts	0.634927526187759	20	cancer
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	chronic inflammatory demyelinating polyneuropathy	0.634841225279261	45	immune
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	response to ivacaftor - efficacy	0.634832430281935	48	otherPhenotypes
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	response to ivacaftor - efficacy	0.634832430281935	48	otherPhenotypes
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	neoplasm	0.634731505143747	3280	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	intestinal obstruction	0.634364034199603	37	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	intestinal obstruction	0.634364034199603	37	gastroIntestinal
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	urinary bladder cancer	0.634051822221657	72	cancer
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	anxiety	0.633991676701545	936	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	anxiety	0.633991676701545	936	psychiatricDisorder
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	Pineoblastoma	0.633859219992769	56	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	anxiety	0.633822468610396	248	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	anxiety	0.633822468610396	248	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	anxiety	0.633822468610396	248	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	anxiety	0.633822468610396	248	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	anxiety	0.633822468610396	248	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	anxiety	0.633822468610396	248	psychiatricDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	body height	0.633664584736138	47	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	body height	0.633664584736138	47	otherPhenotypes
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	pancreatic neuroendocrine tumor	0.633611610827445	356	cancer
Luminescent HTS for small molecule inhibitors of MT1-MMP transcription	MMP14	targetBased	86733	537	Torg-Winchester syndrome	0.633573506874993	23	muculoEskeletalConnective
uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay	MMP14	targetBased	361500	222	Torg-Winchester syndrome	0.633573506874993	23	muculoEskeletalConnective
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	renal cell carcinoma	0.633336943115504	1152	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	renal cell carcinoma	0.633336943115504	1152	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	renal cell carcinoma	0.633336943115504	1152	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	renal cell carcinoma	0.633336943115504	1152	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	renal cell carcinoma	0.633336943115504	1152	cancer
qHTS for Inhibitors of Polymerase Eta	POLH	targetBased	388717	4730	xeroderma pigmentosum	0.633286070298763	248	metabolicEndocrine
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Shock	0.633272503785782	26	otherPhenotypes
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	bipolar I disorder	0.633262908369513	30	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	bipolar I disorder	0.633262908369513	30	psychiatricDisorder
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	type 2 diabetes mellitus	0.633159771804883	32	metabolicEndocrine
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	type 2 diabetes mellitus	0.633159771804883	32	metabolicEndocrine
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	targetBased	288728	10857	genetic disorder	0.633135559067776	84	geneticDisorder
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	targetBased	288728	10857	genetic disorder	0.633135559067776	84	geneticDisorder
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	targetBased	306502	2634	distal hereditary motor neuropathy type 7	0.632249836516357	623	muculoEskeletalConnective
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	targetBased	306502	1509	distal hereditary motor neuropathy type 7	0.632249836516357	623	muculoEskeletalConnective
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Dementia	0.632086682659489	54	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Dementia	0.632086682659489	54	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Dementia	0.632086682659489	54	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Dementia	0.632086682659489	54	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Dementia	0.632086682659489	54	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Dementia	0.632086682659489	54	psychiatricDisorder
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	asthma	0.631902928952217	41	respiratory
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	drug dependence	0.631827536503145	278	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	drug dependence	0.631827536503145	278	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	drug dependence	0.631827536503145	278	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	drug dependence	0.631827536503145	278	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	drug dependence	0.631827536503145	278	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	drug dependence	0.631827536503145	278	psychiatricDisorder
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	heroin dependence	0.631779587579708	51	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	cycloplegia	0.631704381295873	17	visualSystem
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	cycloplegia	0.631704381295873	17	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	cycloplegia	0.631704381295873	17	visualSystem
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	cycloplegia	0.631704381295873	17	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	cycloplegia	0.631704381295873	17	visualSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	esophageal carcinoma	0.631553488700546	1025	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	esophageal carcinoma	0.631553488700546	1025	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	esophageal carcinoma	0.631553488700546	1025	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	esophageal carcinoma	0.631553488700546	1025	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	esophageal carcinoma	0.631553488700546	1025	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	sickle cell anemia	0.631524990132642	24	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	sickle cell anemia	0.631524990132642	24	muculoEskeletalConnective
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	body height	0.631175554191538	20	otherPhenotypes
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	Agitation	0.630698487380588	17	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	Agitation	0.630698487380588	17	psychiatricDisorder
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	breast neoplasm	0.630680665640952	453	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	type 2 diabetes mellitus	0.630637978861556	347	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Dementia	0.630487519911276	45	psychiatricDisorder
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	pulmonary embolism	0.630479729710024	26	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	anxiety	0.630433271106812	260	psychiatricDisorder
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	Abnormality of the cardiovascular system	0.630409551474951	502	cardioVascular
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	Abnormality of the cardiovascular system	0.630409551474951	502	cardioVascular
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	targetBased	304060	10600	serum gamma-glutamyl transferase measurement	0.630287012112818	11	hematologic
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	pathwayBased	7671	874	serum gamma-glutamyl transferase measurement	0.630287012112818	11	hematologic
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	pathwayBased	305439	16717	serum gamma-glutamyl transferase measurement	0.630287012112818	11	hematologic
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	maturity-onset diabetes of the young	0.629780097686834	56	metabolicEndocrine
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	maturity-onset diabetes of the young	0.629780097686834	56	metabolicEndocrine
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	schizophrenia	0.629740114179662	65	psychiatricDisorder
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	thrombotic disease	0.629548975281352	445	cardioVascular
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	osteoarthritis	0.629392602569647	41	muculoEskeletalConnective
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	psoriatic arthritis	0.629378658421174	63	muculoEskeletalConnective
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	myelodysplastic syndrome	0.629372173160002	108	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	endocrine neoplasm	0.629328151945855	4684	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	endocrine neoplasm	0.629328151945855	4684	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	endocrine neoplasm	0.629328151945855	4684	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	endocrine neoplasm	0.629328151945855	4684	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	endocrine neoplasm	0.629328151945855	4684	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	unipolar depression	0.628732651518689	32	psychiatricDisorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	allergic disease	0.628446114609922	34	immune
USP8 deubiquitinase inhibition: Primary qHTS	USP8	targetBased	47480	2010	neurodegenerative disease	0.628428729911184	75	nervousSystem
Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity	FGF22_inhibitors	targetBased	339650	5128	bone development disease	0.628351401578255	15	muculoEskeletalConnective
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Mydriasis	0.628351401578255	15	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Mydriasis	0.628351401578255	15	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Mydriasis	0.628351401578255	15	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Mydriasis	0.628351401578255	15	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Mydriasis	0.628351401578255	15	otherPhenotypes
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	stroke	0.628120473874919	23	nervousSystem
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Hereditary breast and ovarian cancer syndrome	0.628101650010634	752	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Myasthenia gravis	0.628049159950515	18	immune
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Myasthenia gravis	0.628049159950515	18	immune
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	Myasthenia gravis	0.628049159950515	18	immune
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	Myasthenia gravis	0.628049159950515	18	immune
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	Myasthenia gravis	0.628049159950515	18	immune
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Myasthenia gravis	0.628049159950515	18	immune
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Myasthenia gravis	0.628049159950515	18	immune
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	anorexia nervosa	0.627716787694477	23	nervousSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	anorexia nervosa	0.627716787694477	23	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	anorexia nervosa	0.627716787694477	23	nervousSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	anorexia nervosa	0.627716787694477	23	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	anorexia nervosa	0.627716787694477	23	nervousSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	anorexia nervosa	0.627716787694477	23	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	post-traumatic stress disorder	0.627147038346792	44	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	allergic rhinitis	0.627077400922343	17	immune
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	allergic rhinitis	0.627077400922343	17	immune
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	allergic rhinitis	0.627077400922343	17	immune
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	allergic rhinitis	0.627077400922343	17	immune
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	allergic rhinitis	0.627077400922343	17	immune
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	Inherited cancer-predisposing syndrome	0.626904529904571	4219	geneticDisorder
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	lip and oral cavity carcinoma	0.626887753244379	60	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	hypogonadism	0.626709780417037	43	reproductiveSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	hypogonadism	0.626709780417037	43	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	hypogonadism	0.626709780417037	43	reproductiveSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	hypogonadism	0.626709780417037	43	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	hypogonadism	0.626709780417037	43	reproductiveSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	hypogonadism	0.626709780417037	43	reproductiveSystem
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	unipolar depression	0.626689907251647	26	psychiatricDisorder
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	targetBased	340696	540	retinitis pigmentosa 92	0.626498224873465	11	visualSystem
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	bone fracture	0.626471657003301	21	muculoEskeletalConnective
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	parental longevity	0.625504964820304	18	otherPhenotypes
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	follicular lymphoma	0.625483391400951	95	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	acromegaly	0.625090953855627	21	reproductiveSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	acromegaly	0.625090953855627	21	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	acromegaly	0.625090953855627	21	reproductiveSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	acromegaly	0.625090953855627	21	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	acromegaly	0.625090953855627	21	reproductiveSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	acromegaly	0.625090953855627	21	reproductiveSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colorectal neoplasm	0.625072089258988	1870	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colorectal neoplasm	0.625072089258988	1870	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colorectal neoplasm	0.625072089258988	1870	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colorectal neoplasm	0.625072089258988	1870	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colorectal neoplasm	0.625072089258988	1870	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	unspecified peripheral T-cell lymphoma	0.624986273516276	69	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	anxiety disorder	0.624856199454065	112	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	anxiety disorder	0.624856199454065	112	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	anxiety disorder	0.624856199454065	112	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	anxiety disorder	0.624856199454065	112	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	anxiety disorder	0.624856199454065	112	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	anxiety disorder	0.624856199454065	112	psychiatricDisorder
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	neurodegenerative disease	0.624690579486488	367	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	ileus	0.624516078630663	44	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	ileus	0.624516078630663	44	gastroIntestinal
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	graft versus host disease	0.624473599370751	132	immune
Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen	SLC12A5	targetBased	189132	4127	developmental and epileptic encephalopathy	0.624427192659521	1214	nervousSystem
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	Skeletal dysplasia	0.624363486174286	11	muculoEskeletalConnective
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	neoplasm	0.624327417617625	1348	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	neoplasm	0.624327417617625	1348	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Peptic ulcer	0.624294296119937	14	gastroIntestinal
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Peptic ulcer	0.624294296119937	14	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Peptic ulcer	0.624294296119937	14	gastroIntestinal
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Peptic ulcer	0.624294296119937	14	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Peptic ulcer	0.624294296119937	14	gastroIntestinal
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	multiple myeloma	0.624291315565239	141	cancer
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	cancer	0.624251650790347	22455	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	carcinoma	0.624221075469731	20998	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	carcinoma	0.624221075469731	20998	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	carcinoma	0.624221075469731	20998	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	carcinoma	0.624221075469731	20998	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	carcinoma	0.624221075469731	20998	cancer
Glucocerebrosidase	GBA1	targetBased	48118	549	Hereditary late-onset Parkinson disease	0.624207386504889	108	metabolicEndocrine
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	treatment resistant depression	0.624163682944734	29	psychiatricDisorder
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	squamous cell carcinoma	0.624144915124246	254	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	inherited obesity	0.624128943995849	13	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	inherited obesity	0.624128943995849	13	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	inherited obesity	0.624128943995849	13	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	inherited obesity	0.624128943995849	13	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	inherited obesity	0.624128943995849	13	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	inherited obesity	0.624128943995849	13	metabolicEndocrine
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	azoospermia	0.623836516059577	139	reproductiveSystem
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	azoospermia	0.623836516059577	139	reproductiveSystem
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	type 1 diabetes mellitus	0.623714942338902	286	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	medulloblastoma	0.623581877783622	55	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	medulloblastoma	0.623581877783622	55	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	medulloblastoma	0.623581877783622	55	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	medulloblastoma	0.623581877783622	55	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	medulloblastoma	0.623581877783622	55	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	T-Cell Prolymphocytic Leukemia	0.623514123973518	57	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	atopic eczema	0.623231800016832	67	immune
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	genetic disorder	0.623003205316336	565	geneticDisorder
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	genetic disorder	0.623003205316336	565	geneticDisorder
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	Cushing syndrome	0.622867247821216	68	metabolicEndocrine
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	Cushing syndrome	0.622867247821216	68	metabolicEndocrine
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	bilateral oophorectomy	0.622760631678199	15	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	infertility	0.622704166546388	26	reproductiveSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	infertility	0.622704166546388	26	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	infertility	0.622704166546388	26	reproductiveSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	infertility	0.622704166546388	26	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	infertility	0.622704166546388	26	reproductiveSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	infertility	0.622704166546388	26	reproductiveSystem
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	Rare familial disorder with hypertrophic cardiomyopathy	0.622584838782076	123	cardioVascular
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	Rare familial disorder with hypertrophic cardiomyopathy	0.622584838782076	123	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	hyperprolactinemia	0.622566399114305	15	metabolicEndocrine
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	hyperprolactinemia	0.622566399114305	15	metabolicEndocrine
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	hyperprolactinemia	0.622566399114305	15	metabolicEndocrine
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	hyperprolactinemia	0.622566399114305	15	metabolicEndocrine
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	hyperprolactinemia	0.622566399114305	15	metabolicEndocrine
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	hyperprolactinemia	0.622566399114305	15	metabolicEndocrine
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	targetBased	386663	3977	acute promyelocytic leukemia	0.622116387379182	33	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	post-operative sign or symptom	0.621738874881876	17	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	post-operative sign or symptom	0.621738874881876	17	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	female infertility	0.621559948320993	104	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	female infertility	0.621559948320993	104	reproductiveSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	hemorrhage	0.621256851051645	22	hematologic
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	Low back pain	0.620861137391453	42	nervousSystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Fanconi anemia complementation group A	0.620838562759111	6	muculoEskeletalConnective
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	carcinoma	0.620413702006112	1700	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	seasonal allergic rhinitis	0.620287278383327	14	immune
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	seasonal allergic rhinitis	0.620287278383327	14	immune
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	seasonal allergic rhinitis	0.620287278383327	14	immune
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	seasonal allergic rhinitis	0.620287278383327	14	immune
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	seasonal allergic rhinitis	0.620287278383327	14	immune
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	clear cell renal carcinoma	0.620163172618119	38	cancer
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	obesity	0.620061063972936	23	metabolicEndocrine
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	azoospermia	0.619951507505911	67	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	azoospermia	0.619951507505911	67	reproductiveSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	renal colic	0.619673100980468	18	urinarySystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	renal colic	0.619673100980468	18	urinarySystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	depressive disorder	0.619661194229996	48	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	depressive disorder	0.619661194229996	48	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Hyperhidrosis	0.619641488098591	45	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Hyperhidrosis	0.619641488098591	45	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Hyperhidrosis	0.619641488098591	45	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Hyperhidrosis	0.619641488098591	45	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Hyperhidrosis	0.619641488098591	45	otherPhenotypes
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	type 2 diabetes mellitus	0.619586482443362	21	metabolicEndocrine
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	type 2 diabetes mellitus	0.619586482443362	21	metabolicEndocrine
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	type 2 diabetes mellitus	0.619586482443362	21	metabolicEndocrine
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	Inherited cancer-predisposing syndrome	0.619557112817108	1760	geneticDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	targetBased	363803	502	Hyperhidrosis	0.619329000739565	41	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	targetBased	363803	2629	Hyperhidrosis	0.619329000739565	41	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	targetBased	363803	1450	Hyperhidrosis	0.619329000739565	41	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	698	Hyperhidrosis	0.619329000739565	41	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	2133	Hyperhidrosis	0.619329000739565	41	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	1081	Hyperhidrosis	0.619329000739565	41	otherPhenotypes
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	muscle cramp	0.619285523949174	12	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Agitation	0.619285523949174	12	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Agitation	0.619285523949174	12	psychiatricDisorder
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	Nasal congestion	0.619285523949174	12	respiratory
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	Recurrent thrombophlebitis	0.619285523949174	12	hematologic
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	hypogonadism	0.619285523949174	12	reproductiveSystem
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	hypogonadism	0.619285523949174	12	reproductiveSystem
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	hypogonadism	0.619285523949174	12	reproductiveSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	peptic ulcer disease	0.619285523949174	12	gastroIntestinal
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	peptic ulcer disease	0.619285523949174	12	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	peptic ulcer disease	0.619285523949174	12	gastroIntestinal
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	peptic ulcer disease	0.619285523949174	12	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	peptic ulcer disease	0.619285523949174	12	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	unipolar depression	0.619197357878222	24	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	unipolar depression	0.619197357878222	24	psychiatricDisorder
qHTS for Inhibitors of Vif-A3G Interactions: qHTS	APOBEC3G_inhibitors	targetBased	402348	311	HIV infection	0.618941190389532	116	infective
uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay	APOBEC3G_inhibitors	targetBased	331753	931	HIV infection	0.618941190389532	116	infective
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	hemorrhage	0.618589591189615	43	hematologic
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	hemorrhage	0.618589591189615	43	hematologic
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	genetic disorder	0.618419953907871	370	geneticDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Dyspareunia	0.618373164314375	42	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Dyspareunia	0.618373164314375	42	otherPhenotypes
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	neurodegenerative disease	0.618369114146208	709	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	insomnia	0.618331153675178	56	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	endometrial carcinoma	0.617724297967159	47	cancer
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	targetBased	309684	1662	genetic disorder	0.617366412445316	401	geneticDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Hereditary breast and ovarian cancer syndrome	0.617356887059384	249	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	obstructive sleep apnea	0.616870615441254	21	psychiatricDisorder
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	open-angle glaucoma	0.616661170668676	21	visualSystem
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Mantle cell lymphoma	0.616608879193016	210	cancer
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	histiocytic medullary reticulosis	0.616539346649504	312	cancer
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	Retinal dystrophy	0.616194342273178	116	visualSystem
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	Retinal dystrophy	0.616194342273178	116	visualSystem
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	colorectal cancer	0.616184208009642	82	cancer
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	lymphoid neoplasm	0.616157212101945	884	cancer
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	lymphoid neoplasm	0.616157212101945	884	cancer
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	premature birth	0.616021785259648	29	otherPhenotypes
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	osteoarthritis, knee	0.615751427985334	35	muculoEskeletalConnective
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	Atrophy	0.615694330133837	14	otherPhenotypes
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	genetic disorder	0.615649231265639	3260	geneticDisorder
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	genetic disorder	0.615649231265639	3260	geneticDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	fibromyalgia	0.615589784440467	32	muculoEskeletalConnective
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	differentiated thyroid carcinoma	0.615477369838719	35	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	polycystic ovary syndrome	0.615267644013478	263	reproductiveSystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	polycystic ovary syndrome	0.615267644013478	263	reproductiveSystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	polycystic ovary syndrome	0.615267644013478	263	reproductiveSystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	polycystic ovary syndrome	0.615267644013478	263	reproductiveSystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	polycystic ovary syndrome	0.615267644013478	263	reproductiveSystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	polycystic ovary syndrome	0.615267644013478	263	reproductiveSystem
qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1)	TDP1	targetBased	344442	978	spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1	0.615241893026113	162	metabolicEndocrine
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT	TDP1	targetBased	416824	63248	spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1	0.615241893026113	162	metabolicEndocrine
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT	TDP1	targetBased	416856	49238	spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1	0.615241893026113	162	metabolicEndocrine
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	angina pectoris	0.615165132654478	23	cardioVascular
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	46,XX testicular disorder of sex development	0.615040310401099	39	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	46,XX testicular disorder of sex development	0.615040310401099	39	reproductiveSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	obsessive-compulsive disorder	0.614970694532657	62	psychiatricDisorder
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	genetic disorder	0.614877484242807	427	geneticDisorder
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	genetic disorder	0.614877484242807	427	geneticDisorder
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	colorectal neoplasm	0.614843970379271	382	cancer
Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2)	GPT2	targetBased	98912	236	neurodegenerative disease	0.614812938066516	23	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	coronary artery disease	0.614742335189791	48	cardioVascular
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	metabolic syndrome	0.614697417851648	113	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	metabolic syndrome	0.614697417851648	113	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	metabolic syndrome	0.614697417851648	113	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	metabolic syndrome	0.614697417851648	113	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	metabolic syndrome	0.614697417851648	113	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	metabolic syndrome	0.614697417851648	113	metabolicEndocrine
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	pulmonary arterial hypertension	0.614624258622599	235	respiratory
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	dyspepsia	0.614594595559056	21	gastroIntestinal
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	dyspepsia	0.614594595559056	21	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	dyspepsia	0.614594595559056	21	gastroIntestinal
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	dyspepsia	0.614594595559056	21	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	dyspepsia	0.614594595559056	21	gastroIntestinal
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	dyspepsia	0.614594595559056	21	gastroIntestinal
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	Crohn's disease	0.614524204063885	20	immune
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	targetBased	250190	1304	erectile dysfunction	0.614214142126277	12	reproductiveSystem
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	targetBased	255537	2141	erectile dysfunction	0.614214142126277	12	reproductiveSystem
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	delirium	0.614214142126277	12	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	delirium	0.614214142126277	12	psychiatricDisorder
qHTS for Inhibitors of Polymerase Eta	POLH	targetBased	388717	4730	genetic disorder	0.613783140957291	248	geneticDisorder
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	prostate adenocarcinoma	0.613766243992196	71	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	Parkinson disease	0.613478296323205	1196	nervousSystem
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	septic shock	0.613407008594561	33	infective
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	targetBased	76168	1231	congestive heart failure	0.613250657387013	22	cardioVascular
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	pregnancy	0.613137664988923	15	pregnancyPerinatal
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	pregnancy	0.613137664988923	15	pregnancyPerinatal
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	pregnancy	0.612946296670552	11	pregnancyPerinatal
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	post operative nausea and vomiting	0.612946296670552	11	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	post operative nausea and vomiting	0.612946296670552	11	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	post operative nausea and vomiting	0.612946296670552	11	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	post operative nausea and vomiting	0.612946296670552	11	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	post operative nausea and vomiting	0.612946296670552	11	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	morbid obesity	0.612786737888709	18	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	morbid obesity	0.612786737888709	18	metabolicEndocrine
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	Abnormality of the cardiovascular system	0.612683747155337	239	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	pregnancy	0.612682141130405	20	pregnancyPerinatal
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	pregnancy	0.612682141130405	20	pregnancyPerinatal
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	parathyroid disease	0.612533808842894	202	metabolicEndocrine
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	cancer	0.612317425813566	73	cancer
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	breast cancer	0.612252208871859	2961	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	post operative nausea and vomiting	0.612103153859535	24	otherPhenotypes
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	hemorrhage	0.612062449884587	18	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	hemorrhage	0.612062449884587	18	hematologic
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	neurodegenerative disease	0.611849024230215	21	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	osteoarthritis, knee	0.611730200008939	12	muculoEskeletalConnective
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	schizoaffective disorder	0.611730200008939	12	psychiatricDisorder
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	congenital hypothyroidism	0.611703580698182	39	metabolicEndocrine
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	chronic mucocutaneous candidiasis	0.611677577432826	289	immune
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	chronic mucocutaneous candidiasis	0.611677577432826	289	immune
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	gastroesophageal reflux disease	0.611643521081338	12	gastroIntestinal
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	gastroesophageal reflux disease	0.611643521081338	12	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	gastroesophageal reflux disease	0.611643521081338	12	gastroIntestinal
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	gastroesophageal reflux disease	0.611643521081338	12	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	gastroesophageal reflux disease	0.611643521081338	12	gastroIntestinal
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	gastroesophageal reflux disease	0.611643521081338	12	gastroIntestinal
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	colorectal neoplasm	0.611627732068766	81	cancer
Fluorescence polarization assay for PLK1 inhibitors	PLK1	targetBased	97099	518	neurodegenerative disease	0.611292905266571	18	nervousSystem
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	targetBased	364065	10181	neurodegenerative disease	0.611292905266571	18	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	preeclampsia	0.611191772523636	20	pregnancyPerinatal
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	neurodegenerative disease	0.611164613433357	317	nervousSystem
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	ocular hypertension	0.611084615406773	21	visualSystem
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	targetBased	324747	2221	cystinuria	0.610967494573669	95	metabolicEndocrine
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	bronchitis	0.610966153644012	26	respiratory
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Beckwith-Wiedemann syndrome	0.610955952556363	174	cancer
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Beckwith-Wiedemann syndrome	0.610955952556363	174	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	Myalgia	0.610462354553215	11	otherPhenotypes
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	depressive disorder	0.610437333238209	44	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	heart disease	0.610101705726402	24	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	heart disease	0.610101705726402	24	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	social anxiety disorder	0.609866499579936	29	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	social anxiety disorder	0.609866499579936	29	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	social anxiety disorder	0.609866499579936	29	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	social anxiety disorder	0.609866499579936	29	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	social anxiety disorder	0.609866499579936	29	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	social anxiety disorder	0.609866499579936	29	psychiatricDisorder
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	Autism	0.609806441526676	12	psychiatricDisorder
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	stomach neoplasm	0.609719050629167	231	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	irritable bowel syndrome	0.609584926847712	24	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	irritable bowel syndrome	0.609584926847712	24	gastroIntestinal
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	prostate adenocarcinoma	0.609422103028697	210	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	Chronic pain	0.609255866556582	15	nervousSystem
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	Constipation	0.609204549926413	18	otherPhenotypes
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	neuropathic pain	0.609134327145434	84	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	gastroparesis	0.609010949181426	33	gastroIntestinal
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	gastroparesis	0.609010949181426	33	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	gastroparesis	0.609010949181426	33	gastroIntestinal
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	gastroparesis	0.609010949181426	33	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	gastroparesis	0.609010949181426	33	gastroIntestinal
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	gastroparesis	0.609010949181426	33	gastroIntestinal
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	targetBased	72072	2464	neurodegenerative disease	0.608987326393621	21	nervousSystem
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	targetBased	73912	5649	neurodegenerative disease	0.608987326393621	21	nervousSystem
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	endometriosis	0.608846056713265	568	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	endometriosis	0.608846056713265	568	reproductiveSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	movement disorder	0.608815855986794	37	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	head and neck squamous cell carcinoma	0.608750307574734	185	cancer
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	targetBased	288728	10857	neurodegenerative disease	0.608729374700095	14	nervousSystem
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	targetBased	288728	10857	neurodegenerative disease	0.608729374700095	14	nervousSystem
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	carcinoma	0.608626082644483	601	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	skin squamous cell carcinoma	0.608411208348797	413	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	skin squamous cell carcinoma	0.608411208348797	413	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	skin squamous cell carcinoma	0.608411208348797	413	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	skin squamous cell carcinoma	0.608411208348797	413	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	skin squamous cell carcinoma	0.608411208348797	413	cancer
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	neonatal diabetes mellitus	0.608360646017274	151	metabolicEndocrine
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	neonatal diabetes mellitus	0.608360646017274	151	metabolicEndocrine
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	pain	0.608284957389344	18	nervousSystem
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	pain	0.608284957389344	18	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	pain	0.608284957389344	18	nervousSystem
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	pain	0.608284957389344	18	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	pain	0.608284957389344	18	nervousSystem
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	targetBased	96879	811	neurodegenerative disease	0.608234150917648	23	nervousSystem
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	age-related macular degeneration	0.607810318811785	669	visualSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Vomiting	0.607745142219739	20	gastroIntestinal
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Vomiting	0.607745142219739	20	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Vomiting	0.607745142219739	20	gastroIntestinal
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Vomiting	0.607745142219739	20	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Vomiting	0.607745142219739	20	gastroIntestinal
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Vomiting	0.607745142219739	20	gastroIntestinal
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	post-traumatic stress disorder	0.607658019448827	59	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	post-traumatic stress disorder	0.607658019448827	59	psychiatricDisorder
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	malignant endocrine neoplasm	0.607624213372651	402	cancer
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	Intellectual disability	0.607223771004651	138	nervousSystem
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	targetBased	369953	3123	bone development disease	0.607202180524209	10	muculoEskeletalConnective
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	cancer	0.607180358680722	1859	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	injury	0.607137392360614	85	otherPhenotypes
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	STAT3 gain of function	0.606952560260641	770	immune
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	STAT3 gain of function	0.606952560260641	770	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	Crohn's disease	0.606813177486441	22	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	Crohn's disease	0.606813177486441	22	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	Crohn's disease	0.606813177486441	22	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	Crohn's disease	0.606813177486441	22	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	Crohn's disease	0.606813177486441	22	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	Crohn's disease	0.606813177486441	22	immune
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	systemic lupus erythematosus	0.606714042774157	24	muculoEskeletalConnective
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Turner syndrome	0.606613111606686	26	visualSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Turner syndrome	0.606613111606686	26	visualSystem
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	differentiated thyroid carcinoma	0.606300003374867	58	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	substance dependence	0.606253414937565	201	psychiatricDisorder
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	pancreatic adenocarcinoma	0.606244963636864	149	cancer
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	targetBased	639428	9218	neurodegenerative disease	0.606205598209275	33	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	treatment resistant depression	0.605959064966353	29	psychiatricDisorder
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	GRN-related frontotemporal lobar degeneration with Tdp43 inclusions	0.605944606681798	205	psychiatricDisorder
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	GRN-related frontotemporal lobar degeneration with Tdp43 inclusions	0.605944606681798	205	psychiatricDisorder
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pathwayBased	362051	17187	cryopyrin-associated periodic syndrome	0.605771408191478	546	muculoEskeletalConnective
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	hyperprolactinemia	0.605697325591456	11	metabolicEndocrine
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	hyperprolactinemia	0.605697325591456	11	metabolicEndocrine
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	hyperprolactinemia	0.605697325591456	11	metabolicEndocrine
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	mesothelioma	0.605356658796186	276	cancer
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	cholesteryl ester measurement	0.605296400781166	14	metabolicEndocrine
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	cholesteryl ester measurement	0.605296400781166	14	metabolicEndocrine
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	lean body mass	0.605276599282585	33	metabolicEndocrine
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	lean body mass	0.605276599282585	33	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	chronic obstructive pulmonary disease	0.604623538113648	14	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	chronic obstructive pulmonary disease	0.604623538113648	14	respiratory
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	cardiac arrhythmia	0.604597373994676	52	cardioVascular
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	mean reticulocyte volume	0.604514256128834	8	hematologic
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	eating disorder	0.604372553853475	38	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	eating disorder	0.604372553853475	38	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	eating disorder	0.604372553853475	38	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	eating disorder	0.604372553853475	38	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	eating disorder	0.604372553853475	38	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	eating disorder	0.604372553853475	38	psychiatricDisorder
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	respiratory system disease	0.604308638464213	6538	respiratory
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	respiratory system disease	0.604308638464213	6538	respiratory
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	secondary malignant neoplasm	0.604165201566678	34	cancer
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	bronchiectasis	0.604141117825392	510	respiratory
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	bronchiectasis	0.604141117825392	510	respiratory
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	reticulocyte count	0.603933460546532	39	hematologic
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	reticulocyte count	0.603933460546532	39	hematologic
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	Dysmenorrhea	0.603833765267521	17	reproductiveSystem
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid cancer	0.603822893407619	156	cancer
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid cancer	0.603822893407619	156	cancer
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	thyroid cancer	0.603822893407619	156	cancer
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	thyroid cancer	0.603822893407619	156	cancer
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	targetBased	324747	2221	hypotonia-cystinuria syndrome	0.603812914945978	23	metabolicEndocrine
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	hyperthyroidism	0.603756541413275	1906	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	hyperthyroidism	0.603756541413275	1906	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	hyperthyroidism	0.603756541413275	1906	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	hyperthyroidism	0.603756541413275	1906	metabolicEndocrine
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	myelodysplastic syndrome	0.603738282918877	75	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Chemotherapy-induced nausea and vomiting	0.603698410819204	33	otherPhenotypes
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Chemotherapy-induced nausea and vomiting	0.603698410819204	33	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Chemotherapy-induced nausea and vomiting	0.603698410819204	33	otherPhenotypes
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Chemotherapy-induced nausea and vomiting	0.603698410819204	33	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Chemotherapy-induced nausea and vomiting	0.603698410819204	33	otherPhenotypes
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Chemotherapy-induced nausea and vomiting	0.603698410819204	33	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Dysmenorrhea	0.603589229933955	21	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Dysmenorrhea	0.603589229933955	21	reproductiveSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	postpartum depression	0.603347240354886	12	psychiatricDisorder
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	genetic disorder	0.603292790772594	296	geneticDisorder
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).	ULK1	targetBased	30185	575	neurodegenerative disease	0.603278579256237	26	nervousSystem
Primary qHTS assay for inhibitors of Glutamate pyruvate transaminase 2 (GPT2)	GPT2	targetBased	98912	236	genetic disorder	0.603058722541023	70	geneticDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Chemotherapy-induced nausea and vomiting	0.602828840473753	32	otherPhenotypes
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	neuropathic pain	0.602628172465082	20	nervousSystem
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	post operative nausea and vomiting	0.602553424206921	21	otherPhenotypes
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	post operative nausea and vomiting	0.602553424206921	21	otherPhenotypes
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	post operative nausea and vomiting	0.602553424206921	21	otherPhenotypes
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	delirium	0.602430510467206	12	psychiatricDisorder
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	early-onset autosomal dominant Alzheimer disease	0.602429390128475	128	psychiatricDisorder
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	early-onset autosomal dominant Alzheimer disease	0.602429390128475	128	psychiatricDisorder
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	early-onset autosomal dominant Alzheimer disease	0.602429390128475	128	psychiatricDisorder
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	polycystic ovary syndrome	0.602415032685796	174	reproductiveSystem
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	polycystic ovary syndrome	0.602415032685796	174	reproductiveSystem
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	polycystic ovary syndrome	0.602415032685796	174	reproductiveSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	xerostomia	0.602266958722854	14	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	xerostomia	0.602266958722854	14	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	xerostomia	0.602266958722854	14	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	xerostomia	0.602266958722854	14	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	xerostomia	0.602266958722854	14	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	nephrolithiasis	0.602212906787968	11	urinarySystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	nephrolithiasis	0.602212906787968	11	urinarySystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	pain	0.602176088428136	20	nervousSystem
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	multiple sclerosis	0.602040251565065	19	immune
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	reticulocyte measurement	0.601816911607638	34	hematologic
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	reticulocyte measurement	0.601816911607638	34	hematologic
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	coronary artery disease	0.601498428437273	11	cardioVascular
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	coronary artery disease	0.601498428437273	11	cardioVascular
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	influenza	0.601285568397495	9	infective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	septic shock	0.601285568397495	9	infective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	septic shock	0.601285568397495	9	infective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	rib fracture	0.601285568397495	9	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	rib fracture	0.601285568397495	9	muculoEskeletalConnective
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	epilepsy	0.601110466899752	32	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	epilepsy	0.601110466899752	32	nervousSystem
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	neurodegenerative disease	0.601022749475411	13	nervousSystem
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	breast carcinoma in situ	0.600945355982923	284	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	breast carcinoma in situ	0.600945355982923	284	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cutaneous melanoma	0.600703099701458	325	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cutaneous melanoma	0.600703099701458	325	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cutaneous melanoma	0.600703099701458	325	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cutaneous melanoma	0.600703099701458	325	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cutaneous melanoma	0.600703099701458	325	cancer
USP8 deubiquitinase inhibition: Primary qHTS	USP8	targetBased	47480	2010	Cushing syndrome	0.600698602908734	10	metabolicEndocrine
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	non-small cell lung carcinoma	0.600629550249717	203	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	treatment resistant depression	0.600532105955236	12	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	treatment resistant depression	0.600532105955236	12	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	treatment resistant depression	0.600532105955236	12	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	treatment resistant depression	0.600532105955236	12	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	treatment resistant depression	0.600532105955236	12	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	treatment resistant depression	0.600532105955236	12	psychiatricDisorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Bronchiolitis	0.600348864114163	17	respiratory
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Atrophic Vaginitis	0.600186219790317	30	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Atrophic Vaginitis	0.600186219790317	30	reproductiveSystem
qHTS for Inhibitors of Polymerase Kappa	POLK	targetBased	395295	2034	prostate cancer	0.600041049899183	53	cancer
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	targetBased	396029	13426	response to tramadol	0.599617629702221	902	otherPhenotypes
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	targetBased	395981	5516	response to tramadol	0.599617629702221	902	otherPhenotypes
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	digestive system neoplasm	0.599548825894144	391	cancer
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	targetBased	93798	679	neurodegenerative disease	0.599474308138305	16	nervousSystem
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	myocardial infarction	0.599407497681816	152	cardioVascular
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	targetBased	338373	1061	hypertrophic cardiomyopathy	0.599404989335178	27	muculoEskeletalConnective
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	methamphetamine dependence	0.599218832228455	20	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	methamphetamine dependence	0.599218832228455	20	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	methamphetamine dependence	0.599218832228455	20	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	methamphetamine dependence	0.599218832228455	20	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	methamphetamine dependence	0.599218832228455	20	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	methamphetamine dependence	0.599218832228455	20	psychiatricDisorder
uHTS Fluorescent assay for identification of activators of Apaf-1	APAF1_activators	targetBased	331671	1041	neurodegenerative disease	0.599107081143662	29	nervousSystem
uHTS Fluorescent assay for identification of inhibitors of Apaf-1	APAF1_inhibitors	targetBased	331671	2353	neurodegenerative disease	0.599107081143662	29	nervousSystem
qHTS for Inhibitors of Polymerase Kappa	POLK	targetBased	395295	2034	prostate carcinoma	0.599073001448264	42	cancer
A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37	UCHL5	targetBased	330707	1075	neurodegenerative disease	0.599029121048609	10	nervousSystem
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	Hyponatremia	0.599026253305242	24	urinarySystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	methamphetamine dependence	0.598875408626687	20	psychiatricDisorder
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	amelogenesis imperfecta type 1G	0.598819185739921	44	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Nausea and vomiting	0.598733175441831	31	otherPhenotypes
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cholangiocarcinoma	0.598602455799827	436	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cholangiocarcinoma	0.598602455799827	436	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cholangiocarcinoma	0.598602455799827	436	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cholangiocarcinoma	0.598602455799827	436	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cholangiocarcinoma	0.598602455799827	436	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	urticaria	0.598573318267027	11	dermatology
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	depressive disorder	0.598348996827665	10	psychiatricDisorder
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	Mantle cell lymphoma	0.598331794844814	50	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	urinary tract infection	0.598304433739899	28	infective
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	urinary tract infection	0.598304433739899	28	infective
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	age related macular degeneration 7	0.598242739303757	8	visualSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	prostate carcinoma	0.598179746256734	442	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	prostate carcinoma	0.598179746256734	442	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	prostate carcinoma	0.598179746256734	442	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	prostate carcinoma	0.598179746256734	442	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	prostate carcinoma	0.598179746256734	442	cancer
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	non-alcoholic fatty liver disease	0.597702476941513	707	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	non-alcoholic fatty liver disease	0.597702476941513	707	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	non-alcoholic fatty liver disease	0.597702476941513	707	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	chronic kidney disease	0.597603837168746	188	urinarySystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	chronic kidney disease	0.597603837168746	188	urinarySystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	chronic kidney disease	0.597603837168746	188	urinarySystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	chronic kidney disease	0.597603837168746	188	urinarySystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	chronic kidney disease	0.597603837168746	188	urinarySystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	chronic kidney disease	0.597603837168746	188	urinarySystem
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	targetBased	76168	1231	heart failure	0.597582643776577	29	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Myokymia	0.597376524444087	35	otherPhenotypes
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Myokymia	0.597376524444087	35	otherPhenotypes
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	Nausea and vomiting	0.597369836744691	29	otherPhenotypes
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	Nausea and vomiting	0.597369836744691	29	otherPhenotypes
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	Nausea and vomiting	0.597369836744691	29	otherPhenotypes
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	chromophobe renal cell carcinoma	0.597239078637754	77	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	chromophobe renal cell carcinoma	0.597239078637754	77	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	chromophobe renal cell carcinoma	0.597239078637754	77	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	chromophobe renal cell carcinoma	0.597239078637754	77	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	chromophobe renal cell carcinoma	0.597239078637754	77	cancer
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	phospholipids:total lipids ratio	0.597188853998803	12	otherPhenotypes
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	phospholipids:total lipids ratio	0.597188853998803	12	otherPhenotypes
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	cardiac arrhythmia	0.597082684094759	166	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	IGA glomerulonephritis	0.596885730731305	83	urinarySystem
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	Alzheimer disease	0.596827949801317	14	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	ovarian cancer	0.596469532383122	482	cancer
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	cancer	0.596441371396059	6110	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	QT interval	0.596223074271587	24	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	QT interval	0.596223074271587	24	cardioVascular
qHTS for Inhibitors of Polymerase Kappa	POLK	targetBased	395295	2034	Familial prostate cancer	0.596214509781827	32	cancer
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	prediabetes syndrome	0.596101338955186	71	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	prediabetes syndrome	0.596101338955186	71	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	prediabetes syndrome	0.596101338955186	71	metabolicEndocrine
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	major depressive disorder	0.596086455816202	42	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	generalized anxiety disorder	0.595808212813299	59	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	generalized anxiety disorder	0.595808212813299	59	psychiatricDisorder
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	brain injury	0.595686804534385	17	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	hip fracture	0.595650699705387	9	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	hip fracture	0.595650699705387	9	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Recurrent infection of the gastrointestinal tract	0.595650699705387	9	infective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Recurrent infection of the gastrointestinal tract	0.595650699705387	9	infective
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	chronic renal failure syndrome	0.595650699705387	9	urinarySystem
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	Fatigue	0.595643737097559	23	otherPhenotypes
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	familial cold autoinflammatory syndrome	0.595263504725513	254	muculoEskeletalConnective
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	neurodegenerative disease	0.595242557991075	21	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	ventricular tachycardia	0.595189466920042	12	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	sexual dysfunction	0.595062731184444	18	reproductiveSystem
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	sexual dysfunction	0.595062731184444	18	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	conduct disorder	0.595019512773013	24	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	conduct disorder	0.595019512773013	24	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	conduct disorder	0.595019512773013	24	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	conduct disorder	0.595019512773013	24	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	conduct disorder	0.595019512773013	24	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	conduct disorder	0.595019512773013	24	psychiatricDisorder
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	familial hypodysfibrinogenemia	0.594921821134701	17	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	familial hypodysfibrinogenemia	0.594921821134701	17	hematologic
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	brain injury	0.594910589729757	15	nervousSystem
Factor XIIa 1536 HTS	F12_modulation	targetBased	217430	649	angioedema	0.594448014117014	64	dermatology
Allosteric Modulators of D1 Receptors: Primary Screen	D1	targetBased	57705	3413	unipolar depression	0.594121772000262	11	psychiatricDisorder
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	targetBased	361330	3713	unipolar depression	0.594121772000262	11	psychiatricDisorder
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	targetBased	355805	11440	unipolar depression	0.594121772000262	11	psychiatricDisorder
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	Diarrhea	0.594015846742141	46	gastroIntestinal
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	Diarrhea	0.594015846742141	46	gastroIntestinal
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	dysthymic disorder	0.594005318047291	9	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	substance dependence	0.593933381960675	250	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	substance dependence	0.593933381960675	250	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	substance dependence	0.593933381960675	250	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	substance dependence	0.593933381960675	250	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	substance dependence	0.593933381960675	250	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	substance dependence	0.593933381960675	250	psychiatricDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	neurodegenerative disease	0.593816422964424	6952	nervousSystem
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	ST Elevation Myocardial Infarction	0.593802462774375	9	cardioVascular
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	inflammatory bowel disease	0.593795823724006	632	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	inflammatory bowel disease	0.593795823724006	632	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	inflammatory bowel disease	0.593795823724006	632	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	inflammatory bowel disease	0.593795823724006	632	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	inflammatory bowel disease	0.593795823724006	632	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	inflammatory bowel disease	0.593795823724006	632	immune
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	renal cell carcinoma	0.593783534704895	1898	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	polycystic ovary syndrome	0.593532835555096	107	reproductiveSystem
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	listeriosis	0.593396752228544	8	infective
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Nasal congestion	0.593396752228544	8	respiratory
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	heart disease	0.593237032510884	412	cardioVascular
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	pain	0.593212449856628	10	nervousSystem
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	pain	0.593212449856628	10	nervousSystem
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	partial epilepsy	0.592949719312303	9	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	social anxiety disorder	0.592744921862423	17	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lymphoid leukemia	0.592682461616264	926	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lymphoid leukemia	0.592682461616264	926	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lymphoid leukemia	0.592682461616264	926	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lymphoid leukemia	0.592682461616264	926	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lymphoid leukemia	0.592682461616264	926	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	neurodegenerative disease	0.592672623557014	34	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	neurodegenerative disease	0.592672623557014	34	nervousSystem
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	diffuse large B-cell lymphoma	0.592602942376381	397	cancer
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	diffuse large B-cell lymphoma	0.592602942376381	397	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	reticulocyte measurement	0.592574836962001	16	hematologic
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	hereditary breast ovarian cancer syndrome	0.592435458669846	338	cancer
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	targetBased	385746	932	genetic disorder	0.592355600497344	957	geneticDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	major depressive disorder	0.592300374829612	44	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	major depressive disorder	0.592300374829612	44	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	choroid plexus carcinoma	0.592216076816502	68	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	choroid plexus carcinoma	0.592216076816502	68	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	choroid plexus carcinoma	0.592216076816502	68	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	choroid plexus carcinoma	0.592216076816502	68	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	choroid plexus carcinoma	0.592216076816502	68	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	colon carcinoma	0.592081065759334	57	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	colon carcinoma	0.592081065759334	57	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	colon carcinoma	0.592081065759334	57	cancer
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	colon carcinoma	0.592081065759334	57	cancer
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	colon carcinoma	0.592081065759334	57	cancer
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	colon carcinoma	0.592081065759334	57	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	coronary artery disease	0.592008485412301	10	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	coronary artery disease	0.592008485412301	10	cardioVascular
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	Dementia	0.591865722627954	15	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	Dementia	0.591865722627954	15	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	Dementia	0.591865722627954	15	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	diabetic neuropathy	0.591755915992814	28	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	diabetic neuropathy	0.591755915992814	28	nervousSystem
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	squamous cell lung carcinoma	0.591749999583246	57	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	sleep apnea	0.591705290314346	14	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	sleep apnea	0.591705290314346	14	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	neoplasm	0.591556848961583	113	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	colorectal cancer	0.591112604809797	25	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	bone fracture	0.591034537873092	14	muculoEskeletalConnective
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	renal carcinoma	0.590771525813295	872	cancer
Primary cell-based high-throughput screening assay to measure PERK inhibition	PERK_inhibitors	targetBased	217959	370	cancer	0.590706185930871	934	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	adenocarcinoma	0.590697931637223	315	cancer
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	ulcerative colitis	0.590697841480425	26	immune
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	ulcerative colitis	0.590697841480425	26	immune
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	electrocardiography	0.590050079226244	203	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	electrocardiography	0.590050079226244	203	cardioVascular
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	osteogenesis imperfecta	0.590018585582101	59	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	congenital fibrinogen deficiency	0.589911108501056	90	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	congenital fibrinogen deficiency	0.589911108501056	90	hematologic
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	eating disorder	0.589793920351293	42	psychiatricDisorder
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	C-reactive protein measurement	0.589598524652379	30	hematologic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	autism spectrum disorder	0.589529636394361	105	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	pancreatic neoplasm	0.589482433026752	212	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	metastatic colorectal cancer	0.589434707125137	59	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	follicular lymphoma	0.589403135644704	24	cancer
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	382	trait in response to prednisolone	0.589325800565095	50	bioProcess
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	3253	trait in response to prednisolone	0.589325800565095	50	bioProcess
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	concentration of large HDL particles measurement	0.589321137126282	11	metabolicEndocrine
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	concentration of large HDL particles measurement	0.589321137126282	11	metabolicEndocrine
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	neurodegenerative disease	0.589190058569869	85	nervousSystem
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	rickets	0.588911011139894	107	muculoEskeletalConnective
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	Tourette syndrome	0.588857175513129	17	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	Tourette syndrome	0.588857175513129	17	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	Tourette syndrome	0.588857175513129	17	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	bladder transitional cell carcinoma	0.588845903637662	602	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	bladder transitional cell carcinoma	0.588845903637662	602	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	bladder transitional cell carcinoma	0.588845903637662	602	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	bladder transitional cell carcinoma	0.588845903637662	602	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	bladder transitional cell carcinoma	0.588845903637662	602	cancer
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	ischemia reperfusion injury	0.588528225678562	8	otherPhenotypes
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	ischemia reperfusion injury	0.588528225678562	8	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	postmenopausal atrophic vaginitis	0.588528225678562	8	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	postmenopausal atrophic vaginitis	0.588528225678562	8	reproductiveSystem
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	thyroid cancer	0.588445160784701	43	cancer
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	Inherited cancer-predisposing syndrome	0.588352799279746	624	geneticDisorder
Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).	PPP1CA	targetBased	314999	2841	neurodegenerative disease	0.588329498055209	15	nervousSystem
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	neurodegenerative disease	0.588306145605832	37	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	glaucoma	0.588251384537127	9	visualSystem
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	glaucoma	0.588251384537127	9	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	glaucoma	0.588251384537127	9	visualSystem
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	glaucoma	0.588251384537127	9	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	glaucoma	0.588251384537127	9	visualSystem
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	colon carcinoma	0.588130234119545	137	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	infection	0.587888525022768	255	infective
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Epileptic encephalopathy	0.587761656536964	194	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Epileptic encephalopathy	0.587761656536964	194	nervousSystem
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	targetBased	306502	3633	Diarrhea	0.587578994481585	15	gastroIntestinal
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	targetBased	335180	1022	Diarrhea	0.587578994481585	15	gastroIntestinal
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	targetBased	326024	5748	Sleep Disorder	0.587025604857753	69	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	targetBased	326024	1387	Sleep Disorder	0.587025604857753	69	psychiatricDisorder
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	neurodegenerative disease	0.586931833345308	43	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	pregnancy	0.586792686121393	9	pregnancyPerinatal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	opioid dependence	0.586603345912258	54	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	opioid dependence	0.586603345912258	54	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	opioid dependence	0.586603345912258	54	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	opioid dependence	0.586603345912258	54	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	opioid dependence	0.586603345912258	54	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	opioid dependence	0.586603345912258	54	psychiatricDisorder
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	hereditary angioedema	0.586599784505418	14	dermatology
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	pancreatic carcinoma	0.586465101589641	371	cancer
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	neurodegenerative disease	0.586380059223403	8	nervousSystem
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	neurodegenerative disease	0.586380059223403	8	nervousSystem
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	neurodegenerative disease	0.586380059223403	8	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Ewing sarcoma	0.586304863474545	249	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Ewing sarcoma	0.586304863474545	249	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Ewing sarcoma	0.586304863474545	249	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Ewing sarcoma	0.586304863474545	249	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Ewing sarcoma	0.586304863474545	249	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	methamphetamine dependence	0.586268551754346	48	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	alcohol dependence	0.586130803291848	66	psychiatricDisorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	pulpitis	0.586098907288342	12	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	Hypofibrinogenemia	0.586030436486814	33	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	Hypofibrinogenemia	0.586030436486814	33	hematologic
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	squamous cell lung carcinoma	0.585836319535447	61	cancer
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	Rare genetic intellectual disability with developmental anomaly	0.585620633433434	8	geneticDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	secondary Parkinson disease	0.585513080048089	14	metabolicEndocrine
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	leukemia	0.585207833502101	486	cancer
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	leukemia	0.585207833502101	486	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	targetBased	363803	502	asthma	0.585061000347239	16	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	targetBased	363803	2629	asthma	0.585061000347239	16	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	targetBased	363803	1450	asthma	0.585061000347239	16	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	698	asthma	0.585061000347239	16	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	2133	asthma	0.585061000347239	16	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	1081	asthma	0.585061000347239	16	respiratory
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Abnormal central motor function	0.585049361709701	59	otherPhenotypes
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	familial atrial fibrillation	0.584915503283993	198	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	familial atrial fibrillation	0.584915503283993	198	cardioVascular
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	growth hormone-secreting pituitary adenoma	0.584913795504696	9	geneticDisorder
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	acute coronary syndrome	0.584323923650328	11	cardioVascular
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lymphoid leukemia	0.584126459536702	130	cancer
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	Burkitts lymphoma	0.583982765294942	29	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	multiple sclerosis	0.583926180418581	160	immune
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	targetBased	314998	2199	neurodegenerative disease	0.583916454689616	35	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	pain	0.583819867656698	15	nervousSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	pain	0.583819867656698	15	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	pain	0.583819867656698	15	nervousSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	pain	0.583819867656698	15	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	pain	0.583819867656698	15	nervousSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	pain	0.583819867656698	15	nervousSystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	bile duct adenocarcinoma	0.583775539396127	20	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	genetic disorder	0.583772200787619	739	geneticDisorder
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	hepatorenal syndrome	0.583744624649583	14	otherPhenotypes
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	neoplasm	0.583703277674933	62	cancer
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	lymphocyte count	0.583691959694125	53	hematologic
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	Chronic pain	0.583510030116279	12	nervousSystem
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	targetBased	315412	318	major depressive disorder	0.583510030116279	12	psychiatricDisorder
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	targetBased	205582	727	major depressive disorder	0.583510030116279	12	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	kidney failure	0.583495942944549	11	urinarySystem
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	kidney failure	0.583495942944549	11	urinarySystem
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	anemia (phenotype)	0.583287797794901	8	hematologic
qHTS Assay for Inhibitors of BAZ2B	BAZ2B_modulators	targetBased	356826	15709	Neurodevelopmental disorder	0.583262943892584	18	nervousSystem
Primary HTS Assay for S1P3 Antagonists	S1PR3	targetBased	169141	462	monocyte count	0.583242928597541	38	hematologic
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	gastric cancer	0.583218527587673	405	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	proctitis	0.583175100421059	9	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	proctitis	0.583175100421059	9	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	proctitis	0.583175100421059	9	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	proctitis	0.583175100421059	9	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	proctitis	0.583175100421059	9	immune
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	proctitis	0.583175100421059	9	immune
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	dementia	0.583153557937084	700	psychiatricDisorder
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	dementia	0.583153557937084	700	psychiatricDisorder
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	dementia	0.583153557937084	700	psychiatricDisorder
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).	TPT1	targetBased	302663	2452	neurodegenerative disease	0.583074611929383	9	nervousSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	autism spectrum disorder	0.583045313028752	21	psychiatricDisorder
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Takayasu arteritis	0.582949705673375	9	urinarySystem
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	congenital disorder of glycosylation type I	0.582877315384715	260	metabolicEndocrine
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	congenital disorder of glycosylation type I	0.582877315384715	260	metabolicEndocrine
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	congenital disorder of glycosylation type I	0.582877315384715	260	metabolicEndocrine
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	endometrial cancer	0.582805616721057	119	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	non-alcoholic steatohepatitis	0.582785079482869	375	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	non-alcoholic steatohepatitis	0.582785079482869	375	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	non-alcoholic steatohepatitis	0.582785079482869	375	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	non-alcoholic steatohepatitis	0.582785079482869	375	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	non-alcoholic steatohepatitis	0.582785079482869	375	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	non-alcoholic steatohepatitis	0.582785079482869	375	metabolicEndocrine
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	heart failure	0.582667962238769	9	cardioVascular
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	neurodegenerative disease	0.582665511204253	28	nervousSystem
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	neoplasm	0.582604832960078	313	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	anaphylaxis	0.582453837228469	12	immune
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	deafness	0.581946589576287	24	nervousSystem
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	deafness	0.581946589576287	24	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	myocardial infarction	0.581891484264645	13	cardioVascular
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	esophageal squamous cell carcinoma	0.581722333143848	150	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	osteoarthritis	0.581476497553818	17	muculoEskeletalConnective
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	hepatocellular carcinoma	0.581453884185817	29	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	lung disease	0.581433542946119	43	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	lung disease	0.581433542946119	43	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Cough	0.581380049750662	12	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Cough	0.581380049750662	12	respiratory
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	seasonal allergic rhinitis	0.581326863490048	9	immune
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	scoliosis	0.581086621208305	17	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	scoliosis	0.581086621208305	17	muculoEskeletalConnective
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	renal cell carcinoma	0.581080744195547	138	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	conduct disorder	0.580921152944216	8	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	spinal cord disease	0.580512916716499	9	nervousSystem
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	uterine neoplasm	0.580345234831025	177	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	targetBased	363803	502	cardiac arrhythmia	0.580213188041739	7	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	targetBased	363803	2629	cardiac arrhythmia	0.580213188041739	7	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	targetBased	363803	1450	cardiac arrhythmia	0.580213188041739	7	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	tic disorder	0.580042296367147	42	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	tic disorder	0.580042296367147	42	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	tic disorder	0.580042296367147	42	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	tic disorder	0.580042296367147	42	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	tic disorder	0.580042296367147	42	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	tic disorder	0.580042296367147	42	psychiatricDisorder
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	targetBased	309684	1662	Wolf-Hirschhorn syndrome	0.580036883778645	149	psychiatricDisorder
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	targetBased	104728	4230	familial hyperaldosteronism	0.579874415386324	5432	metabolicEndocrine
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	bipolar II disorder	0.579839258155331	11	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	bipolar II disorder	0.579839258155331	11	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	bipolar II disorder	0.579839258155331	11	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	bipolar II disorder	0.579839258155331	11	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	bipolar II disorder	0.579839258155331	11	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	bipolar II disorder	0.579839258155331	11	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	bipolar II disorder	0.579805448943178	8	psychiatricDisorder
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	46,XY complete gonadal dysgenesis	0.579738241896345	77	muculoEskeletalConnective
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	46,XY complete gonadal dysgenesis	0.579738241896345	77	muculoEskeletalConnective
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	urinary bladder carcinoma	0.579693725876986	67	cancer
uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation	EIF4E_inhibition	targetBased	217332	799	neurodegenerative disease	0.579549606498111	10	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	leiomyosarcoma	0.579427927799183	247	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	leiomyosarcoma	0.579427927799183	247	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	leiomyosarcoma	0.579427927799183	247	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	leiomyosarcoma	0.579427927799183	247	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	leiomyosarcoma	0.579427927799183	247	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	portal hypertension	0.579427222756886	14	metabolicEndocrine
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	osteoarthritis, knee	0.579400705699943	14	muculoEskeletalConnective
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	Intellectual disability	0.579381490814232	14	nervousSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	Intellectual disability	0.579381490814232	14	nervousSystem
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	male infertility	0.579314160133462	144	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	male infertility	0.579314160133462	144	reproductiveSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	upper aerodigestive tract neoplasm	0.578977454387374	45	cancer
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	hypertrophic cardiomyopathy	0.578848118498312	10	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	hypertrophic cardiomyopathy	0.578848118498312	10	muculoEskeletalConnective
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	schizoaffective disorder	0.578791172578599	8	psychiatricDisorder
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	lymphoma	0.578691902621926	614	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	overdose	0.578681292639103	12	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	overdose	0.578681292639103	12	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	irritable bowel syndrome	0.578284034396309	9	gastroIntestinal
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	irritable bowel syndrome	0.578284034396309	9	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	irritable bowel syndrome	0.578284034396309	9	gastroIntestinal
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	irritable bowel syndrome	0.578284034396309	9	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	irritable bowel syndrome	0.578284034396309	9	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	myocardial infarction	0.578271542280002	11	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	myocardial infarction	0.578271542280002	11	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	cardiac arrhythmia	0.578250225184157	7	cardioVascular
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	cardiac arrhythmia	0.578250225184157	7	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	cardiac arrhythmia	0.578250225184157	7	cardioVascular
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	cardiac arrhythmia	0.578250225184157	7	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	cardiac arrhythmia	0.578250225184157	7	cardioVascular
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	ovarian neoplasm	0.578223516620776	256	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	substance abuse	0.577999965458365	102	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	substance abuse	0.577999965458365	102	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	substance abuse	0.577999965458365	102	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	substance abuse	0.577999965458365	102	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	substance abuse	0.577999965458365	102	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	substance abuse	0.577999965458365	102	psychiatricDisorder
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	squamous cell lung carcinoma	0.577906415694614	34	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	opioid dependence	0.577905333654408	10	psychiatricDisorder
Fluorescence polarization assay for PLK1 inhibitors	PLK1	targetBased	97099	518	Parkinson disease	0.577878323850478	9	nervousSystem
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	targetBased	364065	10181	Parkinson disease	0.577878323850478	9	nervousSystem
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	cancer	0.577800245386886	206	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	cancer	0.577800245386886	206	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	ventricular tachycardia	0.577574040941104	8	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	substance withdrawal syndrome	0.577358284792966	38	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	substance withdrawal syndrome	0.577358284792966	38	psychiatricDisorder
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	neurodegenerative disease	0.577328189160672	45	nervousSystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	inflammatory bowel disease	0.577230617368294	191	immune
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	obesity	0.577168330395272	6	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	humerus fracture	0.577168330395272	6	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	humerus fracture	0.577168330395272	6	muculoEskeletalConnective
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	humerus fracture	0.577168330395272	6	muculoEskeletalConnective
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	698	cardiac arrhythmia	0.577168330395272	6	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	2133	cardiac arrhythmia	0.577168330395272	6	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	1081	cardiac arrhythmia	0.577168330395272	6	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	post operative nausea and vomiting	0.577168330395272	6	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	post operative nausea and vomiting	0.577168330395272	6	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	ventricular tachycardia	0.577168330395272	6	cardioVascular
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	ventricular tachycardia	0.577168330395272	6	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	ventricular tachycardia	0.577168330395272	6	cardioVascular
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	ventricular tachycardia	0.577168330395272	6	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	ventricular tachycardia	0.577168330395272	6	cardioVascular
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	ventricular tachycardia	0.577168330395272	6	cardioVascular
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	septic shock	0.577168330395272	6	infective
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	sprain	0.577168330395272	6	otherPhenotypes
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	head injury	0.577168330395272	6	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	cerebral palsy	0.577168330395272	6	nervousSystem
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	myxedema	0.577168330395272	6	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Spasticity	0.577168330395272	6	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Hypothermia	0.577168330395272	6	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Hypothermia	0.577168330395272	6	otherPhenotypes
Factor XIIa 1536 HTS	F12_modulation	targetBased	217430	649	Reduced factor XII activity	0.577168330395272	6	hematologic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	constipation disorder	0.577168330395272	6	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	constipation disorder	0.577168330395272	6	gastroIntestinal
Fluorescence polarization assay for PLK1 inhibitors	PLK1	targetBased	97099	518	lysosomal storage disease	0.577168330395272	6	metabolicEndocrine
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	targetBased	364065	10181	lysosomal storage disease	0.577168330395272	6	metabolicEndocrine
Fluorescence polarization assay for PLK1 inhibitors	PLK1	targetBased	97099	518	Alzheimer disease	0.577168330395272	6	nervousSystem
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	targetBased	364065	10181	Alzheimer disease	0.577168330395272	6	nervousSystem
Fluorescence polarization assay for PLK1 inhibitors	PLK1	targetBased	97099	518	multiple sclerosis	0.577168330395272	6	immune
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	targetBased	364065	10181	multiple sclerosis	0.577168330395272	6	immune
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	hemophilia A	0.577168330395272	6	hematologic
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	targetBased	338373	1061	Noonan syndrome	0.577168330395272	6	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	Noonan syndrome	0.577168330395272	6	muculoEskeletalConnective
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	Noonan syndrome	0.577168330395272	6	muculoEskeletalConnective
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	coronary atherosclerosis	0.577168330395272	6	cardioVascular
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	genetic disorder	0.577057896667204	3526	geneticDisorder
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	genetic disorder	0.577057896667204	3526	geneticDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	hereditary breast ovarian cancer syndrome	0.577008661057121	104	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	hereditary breast ovarian cancer syndrome	0.577008661057121	104	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	hereditary breast ovarian cancer syndrome	0.577008661057121	104	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	hereditary breast ovarian cancer syndrome	0.577008661057121	104	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	hereditary breast ovarian cancer syndrome	0.577008661057121	104	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	body fat percentage	0.576341088252982	45	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	body fat percentage	0.576341088252982	45	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	body fat percentage	0.576341088252982	45	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	body fat percentage	0.576341088252982	45	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	body fat percentage	0.576341088252982	45	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	body fat percentage	0.576341088252982	45	metabolicEndocrine
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	schizophrenia	0.576028462802304	99	psychiatricDisorder
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	neurodegenerative disease	0.576017409602427	101	nervousSystem
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	neurodegenerative disease	0.576017409602427	101	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	premature ejaculation	0.575894850070855	11	reproductiveSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	premature ejaculation	0.575894850070855	11	reproductiveSystem
uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay	SENP1	targetBased	363840	774	neurodegenerative disease	0.575703329789328	7	nervousSystem
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	Graves disease	0.575702894356837	2048	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	Graves disease	0.575702894356837	2048	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	Graves disease	0.575702894356837	2048	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	Graves disease	0.575702894356837	2048	metabolicEndocrine
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	primary ovarian insufficiency	0.575632336673213	51	reproductiveSystem
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	pain	0.575594093745969	11	nervousSystem
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	gastric adenocarcinoma	0.575548071830238	88	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	HIV infection	0.575537830851285	26	infective
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	HIV infection	0.575537830851285	26	infective
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	Hypercholesterolemia	0.575286284252107	9	metabolicEndocrine
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Hepatobiliary Neoplasm	0.575005198667495	744	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	CEBALID syndrome	0.574961843030568	17	geneticDisorder
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	hearing loss, autosomal recessive	0.574957700449752	11	nervousSystem
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	hearing loss, autosomal recessive	0.574957700449752	11	nervousSystem
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	mood disorder	0.574924572650151	332	psychiatricDisorder
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	suicidal ideation	0.574864567642163	18	nervousSystem
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	Myocardial Ischemia	0.574534968426493	8	cardioVascular
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	acute respiratory distress syndrome	0.574515955536212	10	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	drug dependence	0.574467276224984	70	psychiatricDisorder
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	genetic disorder	0.574357762572689	450	geneticDisorder
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	targetBased	290726	671	neurodegenerative disease	0.574191290410045	9	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	astrocytoma	0.573950587211972	792	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	astrocytoma	0.573950587211972	792	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	astrocytoma	0.573950587211972	792	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	astrocytoma	0.573950587211972	792	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	astrocytoma	0.573950587211972	792	cancer
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	gestational diabetes	0.573876632832523	32	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	gestational diabetes	0.573876632832523	32	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	gestational diabetes	0.573876632832523	32	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gallbladder carcinoma	0.573784445368201	151	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gallbladder carcinoma	0.573784445368201	151	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gallbladder carcinoma	0.573784445368201	151	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gallbladder carcinoma	0.573784445368201	151	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gallbladder carcinoma	0.573784445368201	151	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	cancer	0.573653134243772	251	cancer
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	cancer	0.573653134243772	251	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	cancer	0.573653134243772	251	cancer
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	cancer	0.573653134243772	251	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	cancer	0.573653134243772	251	cancer
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	cancer	0.573653134243772	251	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	ovarian disease	0.573470389432472	7344	reproductiveSystem
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	targetBased	385746	932	juvenile amyotrophic lateral sclerosis	0.573170704033966	30	nervousSystem
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	cutaneous melanoma	0.573097734825806	104	cancer
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	esophageal cancer	0.572918676553839	22	cancer
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	leukemia	0.572630433777704	14	cancer
E3 Ligase HTS_1536	MDM2	targetBased	207811	220	cancer	0.572600603058696	5421	cancer
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	targetBased	205582	727	intellectual disability, autosomal recessive 59	0.572390863323355	12	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	Malignant Pancreatic Neoplasm	0.572204935185042	204	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	papillary renal cell carcinoma	0.571926902752998	24	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	asthma	0.571802370116916	77	respiratory
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	nevus	0.571671843940988	81	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	irritable bowel syndrome	0.571601682713427	23	gastroIntestinal
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	irritable bowel syndrome	0.571601682713427	23	gastroIntestinal
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	irritable bowel syndrome	0.571601682713427	23	gastroIntestinal
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	irritable bowel syndrome	0.571601682713427	23	gastroIntestinal
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	irritable bowel syndrome	0.571601682713427	23	gastroIntestinal
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	irritable bowel syndrome	0.571601682713427	23	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	breast cancer	0.570632065715757	30	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	breast cancer	0.570632065715757	30	cancer
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	hemoglobin measurement	0.570577910064087	16	hematologic
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	hemoglobin measurement	0.570577910064087	16	hematologic
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	hepatocellular carcinoma	0.570526943027433	87	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Conjunctival telangiectasia	0.570511616340399	6831	visualSystem
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	hereditary neoplastic syndrome	0.570307346678232	260	cancer
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	hereditary neoplastic syndrome	0.570307346678232	260	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	COVID-19	0.570269521289546	42	infective
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	targetBased	369953	1241	genetic disorder	0.570111972447282	56	geneticDisorder
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	genetic disorder	0.569711110838301	1424	geneticDisorder
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	mental or behavioural disorder	0.569683743699563	262	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	acute respiratory distress syndrome	0.569651415559999	9	respiratory
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	acute respiratory distress syndrome	0.569651415559999	9	respiratory
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	anaplastic astrocytoma	0.569608536065496	177	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	anaplastic astrocytoma	0.569608536065496	177	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	anaplastic astrocytoma	0.569608536065496	177	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	anaplastic astrocytoma	0.569608536065496	177	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	anaplastic astrocytoma	0.569608536065496	177	cancer
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	rhabdomyosarcoma	0.569574565978751	92	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	open-angle glaucoma	0.569561257660925	6	visualSystem
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	open-angle glaucoma	0.569561257660925	6	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	open-angle glaucoma	0.569561257660925	6	visualSystem
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	open-angle glaucoma	0.569561257660925	6	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	open-angle glaucoma	0.569561257660925	6	visualSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	rib fracture	0.569561257660925	6	muculoEskeletalConnective
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	cerebral palsy	0.569561257660925	6	nervousSystem
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	cerebral palsy	0.569561257660925	6	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	cerebral palsy	0.569561257660925	6	nervousSystem
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	cerebral palsy	0.569561257660925	6	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	cerebral palsy	0.569561257660925	6	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Neurodevelopmental disorder	0.569435323605255	923	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Neurodevelopmental disorder	0.569435323605255	923	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	Mantle cell lymphoma	0.569305702678426	72	cancer
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	cervical squamous cell carcinoma	0.569304558236886	12	cancer
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	cervical squamous cell carcinoma	0.569304558236886	12	cancer
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	Abnormality of the cardiovascular system	0.569277510327076	411	cardioVascular
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	Abnormality of the cardiovascular system	0.569277510327076	411	cardioVascular
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	Pruritus	0.569007324270006	86	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	depressive disorder	0.568729888416492	32	psychiatricDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	depressive disorder	0.568729888416492	32	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	short QT syndrome	0.568605630843682	215	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	short QT syndrome	0.568605630843682	215	cardioVascular
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	autoimmune disease	0.568589520918476	192	immune
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	autoimmune disease	0.568589520918476	192	immune
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	chronic obstructive pulmonary disease	0.568331115960879	53	respiratory
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	neurodegenerative disease	0.568226999632248	24	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	attention deficit hyperactivity disorder	0.568194468638635	19	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	attention deficit hyperactivity disorder	0.568194468638635	19	psychiatricDisorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	injury	0.568124714348561	40	otherPhenotypes
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	autism spectrum disorder	0.568058344635926	30	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	autism spectrum disorder	0.568058344635926	30	psychiatricDisorder
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	diabetic nephropathy	0.567904792936959	90	metabolicEndocrine
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	cutaneous melanoma	0.567767359841182	34	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	papillary renal cell carcinoma	0.567761442812016	128	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	papillary renal cell carcinoma	0.567761442812016	128	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	papillary renal cell carcinoma	0.567761442812016	128	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	papillary renal cell carcinoma	0.567761442812016	128	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	papillary renal cell carcinoma	0.567761442812016	128	cancer
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	secondary Parkinson disease	0.567451434636309	6	metabolicEndocrine
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	fibromyalgia	0.567270683537583	15	muculoEskeletalConnective
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	fibromyalgia	0.567270683537583	15	muculoEskeletalConnective
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	fibromyalgia	0.567270683537583	15	muculoEskeletalConnective
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	fibromyalgia	0.567270683537583	15	muculoEskeletalConnective
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	fibromyalgia	0.567270683537583	15	muculoEskeletalConnective
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	fibromyalgia	0.567270683537583	15	muculoEskeletalConnective
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	inborn error of immunity	0.567222711159724	483	immune
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	inborn error of immunity	0.567222711159724	483	immune
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	Patent ductus arteriosus	0.567131293854564	20	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	rotator cuff tear	0.567119417340278	15	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	rotator cuff tear	0.567119417340278	15	muculoEskeletalConnective
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	cutaneous melanoma	0.566976009544841	60	cancer
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	lymphoma	0.566768728375716	18	cancer
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	Abnormality of the nervous system	0.566476400857916	112	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	Abnormality of the nervous system	0.566476400857916	112	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	Abnormality of the nervous system	0.566476400857916	112	nervousSystem
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	unspecified peripheral T-cell lymphoma	0.566224706091656	20	cancer
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	cutaneous melanoma	0.566105204863099	9	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	cutaneous melanoma	0.566105204863099	9	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	rhabdomyosarcoma	0.566060561247714	32	cancer
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	pain	0.565948160307315	14	nervousSystem
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	pain	0.565948160307315	14	nervousSystem
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	pain	0.565948160307315	14	nervousSystem
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	anovulation	0.565777313387203	23	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	anovulation	0.565777313387203	23	reproductiveSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	nicotine dependence	0.565774937759867	57	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	nicotine dependence	0.565774937759867	57	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	lung disease	0.565673039075681	12	respiratory
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	cardiac arrest	0.565626365447611	27	cardioVascular
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	cancer	0.565605347025387	92	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	anxiety disorder	0.565599835045342	93	psychiatricDisorder
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	lung adenocarcinoma	0.565482845742141	126	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	eating disorder	0.565476040057905	31	psychiatricDisorder
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	targetBased	76168	1231	hypertension	0.565070002375135	27	cardioVascular
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	bone fracture	0.565035984166105	29	muculoEskeletalConnective
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	targetBased	217959	2616	neurodegenerative disease	0.565035496135817	92	nervousSystem
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	colorectal adenocarcinoma	0.564864589281233	18	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	colorectal adenocarcinoma	0.564864589281233	18	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Status Asthmaticus	0.564750926143729	15	respiratory
Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)	NR2E3	targetBased	362026	1281	Joubert syndrome and related disorders	0.564628920710667	36	nervousSystem
TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).	NR2E3	targetBased	314998	380	Joubert syndrome and related disorders	0.564628920710667	36	nervousSystem
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	382	nephrotic syndrome	0.564523814927137	122	urinarySystem
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	targetBased	305610	3253	nephrotic syndrome	0.564523814927137	122	urinarySystem
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	autoinflammatory syndrome	0.564415235811097	914	muculoEskeletalConnective
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ovarian carcinoma	0.564167801515414	1002	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ovarian carcinoma	0.564167801515414	1002	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ovarian carcinoma	0.564167801515414	1002	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ovarian carcinoma	0.564167801515414	1002	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ovarian carcinoma	0.564167801515414	1002	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Seizure	0.564151783716501	8	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Seizure	0.564151783716501	8	nervousSystem
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	neurodegenerative disease	0.564018684854049	11	nervousSystem
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	neurodegenerative disease	0.564018684854049	11	nervousSystem
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	Reduced left ventricular ejection fraction	0.563971467918354	9	cardioVascular
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	Specific learning disability	0.563878136093242	11	psychiatricDisorder
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	Specific learning disability	0.563878136093242	11	psychiatricDisorder
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	Abnormal facial shape	0.563878136093242	11	otherPhenotypes
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	Abnormal facial shape	0.563878136093242	11	otherPhenotypes
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	stroke	0.563827088782784	12	nervousSystem
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	stroke	0.563827088782784	12	nervousSystem
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	stroke	0.563827088782784	12	nervousSystem
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	targetBased	335214	1652	Seckel syndrome	0.563779003089398	24	psychiatricDisorder
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	T-cell non-Hodgkin lymphoma	0.563737443355213	18	cancer
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	monocyte count	0.563653416927251	46	hematologic
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	targetBased	288728	10857	mitochondrial disease	0.563489628065036	15	geneticDisorder
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	targetBased	288728	10857	mitochondrial disease	0.563489628065036	15	geneticDisorder
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	acute myeloid leukemia	0.563380212187245	510	cancer
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	Thromboembolism	0.563364509169008	126	hematologic
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	eosinophil count	0.563353850272379	31	hematologic
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	hearing loss	0.563348198535835	93	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colon adenocarcinoma	0.563271617866096	225	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colon adenocarcinoma	0.563271617866096	225	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colon adenocarcinoma	0.563271617866096	225	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colon adenocarcinoma	0.563271617866096	225	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colon adenocarcinoma	0.563271617866096	225	cancer
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	neoplasm	0.563185687279908	52761	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	colon carcinoma	0.563185208148079	25	cancer
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	neurodegenerative disease	0.562884079664889	9	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	gastroenteritis	0.562663370717272	11	gastroIntestinal
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	gastroenteritis	0.562663370717272	11	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	gastroenteritis	0.562663370717272	11	gastroIntestinal
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	gastroenteritis	0.562663370717272	11	gastroIntestinal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	gastroenteritis	0.562663370717272	11	gastroIntestinal
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	gastroenteritis	0.562663370717272	11	gastroIntestinal
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	eosinophil count	0.562408491365278	42	hematologic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	hypotension	0.562382434947179	9	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	hypotension	0.562382434947179	9	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	substance dependence	0.562245621886424	59	psychiatricDisorder
qHTS for Inhibitors of Glutaminase (GLS)	GLS	targetBased	405291	844	infantile cataract, skin abnormalities, glutamate excess, and impaired intellectual development	0.562179579674264	9	geneticDisorder
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	Cutaneous T-cell lymphoma	0.562111104478172	44	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	squamous cell carcinoma	0.561703048438636	329	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	brain injury	0.561120224360147	12	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	atrial flutter	0.561048672319976	20	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	atrial flutter	0.561048672319976	20	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	atrial flutter	0.561048672319976	20	cardioVascular
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Eczematoid dermatitis	0.560883027185879	20	otherPhenotypes
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	obesity	0.560691974339547	9	metabolicEndocrine
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	hip fracture	0.560682335264164	17	muculoEskeletalConnective
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	leukocyte count	0.560601777458065	76	hematologic
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Tip-toe gait	0.560405198256835	18	otherPhenotypes
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	follicular lymphoma	0.560395370472155	227	cancer
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	nicotine dependence	0.560198005654315	29	psychiatricDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	non-small cell lung carcinoma	0.560157288727676	289	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	Agitation	0.560128487470336	8	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Respiratory insufficiency	0.560128487470336	8	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Respiratory insufficiency	0.560128487470336	8	respiratory
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	targetBased	353950	4145	neurodegenerative disease	0.559746831113451	37	nervousSystem
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	absent or delayed speech development	0.559554695563483	14	psychiatricDisorder
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	Deeply set eye	0.559554695563483	14	visualSystem
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	head and neck squamous cell carcinoma	0.559322758217218	35	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	head and neck squamous cell carcinoma	0.559322758217218	35	cancer
qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)	PIP4K2A	targetBased	328860	4078	neurodegenerative disease	0.559303232996058	6	nervousSystem
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	heel bone mineral density	0.559275327168255	59	muculoEskeletalConnective
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	heel bone mineral density	0.559275327168255	59	muculoEskeletalConnective
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Borderline personality disorder	0.559271258805975	23	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Borderline personality disorder	0.559271258805975	23	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Borderline personality disorder	0.559271258805975	23	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Borderline personality disorder	0.559271258805975	23	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Borderline personality disorder	0.559271258805975	23	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Borderline personality disorder	0.559271258805975	23	psychiatricDisorder
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	kidney disease	0.558942391032917	360	urinarySystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Red cell distribution width	0.558888079392516	14	hematologic
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	non-Hodgkins lymphoma	0.558721101467953	569	cancer
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	non-Hodgkins lymphoma	0.558721101467953	569	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	rhinitis	0.558652137696846	31	respiratory
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	asthma	0.558542526045273	104	respiratory
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	Abnormal bleeding	0.558431392235399	18	hematologic
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	Abnormal bleeding	0.558431392235399	18	hematologic
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	autosomal dominant nonsyndromic hearing loss	0.558404046933777	123	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	tic disorder	0.558316127425329	18	psychiatricDisorder
qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1)	MCOLN1	targetBased	400814	482	mucolipidosis	0.558287279679423	524	metabolicEndocrine
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	fibrinogen measurement	0.558074033786004	29	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	fibrinogen measurement	0.558074033786004	29	hematologic
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	obesity	0.558027801578465	27	metabolicEndocrine
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	obesity	0.558027801578465	27	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gastric carcinoma	0.557967975359973	759	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gastric carcinoma	0.557967975359973	759	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gastric carcinoma	0.557967975359973	759	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gastric carcinoma	0.557967975359973	759	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gastric carcinoma	0.557967975359973	759	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	peritoneal neoplasm	0.557952605286964	96	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	respiratory system disease	0.557918542338559	323	respiratory
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	hypersomnia	0.557795651831803	7	psychiatricDisorder
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	bone fracture	0.557765397120809	12	muculoEskeletalConnective
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	protein measurement	0.557707909379901	37	hematologic
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	irritable bowel syndrome	0.557687575050289	12	gastroIntestinal
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	irritable bowel syndrome	0.557687575050289	12	gastroIntestinal
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	targetBased	31324	362	lean body mass	0.557680215912674	29	metabolicEndocrine
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adenocarcinoma	0.557676411022396	7865	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adenocarcinoma	0.557676411022396	7865	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adenocarcinoma	0.557676411022396	7865	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adenocarcinoma	0.557676411022396	7865	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adenocarcinoma	0.557676411022396	7865	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	familial atrial fibrillation	0.557484038987195	108	cardioVascular
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	familial pancreatic carcinoma	0.557390044105614	26	cancer
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pathwayBased	362051	17187	juvenile idiopathic arthritis	0.557333022236428	217	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	inherited obesity	0.557144807777269	70	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	inherited obesity	0.557144807777269	70	metabolicEndocrine
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	colorectal cancer	0.557138707214907	161	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	anorexia nervosa	0.557048668979413	32	nervousSystem
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Hot flashes	0.556904492876028	15	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Hot flashes	0.556904492876028	15	otherPhenotypes
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	chronic hepatitis C virus infection	0.556882803103682	6	infective
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	chronic hepatitis C virus infection	0.556882803103682	6	infective
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	chronic hepatitis C virus infection	0.556882803103682	6	infective
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	chronic hepatitis C virus infection	0.556882803103682	6	infective
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	chronic hepatitis C virus infection	0.556882803103682	6	infective
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	chronic hepatitis C virus infection	0.556882803103682	6	infective
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Bradycardia	0.556882803103682	6	cardioVascular
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Bradycardia	0.556882803103682	6	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Bradycardia	0.556882803103682	6	cardioVascular
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Bradycardia	0.556882803103682	6	cardioVascular
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Bradycardia	0.556882803103682	6	cardioVascular
Allosteric Modulators of D1 Receptors: Primary Screen	D1	targetBased	57705	3413	schizophrenia	0.556751417718264	233	psychiatricDisorder
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	targetBased	361330	3713	schizophrenia	0.556751417718264	233	psychiatricDisorder
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	targetBased	355805	11440	schizophrenia	0.556751417718264	233	psychiatricDisorder
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	Osteopenia	0.556646138618613	8	muculoEskeletalConnective
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	skin squamous cell carcinoma	0.556633806525779	44	cancer
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	dyschromatosis universalis hereditaria	0.556368558535973	36	dermatology
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Borderline personality disorder	0.556262633365197	27	psychiatricDisorder
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	thyroid carcinoma	0.556084553629844	50	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	reproductive system disease	0.556069929669968	1974	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	reproductive system disease	0.556069929669968	1974	reproductiveSystem
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	Feeding difficulties	0.556048555043949	12	otherPhenotypes
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	attempted suicide	0.556037572799865	6	nervousSystem
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	Cleft palate	0.556037572799865	6	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Cleft palate	0.556037572799865	6	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Cleft palate	0.556037572799865	6	otherPhenotypes
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	transient neonatal diabetes, dominant/recessive	0.555971773589769	33	pregnancyPerinatal
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	transient neonatal diabetes, dominant/recessive	0.555971773589769	33	pregnancyPerinatal
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	choroid plexus papilloma	0.555890050810532	14	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	choroid plexus papilloma	0.555890050810532	14	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	choroid plexus papilloma	0.555890050810532	14	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	choroid plexus papilloma	0.555890050810532	14	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	choroid plexus papilloma	0.555890050810532	14	nervousSystem
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	targetBased	234915	1245	hereditary neoplastic syndrome	0.555826756510399	103	cancer
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	hypogonadism	0.555819857005913	19	reproductiveSystem
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	diabetic nephropathy	0.555656269282092	300	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	diabetic nephropathy	0.555656269282092	300	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	diabetic nephropathy	0.555656269282092	300	metabolicEndocrine
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	movement disorder	0.555655515890195	27	nervousSystem
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	movement disorder	0.555655515890195	27	nervousSystem
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	targetBased	72072	2464	genetic disorder	0.555418973575424	80	geneticDisorder
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	targetBased	73912	5649	genetic disorder	0.555418973575424	80	geneticDisorder
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	blood protein measurement	0.555401607966835	76	hematologic
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	targetBased	104728	4230	childhood absence epilepsy	0.555369110677203	980	nervousSystem
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	myocardial infarction	0.555353879811961	333	cardioVascular
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	myocardial infarction	0.555353879811961	333	cardioVascular
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	myocardial infarction	0.555353879811961	333	cardioVascular
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	kidney disease	0.555299935898777	14	urinarySystem
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	melanoma	0.555227813487309	130	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	morbid obesity	0.555158533283897	8	metabolicEndocrine
qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)	RECQL	targetBased	234915	1245	Inherited cancer-predisposing syndrome	0.555135100896718	95	geneticDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	amblyopia	0.555091317350212	12	nervousSystem
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	amblyopia	0.555091317350212	12	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	amblyopia	0.555091317350212	12	nervousSystem
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	amblyopia	0.555091317350212	12	nervousSystem
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	amblyopia	0.555091317350212	12	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	respiratory depression	0.554945878660219	261	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	respiratory depression	0.554945878660219	261	respiratory
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	alopecia areata	0.554940346190329	45	dermatology
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	allergic disease	0.554877973171716	8	immune
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	allergic disease	0.554877973171716	8	immune
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	colorectal neoplasm	0.554868394038899	47	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	colorectal neoplasm	0.554868394038899	47	cancer
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	late-onset Parkinson disease	0.554854250374523	6	metabolicEndocrine
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	late-onset Parkinson disease	0.554854250374523	6	metabolicEndocrine
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	late-onset Parkinson disease	0.554854250374523	6	metabolicEndocrine
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	cerebral amyloid angiopathy	0.554715604164536	431	psychiatricDisorder
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	cerebral amyloid angiopathy	0.554715604164536	431	psychiatricDisorder
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	cerebral amyloid angiopathy	0.554715604164536	431	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	peripheral neuropathy	0.554662029590942	19	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	peripheral neuropathy	0.554662029590942	19	nervousSystem
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	pancreatitis	0.554613148487925	169	metabolicEndocrine
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	pancreatitis	0.554613148487925	169	metabolicEndocrine
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	multiple sclerosis	0.554511094041346	18	immune
uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6)	SENP6	targetBased	330392	5817	neurodegenerative disease	0.554494817370566	9	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	head and neck neoplasia	0.554202837992371	247	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Nausea and vomiting	0.554173663816071	11	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Nausea and vomiting	0.554173663816071	11	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Nausea and vomiting	0.554173663816071	11	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Nausea and vomiting	0.554173663816071	11	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Nausea and vomiting	0.554173663816071	11	otherPhenotypes
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	acute coronary syndrome	0.554062551323282	11	cardioVascular
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	depressive disorder	0.553635020531971	10	psychiatricDisorder
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	neoplasm of mature B-cells	0.553583014844976	351	cancer
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	attention deficit hyperactivity disorder	0.553383944086691	12	psychiatricDisorder
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	head and neck squamous cell carcinoma	0.553293708152968	66	cancer
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	head and neck squamous cell carcinoma	0.553293708152968	66	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	post-operative sign or symptom	0.553175059504274	7	otherPhenotypes
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Hyperkalemia	0.553098988776931	11	urinarySystem
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	bone quantitative ultrasound measurement	0.553003830357957	41	muculoEskeletalConnective
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	bone quantitative ultrasound measurement	0.553003830357957	41	muculoEskeletalConnective
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	targetBased	324747	7988	neurodegenerative disease	0.552731722062662	59	nervousSystem
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	coronary artery disease	0.552484115357613	54	cardioVascular
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	lymphocyte count	0.552482559460344	41	hematologic
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	myeloid neoplasm	0.552307095351119	1680	cancer
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	myeloid neoplasm	0.552307095351119	1680	cancer
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	lung disease	0.552280221607979	15	respiratory
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	toxicity	0.552250941038769	6	otherPhenotypes
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	targetBased	148480	6428	Pachydermoperiostosis	0.552231998408656	18	muculoEskeletalConnective
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	Back pain	0.552121233804408	21	nervousSystem
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	arteriosclerosis disorder	0.552064990371929	6	cardioVascular
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	obesity	0.552014995286952	13	metabolicEndocrine
USP8 deubiquitinase inhibition: Primary qHTS	USP8	targetBased	47480	2010	pituitary-dependent Cushing's disease	0.551867769967705	8	metabolicEndocrine
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	endometrial cancer	0.551806592823691	253	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	endometrial cancer	0.551806592823691	253	cancer
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	attention deficit hyperactivity disorder	0.551799572120731	32	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	attention deficit hyperactivity disorder	0.551799572120731	32	psychiatricDisorder
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	body height	0.551680303826237	14	otherPhenotypes
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	body height	0.551680303826237	14	otherPhenotypes
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	Glycogen storage disease due to acid maltase deficiency, adult onset	0.551611095948914	11	muculoEskeletalConnective
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	Glycogen storage disease due to acid maltase deficiency, adult onset	0.551611095948914	11	muculoEskeletalConnective
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	acute lymphoblastic leukemia	0.551609117000469	1706	cancer
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	acute lymphoblastic leukemia	0.551609117000469	1706	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	mental or behavioural disorder	0.551471869587019	1571	psychiatricDisorder
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	Sepsis	0.551397408916636	46	infective
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	carcinoma	0.551307642137785	39	cancer
uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase	ALPI_inhibitors	targetBased	330392	393	inflammatory bowel disease	0.551025850997796	30	immune
uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase	ALPI_inhibitors	targetBased	331670	664	inflammatory bowel disease	0.551025850997796	30	immune
Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase	ALPI_activators	targetBased	195570	326	inflammatory bowel disease	0.551025850997796	30	immune
uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase	ALPI_activators	targetBased	330392	537	inflammatory bowel disease	0.551025850997796	30	immune
uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase	ALPI_activators	targetBased	331670	785	inflammatory bowel disease	0.551025850997796	30	immune
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	kidney neoplasm	0.550908270499343	1037	cancer
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	heritable pulmonary arterial hypertension	0.550807387763399	108	respiratory
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	Abnormal skeletal morphology	0.550489496986252	13	muculoEskeletalConnective
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	carcinoma	0.550324090196856	10180	cancer
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	colorectal adenocarcinoma	0.550149135016612	6	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	Sjogren syndrome	0.549959690731184	17	visualSystem
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	acute myeloid leukemia	0.549734792816803	69	cancer
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	Seizure	0.549729739789671	12	nervousSystem
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	movement disorder	0.549353067496944	104	nervousSystem
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pathwayBased	362051	17187	pericarditis	0.549333638497012	69	cardioVascular
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	ovarian cancer	0.549119798919808	36	cancer
qHTS for Inhibitors of Glutaminase (GLS)	GLS	targetBased	405291	844	developmental and epileptic encephalopathy	0.549037961909993	11	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	orthostatic hypotension	0.549035277361439	18	cardioVascular
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	anxiety disorder	0.548807219432151	18	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	anxiety disorder	0.548807219432151	18	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	anxiety disorder	0.548807219432151	18	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	targetBased	368927	3838	Intellectual disability	0.548715545063125	50	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	allergic rhinitis	0.548658639799238	14	immune
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	post-traumatic stress disorder	0.548657439227214	17	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	post-traumatic stress disorder	0.548657439227214	17	psychiatricDisorder
High throughput discovery of novel modulators of ROMK K+ channel activity: Primary Screen	KCNJ1	targetBased	125268	2463	antenatal Bartter syndrome	0.548091936774417	20	geneticDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	sexual dysfunction	0.547899973728238	18	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	sexual dysfunction	0.547899973728238	18	reproductiveSystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	polycythemia	0.547877540544829	613	muculoEskeletalConnective
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	Primary hemophagocytic lymphohistiocytosis	0.547474714183054	63	immune
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).	PLCB3	targetBased	369953	662	spondylometaphyseal dysplasia with corneal dystrophy	0.547455667781784	6	geneticDisorder
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	heel bone mineral density	0.547319979971764	24	muculoEskeletalConnective
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	heart failure	0.547212563446782	10	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	heart failure	0.547212563446782	10	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	heart failure	0.547212563446782	10	cardioVascular
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	Intellectual disability	0.547021782892492	9	nervousSystem
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	targetBased	386663	3977	neoplasm	0.546990287972955	620	cancer
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	neoplasm	0.546980995818396	895	cancer
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	targetBased	309684	1662	syndromic intellectual disability	0.546843946436569	7	psychiatricDisorder
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)	DAGLB_inhibitors	targetBased	343468	202	osteogenesis imperfecta, type 21	0.546808807855395	11	muculoEskeletalConnective
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	renal colic	0.546604802609276	8	urinarySystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Headache	0.546604802609276	8	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Headache	0.546604802609276	8	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Headache	0.546604802609276	8	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Headache	0.546604802609276	8	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Headache	0.546604802609276	8	otherPhenotypes
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	tic disorder	0.546400426458304	13	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	tic disorder	0.546400426458304	13	psychiatricDisorder
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	targetBased	335777	499	psoriasis	0.546229169969465	140	immune
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	colorectal cancer	0.546180532377725	11	cancer
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	eosinophil count	0.546168104715194	45	hematologic
Factor XIIa 1536 HTS	F12_modulation	targetBased	217430	649	urticaria	0.546000964662808	58	dermatology
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	hereditary neoplastic syndrome	0.545499608537802	1596	cancer
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	hereditary neoplastic syndrome	0.545499608537802	1596	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	myeloid neoplasm	0.545293990265582	4706	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	bladder transitional cell carcinoma	0.545118569063374	43	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	uterine cervix neoplasm	0.544959939222638	510	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	uterine cervix neoplasm	0.544959939222638	510	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	uterine cervix neoplasm	0.544959939222638	510	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	uterine cervix neoplasm	0.544959939222638	510	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	uterine cervix neoplasm	0.544959939222638	510	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	gastric carcinoma	0.544948834234569	37	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	colorectal neoplasm	0.544854494739693	43	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	differentiated thyroid carcinoma	0.544852674219891	180	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	differentiated thyroid carcinoma	0.544852674219891	180	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	differentiated thyroid carcinoma	0.544852674219891	180	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	differentiated thyroid carcinoma	0.544852674219891	180	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	differentiated thyroid carcinoma	0.544852674219891	180	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	neurodegenerative disease	0.544728007188587	19	nervousSystem
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	targetBased	386270	1331	neurodegenerative disease	0.544693329001652	12	nervousSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	Cognitive impairment	0.544595988971466	25	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter	FXN	targetBased	356160	1985	genetic disorder	0.544545957572075	797	geneticDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	bone density	0.544372294829174	60	muculoEskeletalConnective
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	bone density	0.544372294829174	60	muculoEskeletalConnective
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	breast neoplasm	0.544285598520276	6	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	ataxia - telangiectasia variant	0.544159269596901	9	nervousSystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	hepatitis C virus infection	0.544053842545307	19	infective
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	hepatitis C virus infection	0.544053842545307	19	infective
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	hepatitis C virus infection	0.544053842545307	19	infective
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	hepatitis C virus infection	0.544053842545307	19	infective
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	hepatitis C virus infection	0.544053842545307	19	infective
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	hepatitis C virus infection	0.544053842545307	19	infective
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	autism spectrum disorder	0.543942541384409	55	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Lung Sarcomatoid Carcinoma	0.543809040454276	22	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Lung Sarcomatoid Carcinoma	0.543809040454276	22	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Lung Sarcomatoid Carcinoma	0.543809040454276	22	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Lung Sarcomatoid Carcinoma	0.543809040454276	22	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Lung Sarcomatoid Carcinoma	0.543809040454276	22	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	hemorrhage	0.543561973515538	7	hematologic
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	pancreatic ductal adenocarcinoma	0.543444771738886	68	cancer
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	cirrhosis of liver	0.543359118242622	6	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	fecal incontinence	0.543359118242622	6	gastroIntestinal
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	fecal incontinence	0.543359118242622	6	gastroIntestinal
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	intermediate coronary syndrome	0.543359118242622	6	cardioVascular
Allosteric Modulators of D1 Receptors: Primary Screen	D1	targetBased	57705	3413	neurodegenerative disease	0.543335400131825	31	nervousSystem
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	targetBased	361330	3713	neurodegenerative disease	0.543335400131825	31	nervousSystem
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	targetBased	355805	11440	neurodegenerative disease	0.543335400131825	31	nervousSystem
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pathwayBased	362051	17187	Muckle-Wells syndrome	0.543319270372889	54	muculoEskeletalConnective
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	prostate adenocarcinoma	0.543234231990126	23	cancer
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	Paraganglioma	0.543000850613236	125	cancer
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Uveal melanoma	0.542772169908436	179	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	cardiac arrhythmia	0.542720161698728	8	cardioVascular
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	cardiac arrhythmia	0.542720161698728	8	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	cardiac arrhythmia	0.542720161698728	8	cardioVascular
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	cardiac arrhythmia	0.542720161698728	8	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	cardiac arrhythmia	0.542720161698728	8	cardioVascular
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	cardiac arrhythmia	0.542720161698728	8	cardioVascular
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	neuralgia	0.542711443815767	17	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	obstructive sleep apnea	0.542693545696731	18	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	obstructive sleep apnea	0.542693545696731	18	psychiatricDisorder
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	targetBased	326022	1334	interstitial lung disease	0.542477327565812	37	respiratory
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	hypertension	0.542390725803381	20	cardioVascular
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	substance withdrawal syndrome	0.542268057325337	18	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	West syndrome	0.542134231909906	11	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	West syndrome	0.542134231909906	11	psychiatricDisorder
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	Behcet's syndrome	0.542016081643006	30	urinarySystem
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Cognitive impairment	0.541999650506393	1697	nervousSystem
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Cognitive impairment	0.541999650506393	1697	nervousSystem
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Cognitive impairment	0.541999650506393	1697	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	head and neck malignant neoplasia	0.541944538639202	1771	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	head and neck malignant neoplasia	0.541944538639202	1771	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	head and neck malignant neoplasia	0.541944538639202	1771	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	head and neck malignant neoplasia	0.541944538639202	1771	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	head and neck malignant neoplasia	0.541944538639202	1771	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	neoplasm	0.541889017137273	28013	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	atrial fibrillation	0.541829820157546	315	cardioVascular
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	atrial fibrillation	0.541829820157546	315	cardioVascular
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	neutrophil count	0.541800422744609	11	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	neutrophil count	0.541800422744609	11	hematologic
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	SLC6A3-related dopamine transporter deficiency syndrome	0.541755661651788	52	geneticDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	post-operative sign or symptom	0.541614541812703	9	otherPhenotypes
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	post-operative sign or symptom	0.541614541812703	9	otherPhenotypes
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	eosinophil count	0.541528896921096	26	hematologic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	peripheral arterial disease	0.541518657430405	12	cardioVascular
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	allergic disease	0.540851322143723	28	immune
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	leukocyte count	0.540782639544795	27	hematologic
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	leukocyte count	0.540782639544795	27	hematologic
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	follicular thyroid adenoma	0.540640624407186	22	cancer
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	follicular thyroid adenoma	0.540640624407186	22	cancer
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	follicular thyroid adenoma	0.540640624407186	22	cancer
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	follicular thyroid adenoma	0.540640624407186	22	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	complex neurodevelopmental disorder	0.540500710871587	898	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	complex neurodevelopmental disorder	0.540500710871587	898	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Nausea	0.540462795734878	9	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Nausea	0.540462795734878	9	otherPhenotypes
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	pulmonary blastoma	0.540460032301018	138	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Bronchiectasis	0.540316289148883	6	respiratory
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	branchio-oto-renal syndrome	0.540279967714392	41	geneticDisorder
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	Rare genetic deafness	0.540264391088458	42	nervousSystem
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	Rare genetic deafness	0.540264391088458	42	nervousSystem
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	Genetic 46,XY disorder of sex development	0.540259668835204	12	cancer
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	Genetic 46,XY disorder of sex development	0.540259668835204	12	cancer
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	inflammatory bowel disease	0.539973454347842	88	immune
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Anorexia	0.539970044931212	18	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Anorexia	0.539970044931212	18	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Anorexia	0.539970044931212	18	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Anorexia	0.539970044931212	18	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Anorexia	0.539970044931212	18	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Anorexia	0.539970044931212	18	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	stroke	0.539927483209128	7	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	stroke	0.539927483209128	7	nervousSystem
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	targetBased	40473	1400	intellectual disability, autosomal dominant 10	0.539916981653843	14	nervousSystem
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	endometrial cancer	0.539805519610671	45	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	cardiac arrhythmia	0.539628835168446	7	cardioVascular
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	atrial fibrillation	0.539624047756777	26	cardioVascular
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	hematocrit	0.539606154049657	12	hematologic
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	ST Elevation Myocardial Infarction	0.539555581875448	6	cardioVascular
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	myeloid neoplasm	0.539402074530581	535	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adrenal gland pheochromocytoma	0.539378622906823	39	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adrenal gland pheochromocytoma	0.539378622906823	39	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adrenal gland pheochromocytoma	0.539378622906823	39	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adrenal gland pheochromocytoma	0.539378622906823	39	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adrenal gland pheochromocytoma	0.539378622906823	39	cancer
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.	MCL1	targetBased	314998	2139	neurodegenerative disease	0.539248910974092	13	nervousSystem
uHTS of Mcl-1/Bid interaction inhibitors	MCL1	targetBased	218602	2129	neurodegenerative disease	0.539248910974092	13	nervousSystem
uHTS of Mcl-1/Noxa interaction inhibitors	MCL1	targetBased	217330	3334	neurodegenerative disease	0.539248910974092	13	nervousSystem
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	alcohol dependence	0.539074368589372	32	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cervical adenocarcinoma	0.538818108466208	100	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cervical adenocarcinoma	0.538818108466208	100	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cervical adenocarcinoma	0.538818108466208	100	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cervical adenocarcinoma	0.538818108466208	100	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cervical adenocarcinoma	0.538818108466208	100	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	lipodystrophy	0.538756514793434	170	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	lipodystrophy	0.538756514793434	170	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	lipodystrophy	0.538756514793434	170	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	lipodystrophy	0.538756514793434	170	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	lipodystrophy	0.538756514793434	170	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	lipodystrophy	0.538756514793434	170	metabolicEndocrine
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	chronic progressive multiple sclerosis	0.538635520397193	20	immune
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	targetBased	363803	458	neurodegenerative disease	0.538369387010613	9	nervousSystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	coronary artery disease	0.538184411305718	204	cardioVascular
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	coronary artery disease	0.538184411305718	204	cardioVascular
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	coronary artery disease	0.538184411305718	204	cardioVascular
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	coronary artery disease	0.538184411305718	204	cardioVascular
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	coronary artery disease	0.538184411305718	204	cardioVascular
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	coronary artery disease	0.538184411305718	204	cardioVascular
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	Hereditary late-onset Parkinson disease	0.538121040106858	23	metabolicEndocrine
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	Hereditary late-onset Parkinson disease	0.538121040106858	23	metabolicEndocrine
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	Hereditary late-onset Parkinson disease	0.538121040106858	23	metabolicEndocrine
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	erythrocyte count	0.538077017074459	11	hematologic
Primary cell-based high-throughput screening assay to measure PERK inhibition	PERK_inhibitors	targetBased	217959	370	neurodegenerative disease	0.537983171760528	102	nervousSystem
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	autosomal recessive non-syndromic intellectual disability	0.537940614194576	28	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	schizophrenia	0.537788597367771	37	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	schizophrenia	0.537788597367771	37	psychiatricDisorder
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	targetBased	194152	1342	neurodegenerative disease	0.537758733599517	21	nervousSystem
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	lymph node metastatic carcinoma	0.537572300872626	29	cancer
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	infertility	0.537453046426094	68	reproductiveSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	brain cancer	0.537444841116938	459	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	brain cancer	0.537444841116938	459	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	brain cancer	0.537444841116938	459	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	brain cancer	0.537444841116938	459	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	brain cancer	0.537444841116938	459	cancer
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	myeloid leukemia	0.537254273842718	378	cancer
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	mean corpuscular volume	0.537191446714195	32	hematologic
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	heart failure	0.537056766771359	15	cardioVascular
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	melanoma	0.536984685004855	430	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	chronic hepatitis C virus infection	0.536969177145771	8	infective
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	septic shock	0.536969177145771	8	infective
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lung cancer	0.536966635791938	1331	cancer
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	lung carcinoma	0.536803382389076	198	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	lung carcinoma	0.536803382389076	198	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	breast neoplasm	0.536580295784799	144	cancer
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	Abnormal bleeding	0.536543143506856	12	hematologic
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	pancreatic neoplasm	0.536472991523101	54	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	pancreatic neoplasm	0.536472991523101	54	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	Abnormality of the cardiovascular system	0.536386687475283	104	cardioVascular
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	breast adenocarcinoma	0.536209548600684	198	cancer
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	allergic rhinitis	0.535980475306307	47	immune
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cutaneous squamous cell carcinoma	0.535642478113645	93	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cutaneous squamous cell carcinoma	0.535642478113645	93	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cutaneous squamous cell carcinoma	0.535642478113645	93	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cutaneous squamous cell carcinoma	0.535642478113645	93	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cutaneous squamous cell carcinoma	0.535642478113645	93	cancer
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	Hepatobiliary Neoplasm	0.535619794263082	174	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	Hepatobiliary Neoplasm	0.535619794263082	174	cancer
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	Cowden disease	0.535270059891584	275	cancer
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	genetic non-acquired premature ovarian failure	0.535151368505697	11	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	genetic non-acquired premature ovarian failure	0.535151368505697	11	reproductiveSystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	neurodegenerative disease	0.534883338324039	90	nervousSystem
Primary HTS Assay for S1P3 Antagonists	S1PR3	targetBased	169141	462	monocyte percentage of leukocytes	0.534418257486305	9	hematologic
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	sex hormone-binding globulin measurement	0.534121828195915	12	reproductiveSystem
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	Ascending aortic dissection	0.534016505951106	8	otherPhenotypes
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	ovarian cancer	0.533934187309719	334	cancer
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	targetBased	368927	4094	neurodegenerative disease	0.533758386789442	16	nervousSystem
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	targetBased	343468	3417	neurodegenerative disease	0.533758386789442	16	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	myelodysplastic syndrome	0.533745835566975	780	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	myelodysplastic syndrome	0.533745835566975	780	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	myelodysplastic syndrome	0.533745835566975	780	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	myelodysplastic syndrome	0.533745835566975	780	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	myelodysplastic syndrome	0.533745835566975	780	cancer
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	lung carcinoma	0.533631681825241	335	cancer
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	mean corpuscular volume	0.533529352493559	83	hematologic
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	viral disease	0.533448005700228	76	infective
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	gastric adenocarcinoma	0.533364555936172	31	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	Intellectual disability	0.533070204890202	76	nervousSystem
HTS for 14-3-3 protein interaction modulators	YWHAG	targetBased	157962	312	genetic disorder	0.533018150257774	33	geneticDisorder
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	inflammatory bowel disease	0.532992751133878	89	immune
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	allergic rhinitis	0.532859659476675	20	immune
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	toothache	0.532764875117537	11	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	toothache	0.532764875117537	11	muculoEskeletalConnective
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	melanoma	0.532731295041119	55	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	cancer	0.532685560698662	562	cancer
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	urinary bladder cancer	0.532337192362235	30	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	urinary bladder cancer	0.532337192362235	30	cancer
uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay	COPS5	targetBased	363840	1401	Joubert syndrome	0.532318314379688	74	nervousSystem
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	congenital heart disease	0.532266653827459	10	cardioVascular
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	congenital heart disease	0.532266653827459	10	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	targetBased	359206	428	neurodegenerative disease	0.532226285183309	8	nervousSystem
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	eating disorder	0.531818103244732	10	psychiatricDisorder
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	eating disorder	0.531818103244732	10	psychiatricDisorder
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	eating disorder	0.531818103244732	10	psychiatricDisorder
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	head and neck squamous cell carcinoma	0.531641034089883	101	cancer
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	targetBased	138717	842	mean corpuscular hemoglobin concentration	0.531552989154815	14	hematologic
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	uterine neoplasm	0.531396657480323	110	cancer
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	esophageal carcinoma	0.531275226876165	65	cancer
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	targetBased	335777	499	ankylosing spondylitis	0.531074016498844	207	muculoEskeletalConnective
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	diffuse large B-cell lymphoma	0.531063254206481	67	cancer
Colorimetric Assay for Inhibitors for NALP1	NLRP1	targetBased	280024	1717	respiratory papillomatosis, juvenile recurrent, congenital	0.531061820994909	27	geneticDisorder
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	Short stature	0.530962407119983	6	otherPhenotypes
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	Short stature	0.530962407119983	6	otherPhenotypes
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	type 1 diabetes mellitus	0.530795116220742	83	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	type 1 diabetes mellitus	0.530795116220742	83	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	type 1 diabetes mellitus	0.530795116220742	83	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	type 1 diabetes mellitus	0.530795116220742	83	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	type 1 diabetes mellitus	0.530795116220742	83	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	type 1 diabetes mellitus	0.530795116220742	83	metabolicEndocrine
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	bladder transitional cell carcinoma	0.530771379279681	47	cancer
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	graft versus host disease	0.530616370782023	24	immune
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	breast carcinoma	0.530249603412033	201	cancer
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	neuroticism measurement	0.529970620572164	14	nervousSystem
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	neuroticism measurement	0.529970620572164	14	nervousSystem
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	neurodegenerative disease	0.529943602416502	353	nervousSystem
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	pulmonary embolism	0.529837764887743	9	cardioVascular
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	adenoma	0.529784692452108	89	cancer
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	adenoma	0.529784692452108	89	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	adenoma	0.529784692452108	89	cancer
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	adenoma	0.529784692452108	89	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	adenoma	0.529784692452108	89	cancer
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	adenoma	0.529784692452108	89	cancer
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	cardiac arrest	0.529763004236026	10	cardioVascular
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	neuropathic pain	0.529686109361221	14	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	neurotic disorder	0.529577792747223	64	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	neurotic disorder	0.529577792747223	64	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	neurotic disorder	0.529577792747223	64	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	neurotic disorder	0.529577792747223	64	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	neurotic disorder	0.529577792747223	64	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	neurotic disorder	0.529577792747223	64	psychiatricDisorder
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	body mass index	0.529527129428927	12	metabolicEndocrine
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	body mass index	0.529527129428927	12	metabolicEndocrine
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	kidney disease	0.529475545353634	15	urinarySystem
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	atrial flutter	0.529463532047883	9	cardioVascular
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	Headache	0.529395913623577	7	otherPhenotypes
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	acute myeloid leukemia	0.529206458958698	625	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	eosinophil count	0.529196236886013	22	hematologic
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	eosinophil count	0.529196236886013	22	hematologic
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	eosinophil count	0.529196236886013	22	hematologic
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	eosinophil count	0.529196236886013	22	hematologic
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	eosinophil count	0.529196236886013	22	hematologic
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	eosinophil count	0.529196236886013	22	hematologic
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	carcinoma of liver and intrahepatic biliary tract	0.529180688127008	146	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	carcinoma of liver and intrahepatic biliary tract	0.529180688127008	146	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	diabetes mellitus	0.529105742384322	476	metabolicEndocrine
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	postpartum depression	0.528912685748001	21	psychiatricDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	postpartum depression	0.528912685748001	21	psychiatricDisorder
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	schizophrenia	0.528898327260153	32	psychiatricDisorder
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	hemoglobin measurement	0.528898317686333	73	hematologic
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	protein measurement	0.528788155725603	31	hematologic
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	protein measurement	0.528788155725603	31	hematologic
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	ovarian carcinoma	0.528561751035599	76	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	hepatocellular carcinoma	0.528549083483217	245	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	childhood onset asthma	0.528510372937196	12	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	lung cancer	0.528383497749928	27	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	lung cancer	0.528383497749928	27	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	breast cancer	0.528340798710332	266	cancer
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	morbid obesity	0.528103011465632	23	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	morbid obesity	0.528103011465632	23	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	morbid obesity	0.528103011465632	23	metabolicEndocrine
Allosteric Modulators of D1 Receptors: Primary Screen	D1	targetBased	57705	3413	Tourette syndrome	0.528076886310531	23	psychiatricDisorder
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	targetBased	361330	3713	Tourette syndrome	0.528076886310531	23	psychiatricDisorder
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	targetBased	355805	11440	Tourette syndrome	0.528076886310531	23	psychiatricDisorder
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	rotator cuff tear	0.527975236729244	11	muculoEskeletalConnective
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	multiple sclerosis	0.527972301614307	14	immune
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	mean corpuscular hemoglobin	0.527919870832325	21	hematologic
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	Fuchs endothelial corneal dystrophy	0.527795610915018	9	visualSystem
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	electrocardiography	0.527705179950392	17	cardioVascular
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	congestive heart failure	0.527581485904718	6	cardioVascular
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	targetBased	217035	883	sex hormone-binding globulin measurement	0.527559111681462	30	reproductiveSystem
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	infertility	0.527380594556525	28	reproductiveSystem
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	osteogenesis imperfecta	0.527327245164823	65	muculoEskeletalConnective
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	genetic disorder	0.527218213611263	1867	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	genetic disorder	0.527218213611263	1867	geneticDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	heart disease	0.527003319061794	45	cardioVascular
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	substance abuse	0.526861384355099	57	psychiatricDisorder
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	familial restrictive cardiomyopathy	0.526611777023384	59	muculoEskeletalConnective
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	familial restrictive cardiomyopathy	0.526611777023384	59	muculoEskeletalConnective
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	anxiety	0.526319275317686	9	psychiatricDisorder
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	bipolar I disorder	0.526319275317686	9	psychiatricDisorder
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	multiple myeloma	0.526059241881704	50	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Digestive System Carcinoma	0.525636156396741	5759	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Digestive System Carcinoma	0.525636156396741	5759	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Digestive System Carcinoma	0.525636156396741	5759	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Digestive System Carcinoma	0.525636156396741	5759	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Digestive System Carcinoma	0.525636156396741	5759	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	migraine disorder	0.525317902710603	73	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	vaginal cancer	0.525105070833845	10	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	vaginal cancer	0.525105070833845	10	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	vaginal cancer	0.525105070833845	10	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	vaginal cancer	0.525105070833845	10	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	vaginal cancer	0.525105070833845	10	cancer
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	monocyte count	0.525053140584303	46	hematologic
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	multiple myeloma	0.524918664126389	29	cancer
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	anemia (phenotype)	0.524892488999053	11	hematologic
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	targetBased	369953	3123	angiosarcoma	0.524654275968588	7	cancer
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	mean corpuscular hemoglobin concentration	0.524565260505853	15	hematologic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	pulpitis	0.524471038386675	9	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	pulpitis	0.524471038386675	9	muculoEskeletalConnective
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	lymphocyte percentage of leukocytes	0.524444660668715	9	hematologic
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	AL amyloidosis	0.524188480440994	22	muculoEskeletalConnective
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	gastric carcinoma	0.524091359604701	8	cancer
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	targetBased	324747	1043	Chronic pain	0.524065327840843	8	nervousSystem
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	congenital heart disease	0.523986132818436	18	cardioVascular
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	infection	0.523915285191001	83	infective
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	Bronchiectasis	0.523752880488721	210	respiratory
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	Bronchiectasis	0.523752880488721	210	respiratory
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	hyperthyroidism	0.523521299969412	12	metabolicEndocrine
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	targetBased	338328	2501	postaxial polydactyly type A	0.523502780989542	13	muculoEskeletalConnective
uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6_antagonists	targetBased	340696	1654	rheumatoid arthritis	0.523283731423149	34	immune
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	atherosclerosis	0.523118463288717	14	cardioVascular
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	insomnia	0.523021843492775	12	psychiatricDisorder
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	lean body mass	0.522966736589418	12	metabolicEndocrine
Glucocerebrosidase	GBA1	targetBased	48118	549	genetic disorder	0.522961286522107	2389	geneticDisorder
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	grip strength measurement	0.522906509080935	35	muculoEskeletalConnective
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	targetBased	217035	883	serum alanine aminotransferase measurement	0.522832199327453	11	otherPhenotypes
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	targetBased	340696	540	mean corpuscular volume	0.522587039922814	26	hematologic
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	targetBased	290915	2982	Intellectual disability	0.522565290992928	6	nervousSystem
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	targetBased	359244	1307	Intellectual disability	0.522565290992928	6	nervousSystem
RNA aptamer-based HTS for inhibitors of GRK2	GRK2	targetBased	327939	1924	Jeune syndrome	0.522237752095036	12	muculoEskeletalConnective
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	cervical adenocarcinoma	0.522134222563113	17	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	cancer	0.521979003500729	323	cancer
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	cutaneous melanoma	0.521864485975192	44	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	alcohol abuse	0.521574715878931	11	psychiatricDisorder
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	dementia	0.521539092706237	119	psychiatricDisorder
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	targetBased	138717	842	hereditary breast carcinoma	0.521402826406466	18	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	renal carcinoma	0.521275564851696	754	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	renal carcinoma	0.521275564851696	754	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	renal carcinoma	0.521275564851696	754	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	renal carcinoma	0.521275564851696	754	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	renal carcinoma	0.521275564851696	754	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	colonic neoplasm	0.521265092035978	689	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	colonic neoplasm	0.521265092035978	689	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	colonic neoplasm	0.521265092035978	689	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	colonic neoplasm	0.521265092035978	689	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	colonic neoplasm	0.521265092035978	689	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	acne	0.521174640201791	8	dermatology
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	lean body mass	0.521145657342475	17	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	lean body mass	0.521145657342475	17	metabolicEndocrine
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	targetBased	31324	362	fat body mass	0.521144086906474	11	metabolicEndocrine
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	Beta-thalassemia	0.520897841651956	12	urinarySystem
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	mental or behavioural disorder	0.520891499859175	39	psychiatricDisorder
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	mental or behavioural disorder	0.520891499859175	39	psychiatricDisorder
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	pain	0.520819643474188	6	nervousSystem
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	intracranial vasospasm	0.520819643474188	6	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	low tension glaucoma	0.520819643474188	6	nervousSystem
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	breast cancer	0.520819643474188	6	cancer
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	reticulocyte count	0.520785206171264	20	hematologic
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	ovarian cancer	0.520714652864584	43	cancer
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	targetBased	362274	1085	nonsyndromic genetic hearing loss	0.520611792557172	38	nervousSystem
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	targetBased	326024	4934	Platelet-activating factor acetylhydrolase deficiency	0.520209973681166	12	hematologic
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	asthma	0.520166802217511	12	respiratory
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	status epilepticus	0.520086420560293	11	nervousSystem
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	cervical adenocarcinoma	0.520077721092215	24	cancer
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	post operative nausea and vomiting	0.519892362582376	12	otherPhenotypes
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	post operative nausea and vomiting	0.519892362582376	12	otherPhenotypes
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	Atrophic Vaginitis	0.519892362582376	12	reproductiveSystem
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	neutrophil count	0.519531683761622	21	hematologic
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	parp inhibitor response	0.519410926301161	6	otherPhenotypes
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	parp inhibitor response	0.519410926301161	6	otherPhenotypes
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	parp inhibitor response	0.519410926301161	6	otherPhenotypes
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	parp inhibitor response	0.519410926301161	6	otherPhenotypes
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	parp inhibitor response	0.519410926301161	6	otherPhenotypes
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	targetBased	326022	1334	Abnormal pulmonary interstitial morphology	0.519410926301161	6	otherPhenotypes
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	epidermal nevus syndrome	0.519410926301161	6	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	myopathy, congenital, with excess of muscle spindles	0.519410926301161	6	geneticDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	ovulation	0.519258439854514	11	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	ovulation	0.519258439854514	11	reproductiveSystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	neoplasm	0.519243461811769	4416	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	neoplasm	0.519243461811769	4416	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	neoplasm	0.519243461811769	4416	cancer
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	neoplasm	0.519243461811769	4416	cancer
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	neoplasm	0.519243461811769	4416	cancer
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	neoplasm	0.519243461811769	4416	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	hemorrhagic disease	0.519130401904105	26	hematologic
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	psoriasis	0.519072092168666	26	immune
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	eye disease	0.518999582067646	50	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	depressive disorder	0.518981413439618	11	psychiatricDisorder
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	depressive disorder	0.518981413439618	11	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	depressive disorder	0.518981413439618	11	psychiatricDisorder
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	depressive disorder	0.518981413439618	11	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	depressive disorder	0.518981413439618	11	psychiatricDisorder
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	reticulocyte count	0.518931501685393	11	hematologic
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	targetBased	363803	458	ulcerative colitis	0.518921467802981	15	immune
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	allergic disease	0.518691103234877	71	immune
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	opioid dependence	0.518667722386517	13	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	glioma	0.518623288479843	2036	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	glioma	0.518623288479843	2036	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	glioma	0.518623288479843	2036	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	glioma	0.518623288479843	2036	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	glioma	0.518623288479843	2036	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	rheumatoid arthritis	0.518622044684266	7	immune
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	ovarian neoplasm	0.518401315696728	245	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	T-cell acute lymphoblastic leukemia	0.518323037311425	58	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	bone disease	0.518297504276273	499	muculoEskeletalConnective
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	bone disease	0.518297504276273	499	muculoEskeletalConnective
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	leukemia	0.518197290267351	503	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	male reproductive organ cancer	0.518186328667181	44	cancer
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	overactive bladder	0.518182524926282	6	urinarySystem
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	targetBased	363840	3764	head and neck squamous cell carcinoma	0.517986428422721	40	cancer
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	Parkinson disease	0.517948677875559	11	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	high density lipoprotein cholesterol measurement	0.517829028574134	24	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	high density lipoprotein cholesterol measurement	0.517829028574134	24	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	body mass index	0.517791092042884	17	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	body mass index	0.517791092042884	17	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	body mass index	0.517791092042884	17	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	body mass index	0.517791092042884	17	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	body mass index	0.517791092042884	17	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	body mass index	0.517791092042884	17	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	colorectal cancer	0.517736107458662	9	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	colorectal cancer	0.517736107458662	9	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lung neoplasm	0.517562541508203	954	cancer
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	Thyrotoxicosis	0.517506253480117	315	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	Thyrotoxicosis	0.517506253480117	315	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	Thyrotoxicosis	0.517506253480117	315	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	Thyrotoxicosis	0.517506253480117	315	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	sex hormone-binding globulin measurement	0.517365234928652	33	reproductiveSystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	sex hormone-binding globulin measurement	0.517365234928652	33	reproductiveSystem
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	sex hormone-binding globulin measurement	0.517365234928652	33	reproductiveSystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	sex hormone-binding globulin measurement	0.517365234928652	33	reproductiveSystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	sex hormone-binding globulin measurement	0.517365234928652	33	reproductiveSystem
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	sex hormone-binding globulin measurement	0.517365234928652	33	reproductiveSystem
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	neutrophil count	0.517363544154237	15	hematologic
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	neutrophil count	0.517196008031586	27	hematologic
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	familial prostate carcinoma	0.516875235389713	6	cancer
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	interleukin 1 receptor-like 1 measurement	0.516816961193787	14	immune
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	systemic mastocytosis	0.516815843873698	12	cancer
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	congenital heart disease	0.516813251834099	7	cardioVascular
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Endometrial Polyp	0.516802768100669	42	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Endometrial Polyp	0.516802768100669	42	cancer
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	meningioma	0.516735037687015	12	cancer
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	targetBased	405130	6428	Hyperglycemia	0.516596040424956	758	metabolicEndocrine
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	targetBased	373462	23	Hyperglycemia	0.516596040424956	758	metabolicEndocrine
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	targetBased	405130	6428	Hyperglycemia	0.516596040424956	758	metabolicEndocrine
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	targetBased	217819	5697	cognitive function measurement	0.516586227462943	16	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	restless legs syndrome	0.516582222217723	9	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	restless legs syndrome	0.516582222217723	9	nervousSystem
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	endometrium neoplasm	0.516566251982747	98	cancer
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	Ischemic stroke	0.516525873530802	9	cardioVascular
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	Cough	0.516525873530802	9	respiratory
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	overactive bladder	0.516503334056033	9	urinarySystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	overactive bladder	0.516503334056033	9	urinarySystem
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Menorrhagia	0.516421046023942	9	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Menorrhagia	0.516421046023942	9	reproductiveSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	brain neoplasm	0.516390636682191	6	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	brain neoplasm	0.516390636682191	6	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	colorectal adenocarcinoma	0.516313607375484	40	cancer
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	sexual dysfunction	0.516153972197123	6	reproductiveSystem
Primary HTS Assay for S1P3 Antagonists	S1PR3	targetBased	169141	462	leukocyte count	0.516140572346041	39	hematologic
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	Thrombocytopenia	0.515889133368594	11	hematologic
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	prostate carcinoma	0.515874114696088	13	cancer
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	lung adenocarcinoma	0.515767117951293	97	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	lung adenocarcinoma	0.515767117951293	97	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Myelodysplastic/Myeloproliferative Neoplasm	0.515763988754042	39	cancer
uHTS HTRF assay for identification of inhibitors of SUMOylation	UBE2I	targetBased	290915	1039	neurodegenerative disease	0.515732094857419	8	nervousSystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	acute graft vs. host disease	0.515680643226986	9	immune
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	targetBased	335239	2035	post operative nausea and vomiting	0.515680643226986	9	otherPhenotypes
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	targetBased	335239	279	post operative nausea and vomiting	0.515680643226986	9	otherPhenotypes
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	targetBased	64908	446	post operative nausea and vomiting	0.515680643226986	9	otherPhenotypes
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	targetBased	64908	641	post operative nausea and vomiting	0.515680643226986	9	otherPhenotypes
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	coagulation factor measurement	0.515638045408026	6	hematologic
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	cardiac arrest	0.515630405814729	31	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	cardiac arrest	0.515630405814729	31	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	cardiac arrest	0.515630405814729	31	cardioVascular
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	targetBased	639428	9218	polycystic ovary syndrome	0.515572552941364	60	reproductiveSystem
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	triglyceride measurement	0.515570905781065	10	metabolicEndocrine
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	triglyceride measurement	0.515570905781065	10	metabolicEndocrine
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	T-B+ severe combined immunodeficiency	0.515494163057825	40	immune
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	serum alanine aminotransferase measurement	0.515407329254512	20	otherPhenotypes
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	serum alanine aminotransferase measurement	0.515407329254512	20	otherPhenotypes
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	serum alanine aminotransferase measurement	0.515407329254512	20	otherPhenotypes
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	serum alanine aminotransferase measurement	0.515407329254512	20	otherPhenotypes
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	serum alanine aminotransferase measurement	0.515407329254512	20	otherPhenotypes
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	serum alanine aminotransferase measurement	0.515407329254512	20	otherPhenotypes
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	blood phosphate measurement	0.515354604839092	23	hematologic
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	body height	0.515300145843167	11	otherPhenotypes
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	triglyceride measurement	0.515247998154276	14	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	triglyceride measurement	0.515247998154276	14	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	triglyceride measurement	0.515247998154276	14	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	triglyceride measurement	0.515247998154276	14	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	triglyceride measurement	0.515247998154276	14	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	triglyceride measurement	0.515247998154276	14	metabolicEndocrine
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	chronic kidney disease	0.515099145760397	31	urinarySystem
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	lymphoid neoplasm	0.515089787821532	44	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	cocaine dependence	0.515032348421456	92	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	cocaine dependence	0.515032348421456	92	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	cocaine dependence	0.515032348421456	92	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	cocaine dependence	0.515032348421456	92	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	cocaine dependence	0.515032348421456	92	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	cocaine dependence	0.515032348421456	92	psychiatricDisorder
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	targetBased	218528	711	movement disorder	0.514885375373638	44	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	targetBased	218528	770	movement disorder	0.514885375373638	44	nervousSystem
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	targetBased	218528	750	movement disorder	0.514885375373638	44	nervousSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Duchenne muscular dystrophy	0.514857952397938	8	muculoEskeletalConnective
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	acute myeloid leukemia	0.514639149025548	44	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	developmental and epileptic encephalopathy, 1	0.514339544478264	6	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	developmental and epileptic encephalopathy, 1	0.514339544478264	6	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	infantile epileptic-dyskinetic encephalopathy	0.514339544478264	6	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	infantile epileptic-dyskinetic encephalopathy	0.514339544478264	6	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Spasticity - intellectual disability - X-linked epilepsy	0.514339544478264	6	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Spasticity - intellectual disability - X-linked epilepsy	0.514339544478264	6	nervousSystem
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	thrombotic disease	0.514268280638907	18	cardioVascular
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	thrombotic disease	0.514268280638907	18	cardioVascular
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	musculoskeletal system disease	0.514238155627858	99	muculoEskeletalConnective
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	targetBased	338328	2501	preaxial polydactyly of fingers	0.514204542415849	6	muculoEskeletalConnective
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	nodular goiter	0.514169279031916	7	metabolicEndocrine
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	targetBased	76168	1231	pulmonary hypertension	0.514121558566674	17	cardioVascular
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	mean corpuscular volume	0.514100334861674	12	hematologic
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	mean corpuscular volume	0.514100334861674	12	hematologic
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	eosinophil count	0.514078667291535	14	hematologic
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	Ovarian Small Cell Carcinoma	0.514054706433331	164	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	adenoid cystic carcinoma	0.513954747920079	22	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	adenoid cystic carcinoma	0.513954747920079	22	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	adenoid cystic carcinoma	0.513954747920079	22	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	adenoid cystic carcinoma	0.513954747920079	22	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	adenoid cystic carcinoma	0.513954747920079	22	cancer
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	colorectal neoplasm	0.513929896480345	19	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Headache	0.513896061529299	13	otherPhenotypes
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	coronary artery disease	0.513875832928574	147	cardioVascular
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	coronary artery disease	0.513875832928574	147	cardioVascular
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	targetBased	292323	567	Abnormality of movement	0.513867929573946	8	otherPhenotypes
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	mean corpuscular volume	0.513853241245553	11	hematologic
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	mean corpuscular volume	0.513853241245553	11	hematologic
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	burn	0.513776057609053	6	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	burn	0.513776057609053	6	otherPhenotypes
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	multiple sclerosis	0.513718581157192	56	immune
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	platelet count	0.513483389362432	9	hematologic
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	platelet count	0.513483389362432	9	hematologic
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	myeloid white cell count	0.513455010475936	27	hematologic
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	targetBased	369953	3080	genetic disorder	0.513418809780063	473	geneticDisorder
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	eosinophil count	0.513404591520698	15	hematologic
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	eosinophil count	0.513404591520698	15	hematologic
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	peritoneum cancer	0.513391963949566	148	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	cerebellar ataxia	0.513266557507496	23	nervousSystem
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	targetBased	363840	3086	high density lipoprotein cholesterol measurement	0.513255797802339	14	metabolicEndocrine
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	metabolic syndrome	0.513066064153847	6	metabolicEndocrine
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	targetBased	331671	10022	bone marrow failure syndrome 6	0.513043524679079	6	muculoEskeletalConnective
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	coronary artery disease	0.513031657023707	18	cardioVascular
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	targetBased	31324	362	forced expiratory volume	0.512931148576678	8	respiratory
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	bronchoconstriction	0.512930827305237	6	otherPhenotypes
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	inherited prion disease	0.512862562729102	89	geneticDisorder
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	targetBased	639428	9218	sex hormone-binding globulin measurement	0.512797449636891	11	reproductiveSystem
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	cholangiocarcinoma	0.512777658836874	32	cancer
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	hematocrit	0.512591213709501	11	hematologic
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	hematocrit	0.512591213709501	11	hematologic
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	retinitis pigmentosa	0.512584351790701	68	metabolicEndocrine
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	blood protein measurement	0.512519522163457	23	hematologic
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	Parkinson disease	0.512498148428698	185	nervousSystem
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	gestational diabetes	0.512465339236712	62	metabolicEndocrine
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	erythrocyte count	0.512458045532973	12	hematologic
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Digestive System Carcinoma	0.512405747440022	957	cancer
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	cholestasis	0.512356311300188	11	gastroIntestinal
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	cholestasis	0.512356311300188	11	gastroIntestinal
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	lymphocyte percentage of leukocytes	0.512208341739393	15	hematologic
Allosteric Modulators of D1 Receptors: Primary Screen	D1	targetBased	57705	3413	hypertension	0.512185146348314	6	cardioVascular
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	targetBased	361330	3713	hypertension	0.512185146348314	6	cardioVascular
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	targetBased	355805	11440	hypertension	0.512185146348314	6	cardioVascular
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	hematopoietic and lymphoid system neoplasm	0.511943760414391	550	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	multiple sclerosis	0.511922137474039	26	immune
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	multiple sclerosis	0.511922137474039	26	immune
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	multiple sclerosis	0.511922137474039	26	immune
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	multiple sclerosis	0.511922137474039	26	immune
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	multiple sclerosis	0.511922137474039	26	immune
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Parkinson disease	0.511918072179894	141	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Parkinson disease	0.511918072179894	141	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Parkinson disease	0.511918072179894	141	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Parkinson disease	0.511918072179894	141	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Parkinson disease	0.511918072179894	141	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	head and neck carcinoma	0.511917474474916	1579	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	head and neck carcinoma	0.511917474474916	1579	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	head and neck carcinoma	0.511917474474916	1579	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	head and neck carcinoma	0.511917474474916	1579	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	head and neck carcinoma	0.511917474474916	1579	cancer
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	targetBased	290915	2982	Global developmental delay	0.511899646334581	8	otherPhenotypes
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	targetBased	359244	1307	Global developmental delay	0.511899646334581	8	otherPhenotypes
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Alzheimer disease	0.511773771609474	12	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Alzheimer disease	0.511773771609474	12	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Alzheimer disease	0.511773771609474	12	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Alzheimer disease	0.511773771609474	12	nervousSystem
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Alzheimer disease	0.511773771609474	12	nervousSystem
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	triglyceride measurement	0.511763821304796	8	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	targetBased	363803	458	vital capacity	0.511751699353967	12	nervousSystem
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	lysosomal storage disease	0.511744604694731	47	metabolicEndocrine
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	panic disorder	0.511722812322968	23	psychiatricDisorder
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	head and neck squamous cell carcinoma	0.511667802800374	19	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	head and neck squamous cell carcinoma	0.511667802800374	19	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	binge eating	0.511646077243436	8	psychiatricDisorder
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid hypoplasia	0.511564109249492	41	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	thyroid hypoplasia	0.511564109249492	41	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	thyroid hypoplasia	0.511564109249492	41	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	thyroid hypoplasia	0.511564109249492	41	metabolicEndocrine
HTS Assay for Peg3 Promoter Inhibitors	PPP1R15A	targetBased	359244	6145	neurodegenerative disease	0.511414146696408	9	nervousSystem
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	narcolepsy	0.511411229293004	40	psychiatricDisorder
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	peripheral neuropathy	0.511377243461816	809	nervousSystem
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	allergic disease	0.511316437424948	6	immune
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	diabetes mellitus	0.511277238254476	101	metabolicEndocrine
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	targetBased	343786	1253	Cholestasis	0.511236770729013	31	otherPhenotypes
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	targetBased	296501	2737	Cholestasis	0.511236770729013	31	otherPhenotypes
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.	ADAM10_inhibitors	targetBased	369953	2294	Alzheimer disease	0.511119614331058	17	nervousSystem
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	severe acute respiratory syndrome	0.511088225242917	8	infective
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	sarcoma	0.510898490357025	221	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	lymphocyte count	0.510858872706143	13	hematologic
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	severe acute respiratory syndrome	0.510857776805646	30	infective
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	targetBased	315412	318	schizophrenia	0.510856626964792	17	psychiatricDisorder
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	mean corpuscular hemoglobin concentration	0.510821888035741	32	hematologic
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	clear cell renal carcinoma	0.510792843766613	21	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	clear cell renal carcinoma	0.510792843766613	21	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	clear cell renal carcinoma	0.510792843766613	21	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	clear cell renal carcinoma	0.510792843766613	21	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	clear cell renal carcinoma	0.510792843766613	21	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	marginal zone B-cell lymphoma	0.510788412662706	8	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Malignant Pancreatic Neoplasm	0.510758820729503	70	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lysosomal storage disease	0.510748835743924	23	metabolicEndocrine
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lysosomal storage disease	0.510748835743924	23	metabolicEndocrine
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lysosomal storage disease	0.510748835743924	23	metabolicEndocrine
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lysosomal storage disease	0.510748835743924	23	metabolicEndocrine
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lysosomal storage disease	0.510748835743924	23	metabolicEndocrine
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	non-small cell lung carcinoma	0.510746001221223	4077	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	acute myocardial infarction	0.510726398888352	17	cardioVascular
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	bladder transitional cell carcinoma	0.510720357404753	27	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	bladder transitional cell carcinoma	0.510720357404753	27	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Thrombocytopenia	0.510664605818772	117	hematologic
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	carcinoma of liver and intrahepatic biliary tract	0.510579263830081	59	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Hepatobiliary Neoplasm	0.510567791113922	2837	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Hepatobiliary Neoplasm	0.510567791113922	2837	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Hepatobiliary Neoplasm	0.510567791113922	2837	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Hepatobiliary Neoplasm	0.510567791113922	2837	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Hepatobiliary Neoplasm	0.510567791113922	2837	cancer
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	reticulocyte count	0.510475068680431	24	hematologic
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Hepatobiliary Neoplasm	0.510429822432812	274	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Hepatobiliary Neoplasm	0.510429822432812	274	cancer
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	microphthalmia	0.510387699900412	12	visualSystem
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	Dementia	0.510298457303692	16	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	chronic kidney disease	0.510228231583128	12	urinarySystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	chronic kidney disease	0.510228231583128	12	urinarySystem
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	neoplasm	0.510157872963492	4780	cancer
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	ovarian cancer	0.510139151355727	22	cancer
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	ovarian cancer	0.510139151355727	22	cancer
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	ovarian cancer	0.510139151355727	22	cancer
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	ovarian cancer	0.510139151355727	22	cancer
Cell-based high throughput primary assay to identify activators of GPR151	GPR151	targetBased	642701	6746	body fat percentage	0.510129293451637	14	metabolicEndocrine
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	Microcephaly	0.510065718520128	15	otherPhenotypes
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	Microcephaly	0.510065718520128	15	otherPhenotypes
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	Alzheimer disease	0.509978156110572	6	nervousSystem
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	prostate carcinoma	0.509965207659139	140	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	chronic myeloproliferative disorder	0.509912994147925	5588	cancer
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	targetBased	353950	4145	thyroid hypoplasia	0.509848214804856	35	metabolicEndocrine
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Combined immunodeficiency	0.509775695278464	11	immune
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Combined immunodeficiency	0.509775695278464	11	immune
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	sexual dysfunction	0.509695304165687	17	reproductiveSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	sexual dysfunction	0.509695304165687	17	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	sexual dysfunction	0.509695304165687	17	reproductiveSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	sexual dysfunction	0.509695304165687	17	reproductiveSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	sexual dysfunction	0.509695304165687	17	reproductiveSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	sexual dysfunction	0.509695304165687	17	reproductiveSystem
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	Combined immunodeficiency	0.509686858131481	33	immune
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	malaria	0.509680221819924	11	infective
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	chronic myelogenous leukemia	0.509598213983665	271	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	drug dependence	0.509507133272657	51	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	panic disorder	0.509506968390538	11	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	panic disorder	0.509506968390538	11	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	panic disorder	0.509506968390538	11	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	panic disorder	0.509506968390538	11	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	panic disorder	0.509506968390538	11	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	panic disorder	0.509506968390538	11	psychiatricDisorder
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	ovarian cancer	0.509499952146859	147	cancer
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	cystic fibrosis	0.509487978883046	12	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Cognitive impairment	0.509396915955061	14	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Cognitive impairment	0.509396915955061	14	nervousSystem
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	targetBased	104728	4230	Seizure	0.509373379751668	11	nervousSystem
HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails	HP1-betaChromodomainInteractionsInhibitors	targetBased	383363	2142	viral disease	0.509151952880039	8	infective
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	C-reactive protein measurement	0.509064091101982	9	hematologic
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	C-reactive protein measurement	0.509064091101982	9	hematologic
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome	0.509035254749426	9	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	cerebral cortical dysplasia	0.508992815545776	120	nervousSystem
qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1)	APEX1_inhibitors	targetBased	345898	1172	neurodegenerative disease	0.508986414703378	19	nervousSystem
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	vitamin deficiency	0.508869431197495	75	otherPhenotypes
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	phakomatosis pigmentokeratotica	0.508862452109535	6	cancer
qHTS for Inhibitors of Glutaminase (GLS)	GLS	targetBased	405291	844	mean platelet volume	0.508735256331516	15	hematologic
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	carcinoma of liver and intrahepatic biliary tract	0.508700009478479	2659	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Tics	0.508640410022131	20	otherPhenotypes
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Tics	0.508640410022131	20	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Tics	0.508640410022131	20	otherPhenotypes
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Tics	0.508640410022131	20	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Tics	0.508640410022131	20	otherPhenotypes
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Tics	0.508640410022131	20	otherPhenotypes
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	targetBased	639428	9218	pulse pressure measurement	0.508571324863295	6	cardioVascular
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	targetBased	364053	2026	BOR syndrome	0.508497845130564	95	urinarySystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	breast adenocarcinoma	0.508319648934431	47	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	alcohol-related disorders	0.508266406705186	113	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	alcohol-related disorders	0.508266406705186	113	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	cutaneous lupus erythematosus	0.508265156028171	6	muculoEskeletalConnective
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	Red cell distribution width	0.508248795307349	14	hematologic
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	Red cell distribution width	0.508248795307349	14	hematologic
Glucocerebrosidase	GBA1	targetBased	48118	549	Thrombocytopenia	0.508225184903392	29	hematologic
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	peripheral arterial disease	0.507918611603607	9	cardioVascular
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	neuroblastoma	0.507751259134717	1059	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	neuroblastoma	0.507751259134717	1059	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	neuroblastoma	0.507751259134717	1059	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	neuroblastoma	0.507751259134717	1059	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	neuroblastoma	0.507751259134717	1059	cancer
qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1)	TDP1	targetBased	344442	978	Spinocerebellar ataxia type 1 with axonal neuropathy	0.507687855850537	23	visualSystem
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT	TDP1	targetBased	416824	63248	Spinocerebellar ataxia type 1 with axonal neuropathy	0.507687855850537	23	visualSystem
qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT	TDP1	targetBased	416856	49238	Spinocerebellar ataxia type 1 with axonal neuropathy	0.507687855850537	23	visualSystem
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Bradycardia	0.507645320472039	6	cardioVascular
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	thrombophilia	0.507615061227162	11	hematologic
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	thrombophilia	0.507615061227162	11	hematologic
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	Immunodeficiency	0.507538257966889	8	immune
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	Apnea	0.507493179017352	6	respiratory
Identification of Molecular Probes that Activate MRP-1	ABCC1_activators	targetBased	138717	842	mean corpuscular volume	0.507486032664877	11	hematologic
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	uterine disorder	0.507476068058557	607	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	uterine disorder	0.507476068058557	607	reproductiveSystem
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	Intellectual disability	0.507442465199123	6	nervousSystem
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	Red cell distribution width	0.507420205788685	11	hematologic
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	alcohol-related disorders	0.507369097179461	79	psychiatricDisorder
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease - ophthalmoplegia - cardiovascular calcification	0.507250879663592	6	metabolicEndocrine
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	targetBased	314998	2199	severe acute respiratory syndrome	0.507239609926207	6	infective
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	targetBased	363840	2624	hematocrit	0.507214442929743	62	hematologic
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	targetBased	319204	3065	low density lipoprotein cholesterol measurement	0.507078142237239	11	metabolicEndocrine
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	targetBased	316970	306	low density lipoprotein cholesterol measurement	0.507078142237239	11	metabolicEndocrine
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	colorectal cancer	0.507044449991793	11	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	fungal infectious disease	0.507022442086813	6	infective
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Asperger syndrome	0.506901236061246	11	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Asperger syndrome	0.506901236061246	11	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Asperger syndrome	0.506901236061246	11	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Asperger syndrome	0.506901236061246	11	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Asperger syndrome	0.506901236061246	11	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Asperger syndrome	0.506901236061246	11	psychiatricDisorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	leukocyte count	0.506555108845403	36	hematologic
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	hypothyroidism	0.506525369873782	28	metabolicEndocrine
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	hypothyroidism	0.506525369873782	28	metabolicEndocrine
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	neuroticism measurement	0.506410375043145	23	nervousSystem
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	neuroticism measurement	0.506410375043145	23	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	neuroticism measurement	0.506410375043145	23	nervousSystem
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	neuroticism measurement	0.506410375043145	23	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	neuroticism measurement	0.506410375043145	23	nervousSystem
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	neuroticism measurement	0.506410375043145	23	nervousSystem
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	uterine neoplasm	0.506284165020475	31	cancer
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	uterine neoplasm	0.506284165020475	31	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	neoplasm	0.505795193234879	607	cancer
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	neoplasm	0.505795193234879	607	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	neoplasm	0.505795193234879	607	cancer
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	neoplasm	0.505795193234879	607	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	neoplasm	0.505795193234879	607	cancer
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	neoplasm	0.505795193234879	607	cancer
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	targetBased	335239	2035	depressive disorder	0.505733262637839	22	psychiatricDisorder
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	targetBased	335239	279	depressive disorder	0.505733262637839	22	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	fibromyalgia	0.505730515267723	51	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	fibromyalgia	0.505730515267723	51	muculoEskeletalConnective
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	cirrhosis of liver	0.505376346678683	6	cancer
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	osteogenesis imperfecta	0.504678620737738	61	muculoEskeletalConnective
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	melanocytic neoplasm	0.504583292790778	93	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	cocaine dependence	0.504413979083123	32	psychiatricDisorder
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	targetBased	362274	1085	Rare genetic deafness	0.504264981526539	6	nervousSystem
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Hepatomegaly	0.504139263648615	7	otherPhenotypes
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	reproductive system disease	0.504093319777361	503	reproductiveSystem
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	cancer	0.504017619130342	164	cancer
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	targetBased	309684	1662	acute lymphoblastic leukemia	0.503855438557983	70	cancer
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	sex hormone-binding globulin measurement	0.503853378066006	11	reproductiveSystem
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	sex hormone-binding globulin measurement	0.503853378066006	11	reproductiveSystem
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	cancer	0.503838946288405	618	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Digestive System Carcinoma	0.503659990048741	223	cancer
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	respiratory system disease	0.503522045856373	15	respiratory
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	immunodeficiency 69	0.503413308689518	8	immune
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	epidermal appendage tumor	0.503317945774591	53	cancer
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	platelet count	0.503196509516558	9	hematologic
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	targetBased	314998	2199	platelet count	0.503049386602255	26	hematologic
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	anaplastic large cell lymphoma	0.503028356338076	26	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	breast-ovarian cancer, familial, susceptibility to, 1	0.502921046560576	8	geneticDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	pain	0.502874234984747	10	nervousSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	pain	0.502874234984747	10	nervousSystem
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	nephrolithiasis	0.502807214536861	17	urinarySystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	familial pancreatic carcinoma	0.502665805472282	18	cancer
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	targetBased	290915	2982	neurodegenerative disease	0.502663178367153	8	nervousSystem
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	targetBased	359244	1307	neurodegenerative disease	0.502663178367153	8	nervousSystem
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	colorectal neoplasm	0.502617440457158	133	cancer
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1)	PRMT1	targetBased	369953	4757	neurodegenerative disease	0.502599783695389	6	nervousSystem
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	targetBased	31324	362	body fat distribution	0.502294312755366	6	metabolicEndocrine
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	unipolar depression	0.502143011397617	12	psychiatricDisorder
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	carcinoma of liver and intrahepatic biliary tract	0.502012600305333	78	cancer
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	Inherited cancer-predisposing syndrome	0.501948780881195	46	geneticDisorder
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	Inherited cancer-predisposing syndrome	0.501948780881195	46	geneticDisorder
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	essential tremor	0.501948282330665	41	otherPhenotypes
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	essential tremor	0.501948282330665	41	otherPhenotypes
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	essential tremor	0.501948282330665	41	otherPhenotypes
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	nasopharyngeal neoplasm	0.501942833355626	6	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	HER2 Positive Breast Carcinoma	0.501942833355626	6	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	HER2 Positive Breast Carcinoma	0.501942833355626	6	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	bone quantitative ultrasound measurement	0.501865676168539	11	muculoEskeletalConnective
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	ABeta amyloidosis, Iowa type	0.501814132954698	6	psychiatricDisorder
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	ABeta amyloidosis, Iowa type	0.501814132954698	6	psychiatricDisorder
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	ABeta amyloidosis, Iowa type	0.501814132954698	6	psychiatricDisorder
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	diabetes mellitus	0.501787244287448	334	metabolicEndocrine
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	diabetes mellitus	0.501787244287448	334	metabolicEndocrine
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	genetic disorder	0.501739416565902	42	geneticDisorder
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	targetBased	639428	9218	alkaline phosphatase measurement	0.501543697849377	18	otherPhenotypes
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	cancer	0.501389938673998	20821	cancer
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	targetBased	46715	2829	ovarian cancer	0.501322871917439	40	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	aortic aneurysm	0.501060091567992	63	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	head and neck squamous cell carcinoma	0.500992087079442	21	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	head and neck squamous cell carcinoma	0.500992087079442	21	cancer
Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression	SNCA	pathwayBased	140118	236	blood protein measurement	0.500923769056078	6	hematologic
qHTS of alpha-syn Inhibitors	SNCA	pathwayBased	368791	501	blood protein measurement	0.500923769056078	6	hematologic
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	ABeta amyloidosis, dutch type	0.500813042182858	9	psychiatricDisorder
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	ABeta amyloidosis, dutch type	0.500813042182858	9	psychiatricDisorder
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	ABeta amyloidosis, dutch type	0.500813042182858	9	psychiatricDisorder
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	genetic disorder	0.500803416027687	332	geneticDisorder
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	body mass index	0.500783917608923	23	metabolicEndocrine
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	asthma	0.500776184626738	37	respiratory
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	asthma	0.500776184626738	37	respiratory
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	stomach neoplasm	0.500764838812246	68	cancer
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	Encephalopathy	0.500700306923787	18	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	leukemia	0.500371196337833	17	cancer
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	leukemia	0.500371196337833	17	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	esophageal cancer	0.500369861549014	257	cancer
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	monocyte percentage of leukocytes	0.500311638356786	12	hematologic
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	monocyte count	0.500249908552602	11	hematologic
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	monocyte count	0.500249908552602	11	hematologic
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	gambling behaviour	0.500222256227568	15	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	gambling behaviour	0.500222256227568	15	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	gambling behaviour	0.500222256227568	15	psychiatricDisorder
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	melanoma	0.500221889593926	2582	cancer
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	soft tissue sarcoma	0.500101901111415	2368	cancer
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	Romano-Ward syndrome	0.93814629135582	1206	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	Romano-Ward syndrome	0.93814629135582	1206	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	Romano-Ward syndrome	0.93814629135582	1206	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	targetBased	368927	3838	intellectual disability - sparse hair - brachydactyly	0.93166243656651	470	geneticDisorder
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	MPI-congenital disorder of glycosylation	0.92306803154231	773	metabolicEndocrine
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	MPI-congenital disorder of glycosylation	0.92306803154231	773	metabolicEndocrine
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	MPI-congenital disorder of glycosylation	0.92306803154231	773	metabolicEndocrine
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	familial amyotrophic lateral sclerosis	0.91464415824384	482	nervousSystem
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	familial amyotrophic lateral sclerosis	0.91464415824384	482	nervousSystem
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	targetBased	72072	2464	HSD10 mitochondrial disease	0.91026921331801	81	nervousSystem
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	targetBased	73912	5649	HSD10 mitochondrial disease	0.91026921331801	81	nervousSystem
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	infantile hypophosphatasia	0.90622530582871	371	metabolicEndocrine
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	hereditary breast carcinoma	0.89275999234869	1170	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	aneurysm-osteoarthritis syndrome	0.88651169542596	492	muculoEskeletalConnective
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	neoplasm	0.87594830406283	8058	cancer
Glucocerebrosidase	GBA1	targetBased	48118	549	Gaucher disease perinatal lethal	0.87178890644602	119	metabolicEndocrine
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	46,XY sex reversal 3	0.87124875351183	101	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	46,XY sex reversal 3	0.87124875351183	101	reproductiveSystem
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	hereditary hyperferritinemia with congenital cataracts	0.86894222650151	294	visualSystem
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2	0.83274242648193	85	psychiatricDisorder
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	targetBased	288728	10857	Congenital cataract - progressive muscular hypotonia - hearing loss - developmental delay	0.82172283003768	36	muculoEskeletalConnective
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	targetBased	288728	10857	Congenital cataract - progressive muscular hypotonia - hearing loss - developmental delay	0.82172283003768	36	muculoEskeletalConnective
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	cancer	0.80515992647272	2411	cancer
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	hereditary breast carcinoma	0.79096845653944	4641	cancer
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	breast carcinoma	0.79025743556127	934	cancer
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	familial hyperthyroidism due to mutations in TSH receptor	0.78816112707411	209	metabolicEndocrine
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	familial hyperthyroidism due to mutations in TSH receptor	0.78816112707411	209	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	familial hyperthyroidism due to mutations in TSH receptor	0.78816112707411	209	metabolicEndocrine
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	familial hyperthyroidism due to mutations in TSH receptor	0.78816112707411	209	metabolicEndocrine
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	targetBased	369953	3080	neonatal inflammatory skin and bowel disease	0.78132175077845	681	muculoEskeletalConnective
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	major depressive disorder	0.77144510239322	225	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	major depressive disorder	0.77144510239322	225	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	major depressive disorder	0.77144510239322	225	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	major depressive disorder	0.77144510239322	225	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	major depressive disorder	0.77144510239322	225	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	major depressive disorder	0.77144510239322	225	psychiatricDisorder
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	targetBased	344733	7043	Coffin-Siris syndrome	0.76887560431398	1260	muculoEskeletalConnective
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	breast adenocarcinoma	0.76578869022397	161	cancer
A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.	GMNN	targetBased	343234	9888	Ear-patella-short stature syndrome	0.76120314187953	15	muculoEskeletalConnective
A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.	GMNN	targetBased	342279	6233	Ear-patella-short stature syndrome	0.76120314187953	15	muculoEskeletalConnective
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	Charcot-Marie-Tooth disease type 2Y	0.75846913329776	32	geneticDisorder
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	cancer	0.74895001267032	16259	cancer
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	cancer	0.74895001267032	16259	cancer
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	targetBased	276265	806	thyroid hormone resistance syndrome	0.74824198378622	236	metabolicEndocrine
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	cryopyrin-associated periodic syndrome	0.74279650622679	2442	muculoEskeletalConnective
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	breast carcinoma	0.73759684515586	1997	cancer
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	ovarian neoplasm	0.73592106151764	111	cancer
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	targetBased	189882	6790	Lopes-Maciel-Rodan syndrome	0.73275567258744	41	nervousSystem
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	targetBased	48068	449	Lopes-Maciel-Rodan syndrome	0.73275567258744	41	nervousSystem
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	targetBased	220571	2380	Lopes-Maciel-Rodan syndrome	0.73275567258744	41	nervousSystem
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	targetBased	223611	305	Lopes-Maciel-Rodan syndrome	0.73275567258744	41	nervousSystem
Colorimetric Assay for Inhibitors for NALP1	NLRP1	targetBased	280024	1717	autoinflammation with arthritis and dyskeratosis	0.73031758163649	44	geneticDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gastric cancer	0.72652111587925	459	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gastric cancer	0.72652111587925	459	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gastric cancer	0.72652111587925	459	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gastric cancer	0.72652111587925	459	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gastric cancer	0.72652111587925	459	cancer
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	Blomstrand lethal chondrodysplasia	0.71396083712997	35	muculoEskeletalConnective
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	male infertility with azoospermia or oligozoospermia due to single gene mutation	0.71262050292756	170	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	male infertility with azoospermia or oligozoospermia due to single gene mutation	0.71262050292756	170	reproductiveSystem
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	prostate adenocarcinoma	0.71034534298668	56	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	melanoma	0.70849417048193	39	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	melanoma	0.70849417048193	39	cancer
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	Dyschromatosis universalis	0.70609412607071	11	geneticDisorder
Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE)	SIAE	targetBased	369933	2555	autoimmune disease	0.70498382256379	32	immune
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	cancer	0.70224437864131	665	cancer
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	genetic disorder	0.69650168059488	1794	geneticDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ovarian epithelial tumor	0.69364717737818	786	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ovarian epithelial tumor	0.69364717737818	786	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ovarian epithelial tumor	0.69364717737818	786	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ovarian epithelial tumor	0.69364717737818	786	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ovarian epithelial tumor	0.69364717737818	786	cancer
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	targetBased	338373	1061	cancer	0.69134586295159	158	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	rheumatoid arthritis	0.68876863655042	227	immune
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	lung adenocarcinoma	0.68606434581265	211	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	periodic paralysis	0.68356093063422	449	muculoEskeletalConnective
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	genetic disorder	0.68352650558631	1733	geneticDisorder
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	lung carcinoid tumor	0.67824858781795	26	cancer
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	colorectal adenocarcinoma	0.67820446347352	59	cancer
qHTS Assay for Identification of Novel General Anesthetics	FTL	targetBased	341499	255	L-ferritin deficiency	0.67761879609898	14	hematologic
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	unipolar depression	0.67704520260216	473	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	opioid dependence	0.67511318074411	666	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	opioid dependence	0.67511318074411	666	psychiatricDisorder
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	non-alcoholic fatty liver disease	0.67440205565891	877	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	non-alcoholic fatty liver disease	0.67440205565891	877	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	non-alcoholic fatty liver disease	0.67440205565891	877	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	non-alcoholic fatty liver disease	0.67440205565891	877	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	non-alcoholic fatty liver disease	0.67440205565891	877	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	non-alcoholic fatty liver disease	0.67440205565891	877	metabolicEndocrine
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	migraine disorder	0.66863024609379	163	nervousSystem
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	neoplasm	0.66776754745673	3322	cancer
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	pain	0.66739120894794	1664	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	type 2 diabetes mellitus	0.66637441362342	573	metabolicEndocrine
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	type 2 diabetes mellitus	0.66637441362342	573	metabolicEndocrine
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Crohn's disease	0.66633861809884	35	immune
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	cancer	0.66498110324478	4383	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	vitamin D deficiency	0.66393764534113	198	otherPhenotypes
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	breast neoplasm	0.66299167834792	1506	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Airway obstruction	0.66063970750587	92	respiratory
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	ocular hypertension	0.66025094772883	116	visualSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	targetBased	363803	502	chronic obstructive pulmonary disease	0.65800497078166	173	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	targetBased	363803	2629	chronic obstructive pulmonary disease	0.65800497078166	173	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	targetBased	363803	1450	chronic obstructive pulmonary disease	0.65800497078166	173	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	698	chronic obstructive pulmonary disease	0.65800497078166	173	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	2133	chronic obstructive pulmonary disease	0.65800497078166	173	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	1081	chronic obstructive pulmonary disease	0.65800497078166	173	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	aggressive behavior	0.65723170170587	63	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	aggressive behavior	0.65723170170587	63	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	aggressive behavior	0.65723170170587	63	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	aggressive behavior	0.65723170170587	63	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	aggressive behavior	0.65723170170587	63	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	aggressive behavior	0.65723170170587	63	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	aggressive behavior	0.65723170170587	63	psychiatricDisorder
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	pharyngitis	0.65652647227677	59	respiratory
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	targetBased	335239	2035	schizophrenia	0.65253676906973	96	psychiatricDisorder
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	targetBased	335239	279	schizophrenia	0.65253676906973	96	psychiatricDisorder
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Atrophy	0.65174071862781	45	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Atrophy	0.65174071862781	45	otherPhenotypes
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Splenomegaly	0.65073716130998	289	otherPhenotypes
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	relapsing-remitting multiple sclerosis	0.64736606261308	54	immune
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	targetBased	343467	1710	vital capacity	0.64677440372713	18	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	esophageal squamous cell carcinoma	0.64655628137229	1225	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	esophageal squamous cell carcinoma	0.64655628137229	1225	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	esophageal squamous cell carcinoma	0.64655628137229	1225	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	esophageal squamous cell carcinoma	0.64655628137229	1225	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	esophageal squamous cell carcinoma	0.64655628137229	1225	cancer
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	relapsing-remitting multiple sclerosis	0.64372552302434	48	immune
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	relapsing-remitting multiple sclerosis	0.64372552302434	48	immune
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335239	801	heart failure	0.64314305161478	117	cardioVascular
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	targetBased	335238	390	heart failure	0.64314305161478	117	cardioVascular
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	relapsing-remitting multiple sclerosis	0.64002439670588	53	immune
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	injury	0.63920957677244	77	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	injury	0.63920957677244	77	otherPhenotypes
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	connective tissue disease	0.63854754175007	547	muculoEskeletalConnective
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	cancer	0.63814917384931	1823	cancer
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	cancer	0.63814917384931	1823	cancer
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	malignant endocrine neoplasm	0.63675759302262	43	cancer
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	1225	46,XY partial gonadal dysgenesis	0.63355396095555	57	reproductiveSystem
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	targetBased	64908	359	46,XY partial gonadal dysgenesis	0.63355396095555	57	reproductiveSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	malignant endocrine neoplasm	0.63110038811149	4107	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	malignant endocrine neoplasm	0.63110038811149	4107	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	malignant endocrine neoplasm	0.63110038811149	4107	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	malignant endocrine neoplasm	0.63110038811149	4107	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	malignant endocrine neoplasm	0.63110038811149	4107	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	bone fracture	0.63093617484398	26	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	bone fracture	0.63093617484398	26	muculoEskeletalConnective
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	bipolar disorder	0.62804776439785	139	psychiatricDisorder
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	premature birth	0.62556973411477	24	otherPhenotypes
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	follow-up	0.62497799817203	20	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	Estrogen resistance syndrome	0.62458590288883	44	reproductiveSystem
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	Estrogen resistance syndrome	0.62458590288883	44	reproductiveSystem
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	lung adenocarcinoma	0.62431172792332	91	cancer
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	targetBased	318291	483	multiple myeloma	0.62323885367771	117	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	delirium	0.62243839148902	20	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	delirium	0.62243839148902	20	psychiatricDisorder
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	endometrial carcinoma	0.62230136368295	16	cancer
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	Parkinson disease	0.62030182859644	1115	nervousSystem
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	Parkinson disease	0.62030182859644	1115	nervousSystem
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	Parkinson disease	0.62030182859644	1115	nervousSystem
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	targetBased	405685	308	hypoparathyroidism	0.61948357909798	44	metabolicEndocrine
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	head and neck malignant neoplasia	0.61852796016747	404	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	obesity	0.61655642640449	21	metabolicEndocrine
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	lung adenocarcinoma	0.61641044122721	104	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	osteoarthritis, hip	0.61595213184444	18	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	osteoarthritis, hip	0.61595213184444	18	muculoEskeletalConnective
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	familial partial lipodystrophy, Dunnigan type	0.61433213627937	87	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	familial partial lipodystrophy, Dunnigan type	0.61433213627937	87	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	familial partial lipodystrophy, Dunnigan type	0.61433213627937	87	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	familial partial lipodystrophy, Dunnigan type	0.61433213627937	87	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	familial partial lipodystrophy, Dunnigan type	0.61433213627937	87	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	familial partial lipodystrophy, Dunnigan type	0.61433213627937	87	metabolicEndocrine
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	frontotemporal dementia with motor neuron disease	0.61360595321776	264	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	targetBased	369953	2602	genetic disorder	0.61267091078001	129	geneticDisorder
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	neurodegenerative disease	0.61128822057763	13	nervousSystem
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	genetic disorder	0.60810299220029	4821	geneticDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	targetBased	64908	366	Tourette syndrome	0.60757010167286	18	psychiatricDisorder
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	targetBased	61606	416	Tourette syndrome	0.60757010167286	18	psychiatricDisorder
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	targetBased	194629	219	cutaneous melanoma	0.60668394398872	21	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	targetBased	194628	521	cutaneous melanoma	0.60668394398872	21	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	pain agnosia	0.60508047996565	11	psychiatric disorder
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	pain agnosia	0.60508047996565	11	psychiatric disorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	uterine neoplasm	0.60477961198684	1095	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	uterine neoplasm	0.60477961198684	1095	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	uterine neoplasm	0.60477961198684	1095	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	uterine neoplasm	0.60477961198684	1095	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	uterine neoplasm	0.60477961198684	1095	cancer
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	infertility	0.60466648961276	9	reproductiveSystem
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	infertility	0.60466648961276	9	reproductiveSystem
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	infertility	0.60466648961276	9	reproductiveSystem
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	chronic bronchitis	0.60466648961276	9	respiratory
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	chronic bronchitis	0.60466648961276	9	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	chronic bronchitis	0.60466648961276	9	respiratory
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	chronic bronchitis	0.60466648961276	9	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	chronic bronchitis	0.60466648961276	9	respiratory
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	acromegaly	0.60466648961276	9	reproductiveSystem
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	acromegaly	0.60466648961276	9	reproductiveSystem
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	acromegaly	0.60466648961276	9	reproductiveSystem
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	Agitation	0.60466648961276	9	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	Agitation	0.60466648961276	9	psychiatricDisorder
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	Central diabetes insipidus	0.60466648961276	9	metabolicEndocrine
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	targetBased	324747	813	Abdominal distention	0.60466648961276	9	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Muscle spasm	0.60466648961276	9	muculoEskeletalConnective
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	targetBased	363803	502	peptic ulcer disease	0.60466648961276	9	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	targetBased	363803	2629	peptic ulcer disease	0.60466648961276	9	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	targetBased	363803	1450	peptic ulcer disease	0.60466648961276	9	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	698	peptic ulcer disease	0.60466648961276	9	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	2133	peptic ulcer disease	0.60466648961276	9	gastroIntestinal
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	targetBased	363803	1081	peptic ulcer disease	0.60466648961276	9	gastroIntestinal
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Neurodevelopmental disorder	0.60292127111447	19	nervousSystem
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	targetBased	407539	2380	Chemotherapy-induced nausea and vomiting	0.60185244135153	30	otherPhenotypes
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	targetBased	364051	9106	Chemotherapy-induced nausea and vomiting	0.60185244135153	30	otherPhenotypes
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	targetBased	407539	2380	Chemotherapy-induced nausea and vomiting	0.60185244135153	30	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Headache	0.60183546143348	19	otherPhenotypes
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Headache	0.60183546143348	19	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Headache	0.60183546143348	19	otherPhenotypes
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Headache	0.60183546143348	19	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Headache	0.60183546143348	19	otherPhenotypes
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Headache	0.60183546143348	19	otherPhenotypes
SSB-PriA antibiotic resistant target AlphaScreen	Klebsiella pneumonia SSB-PriA interaction	targetBased	431236	2568	neurodegenerative disease	0.60023710564504	20	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	targetBased	369953	2602	neurodegenerative disease	0.59632424455501	11	nervousSystem
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	neurodegenerative disease	0.59512464250193	58	nervousSystem
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	targetBased	326024	350	neurodegenerative disease	0.59508041112244	192	nervousSystem
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	targetBased	343468	285	hereditary neoplastic syndrome	0.59216265599301	644	cancer
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	Roussy-LÃ©vy syndrome	0.59205178605105	42	nervousSystem
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	Nausea	0.59173377598045	12	otherPhenotypes
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	Nausea	0.59173377598045	12	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	Nausea	0.59173377598045	12	otherPhenotypes
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	Nausea	0.59173377598045	12	otherPhenotypes
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	Nausea	0.59173377598045	12	otherPhenotypes
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	Nausea	0.59173377598045	12	otherPhenotypes
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	Cognitive impairment	0.59152190496849	179	nervousSystem
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	colonic neoplasm	0.59125709347292	27	cancer
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	calcium measurement	0.59105234661804	15	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	mood disorder	0.59091958364141	767	psychiatricDisorder
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	acute respiratory distress syndrome	0.59062134940304	12	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	acute respiratory distress syndrome	0.59062134940304	12	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	asthma	0.59019417757692	24	respiratory
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	asthma	0.59019417757692	24	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	asthma	0.59019417757692	24	respiratory
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	asthma	0.59019417757692	24	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	asthma	0.59019417757692	24	respiratory
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	motion sickness	0.58943430842421	23	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	motion sickness	0.58943430842421	23	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	motion sickness	0.58943430842421	23	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	motion sickness	0.58943430842421	23	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	motion sickness	0.58943430842421	23	otherPhenotypes
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Burkitts lymphoma	0.58936406559799	275	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Burkitts lymphoma	0.58936406559799	275	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Burkitts lymphoma	0.58936406559799	275	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Burkitts lymphoma	0.58936406559799	275	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Burkitts lymphoma	0.58936406559799	275	cancer
Thrombin 1536 HTS	F2_modulation	targetBased	217233	557	acute coronary syndrome	0.58681113834509	26	cardioVascular
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	cervical cancer	0.58247055398953	168	cancer
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	schizophrenia	0.58146298491719	81	psychiatricDisorder
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	schizophrenia	0.58146298491719	81	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	schizophrenia	0.58146298491719	81	psychiatricDisorder
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	schizophrenia	0.58146298491719	81	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	schizophrenia	0.58146298491719	81	psychiatricDisorder
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	poisoning	0.57993179479527	9	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	poisoning	0.57993179479527	9	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	poisoning	0.57993179479527	9	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	poisoning	0.57993179479527	9	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	poisoning	0.57993179479527	9	otherPhenotypes
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	760	blood coagulation disease	0.57927882376402	97	hematologic
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	targetBased	369953	498	blood coagulation disease	0.57927882376402	97	hematologic
HTS for 14-3-3 protein interaction modulators	YWHAG	targetBased	157962	312	developmental and epileptic encephalopathy	0.57853134759266	33	nervousSystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	Fanconi anemia	0.57760274438034	421	muculoEskeletalConnective
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	melanocytic neoplasm	0.57720847430598	187	cancer
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pathwayBased	362051	17187	gout	0.57690435150965	63	muculoEskeletalConnective
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	Osteopenia	0.57648010585294	47	muculoEskeletalConnective
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	type 2 diabetes mellitus	0.57586675548928	30	metabolicEndocrine
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	sarcoma	0.57334986414968	191	cancer
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	abnormal glucose tolerance	0.57280694202758	8	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	abnormal glucose tolerance	0.57280694202758	8	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	abnormal glucose tolerance	0.57280694202758	8	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	abnormal glucose tolerance	0.57280694202758	8	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	abnormal glucose tolerance	0.57280694202758	8	metabolicEndocrine
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	abnormal glucose tolerance	0.57280694202758	8	metabolicEndocrine
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	esophageal varices	0.57280694202758	8	gastroIntestinal
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	frontotemporal dementia	0.57224695468469	913	psychiatricDisorder
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	frontotemporal dementia	0.57224695468469	913	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	respiratory system disease	0.57220528861961	170	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	substance abuse	0.57215424526313	13	psychiatricDisorder
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	eosinophil percentage of leukocytes	0.57119427655971	11	hematologic
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	eosinophil percentage of leukocytes	0.57119427655971	11	hematologic
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	carcinoma of liver and intrahepatic biliary tract	0.56918270779896	653	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	epilepsy	0.56770916893568	14	nervousSystem
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	lymphoid neoplasm	0.56726113328905	802	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	respiratory system disease	0.56428276068475	66	respiratory
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	respiratory system disease	0.56428276068475	66	respiratory
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	monocyte count	0.56162009245327	10	hematologic
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	monocyte count	0.56162009245327	10	hematologic
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	cancer	0.56085201851383	53	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	prostate cancer	0.56074255087829	294	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	prostate cancer	0.56074255087829	294	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	prostate cancer	0.56074255087829	294	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	prostate cancer	0.56074255087829	294	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	prostate cancer	0.56074255087829	294	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	nicotine dependence	0.55928325716652	8	psychiatricDisorder
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	adult T-cell leukemia/lymphoma	0.55928325716652	8	cancer
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	Dementia	0.55756748337005	12	psychiatricDisorder
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	hemoglobin measurement	0.55712159008365	14	hematologic
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	type 2 diabetes mellitus	0.55611341627735	228	metabolicEndocrine
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	type 2 diabetes mellitus	0.55611341627735	228	metabolicEndocrine
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	pathwayBased	271402	1048	dementia	0.55546276458891	1658	psychiatricDisorder
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	pathwayBased	267412	5703	dementia	0.55546276458891	1658	psychiatricDisorder
qHTS Assay for Tau Filament Binding	MAPT	targetBased	69668	1391	dementia	0.55546276458891	1658	psychiatricDisorder
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	targetBased	263421	615	familial isolated hyperparathyroidism	0.55473784931811	85	cancer
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	anemia	0.55367092794918	6	hematologic
Factor XIa 1536 HTS	F11_modulation	targetBased	218707	302	deep vein thrombosis	0.55243395918738	42	hematologic
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	bladder tumor	0.55177181402749	130	cancer
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	targetBased	199169	715	diabetes mellitus	0.55166609042028	16	metabolicEndocrine
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	targetBased	302297	1165	diabetes mellitus	0.55166609042028	16	metabolicEndocrine
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	breast neoplasm	0.54706759205653	11	cancer
High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity	MARVELD2	targetBased	362274	1085	hearing loss	0.54644243570006	75	nervousSystem
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	pathwayBased	376029	3978	lymph node metastatic carcinoma	0.54643680192594	81	cancer
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	cancer	0.54326808569933	4699	cancer
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	targetBased	31324	362	body height	0.54316419394014	12	otherPhenotypes
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	Malignant Mesothelioma	0.54276713631072	132	cancer
qHTS for Inhibitors of WRN Helicase	WRN	targetBased	364011	1678	melanoma	0.54225293911469	19	cancer
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	melanoma	0.53648241518688	2725	cancer
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	melanoma	0.53648241518688	2725	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Intellectual disability	0.53550223619396	42	nervousSystem
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Intellectual disability	0.53550223619396	42	nervousSystem
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	Abnormal heart morphology	0.53214174757145	9	cardioVascular
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	Abnormal heart morphology	0.53214174757145	9	cardioVascular
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	carcinoid tumor	0.53134326398704	73	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	carcinoid tumor	0.53134326398704	73	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	carcinoid tumor	0.53134326398704	73	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	carcinoid tumor	0.53134326398704	73	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	carcinoid tumor	0.53134326398704	73	cancer
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	leukemia	0.52960653881427	339	cancer
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	alcohol abuse	0.52882174426934	68	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	alcohol abuse	0.52882174426934	68	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	alcohol abuse	0.52882174426934	68	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	alcohol abuse	0.52882174426934	68	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	alcohol abuse	0.52882174426934	68	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	alcohol abuse	0.52882174426934	68	psychiatricDisorder
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	targetBased	339674	2841	COVID-19	0.52662355822706	8	infective
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	psoriasis	0.52623853206338	110	immune
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	pericarditis	0.52560928186248	6	cardioVascular
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	Sciatica	0.52560928186248	6	muculoEskeletalConnective
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	Sciatica	0.52560928186248	6	muculoEskeletalConnective
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	targetBased	305610	3794	COVID-19	0.52560928186248	6	infective
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	targetBased	363840	3086	COVID-19	0.52529188517202	104	infective
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	obsessive-compulsive disorder	0.52519332062715	39	psychiatricDisorder
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	brain neoplasm	0.52338689289213	78	cancer
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	birth weight	0.52265879869217	12	otherPhenotypes
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	birth weight	0.52265879869217	12	otherPhenotypes
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	cystic fibrosis	0.52252841740507	12	respiratory
Primary HTS assay for chemical inhibitors of TNF alpha stimulated VCAM1 expression	VCAM1_expression	targetBased	94498	457	lymphocyte count	0.52226432746613	21	hematologic
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	Malignant Urinary System Neoplasm	0.52220433972734	1683	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	Malignant Urinary System Neoplasm	0.52220433972734	1683	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	Malignant Urinary System Neoplasm	0.52220433972734	1683	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	Malignant Urinary System Neoplasm	0.52220433972734	1683	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	Malignant Urinary System Neoplasm	0.52220433972734	1683	cancer
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	oral cavity carcinoma	0.51917183544761	40	cancer
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	stroke	0.51828395256274	6	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	alcohol drinking	0.51828395256274	6	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	alcohol drinking	0.51828395256274	6	nervousSystem
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	targetBased	363803	2412	Hallucinations	0.51738963111677	18	psychiatricDisorder
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	kidney neoplasm	0.51632178998452	831	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	kidney neoplasm	0.51632178998452	831	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	kidney neoplasm	0.51632178998452	831	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	kidney neoplasm	0.51632178998452	831	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	kidney neoplasm	0.51632178998452	831	cancer
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	targetBased	195560	517	Low alkaline phosphatase	0.51560110774517	24	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	Drooling	0.51539889979238	8	otherPhenotypes
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	Drooling	0.51539889979238	8	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	Drooling	0.51539889979238	8	otherPhenotypes
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	Drooling	0.51539889979238	8	otherPhenotypes
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	Drooling	0.51539889979238	8	otherPhenotypes
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	targetBased	86095	1114	breast carcinoma in situ	0.51521839195996	16	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	urothelial carcinoma	0.51408234512013	433	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	urothelial carcinoma	0.51408234512013	433	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	urothelial carcinoma	0.51408234512013	433	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	urothelial carcinoma	0.51408234512013	433	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	urothelial carcinoma	0.51408234512013	433	cancer
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	Global developmental delay	0.51395404279331	26	otherPhenotypes
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	lymphoma	0.51373824732454	888	cancer
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	lymphoma	0.51373824732454	888	cancer
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	Crohn's disease	0.51331093980131	8	immune
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	215667	993	neurodegenerative disease	0.51129791900956	25	nervousSystem
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	targetBased	218234	1620	neurodegenerative disease	0.51129791900956	25	nervousSystem
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	334825	423	carcinoma of liver and intrahepatic biliary tract	0.51063753622872	34	cancer
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	targetBased	337446	1356	carcinoma of liver and intrahepatic biliary tract	0.51063753622872	34	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lung carcinoma	0.51063680830263	3214	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lung carcinoma	0.51063680830263	3214	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lung carcinoma	0.51063680830263	3214	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lung carcinoma	0.51063680830263	3214	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lung carcinoma	0.51063680830263	3214	cancer
uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells	TNFSF10	targetBased	217035	883	aspartate aminotransferase measurement	0.51056837906566	8	hematologic
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	skin carcinoma	0.51020778667764	424	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	skin carcinoma	0.51020778667764	424	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	skin carcinoma	0.51020778667764	424	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	skin carcinoma	0.51020778667764	424	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	skin carcinoma	0.51020778667764	424	cancer
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	acute bronchiolitis	0.51000069558534	6	respiratory
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	targetBased	71016	346	cutaneous melanoma	0.50942246785541	78	cancer
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	hypertension	0.50567174512419	25	cardioVascular
Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set	ABCB6_inhibitors	targetBased	362098	692	microphthalmia, isolated, with coloboma	0.50452073307516	9	visualSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	stomach neoplasm	0.50387992859265	589	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	stomach neoplasm	0.50387992859265	589	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	stomach neoplasm	0.50387992859265	589	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	stomach neoplasm	0.50387992859265	589	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	stomach neoplasm	0.50387992859265	589	cancer
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	targetBased	305610	2592	lean body mass	0.50328478437926	17	metabolicEndocrine
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	bile duct adenocarcinoma	0.50193157436328	15	cancer
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	head and neck neoplasia	0.50151206457427	2001	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	head and neck neoplasia	0.50151206457427	2001	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	head and neck neoplasia	0.50151206457427	2001	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	head and neck neoplasia	0.50151206457427	2001	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	head and neck neoplasia	0.50151206457427	2001	cancer
qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase	PKM	targetBased	263662	892	neurodegenerative disease	0.50081897368671	10	nervousSystem
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	colorectal neoplasm	0.50059601177339	285	cancer
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	targetBased	193542	587	Pilomatrixoma	0.8876009025445	134	cancer
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	autosomal dominant cerebellar ataxia, deafness and narcolepsy	0.8534316413014	93	psychiatricDisorder
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	targetBased	331360	2760	melanoma, cutaneous malignant, susceptibility to, 8	0.7731628481319	633	geneticDisorder
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	targetBased	642362	5830	melanoma, cutaneous malignant, susceptibility to, 8	0.7731628481319	633	geneticDisorder
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	fatal familial insomnia	0.7364832327914	188	psychiatricDisorder
Colorimetric Assay for Inhibitors for NALP1	NLRP1	targetBased	280024	1717	Corneal intraepithelial dyskeratosis with palmoplantar hyperkeratosis and laryngeal dyskeratosis	0.7275973224838	33	visualSystem
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	genetic disorder	0.7237869558487	1491	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	genetic disorder	0.7237869558487	1491	geneticDisorder
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	ventricular tachycardia	0.6948342910003	133	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	ventricular tachycardia	0.6948342910003	133	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	ventricular tachycardia	0.6948342910003	133	cardioVascular
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	targetBased	310014	1321	genetic disorder	0.6915703602054	922	geneticDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	mood disorder	0.6712322106451	702	psychiatricDisorder
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	mood disorder	0.6712322106451	702	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	mood disorder	0.6712322106451	702	psychiatricDisorder
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	mood disorder	0.6712322106451	702	psychiatricDisorder
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	mood disorder	0.6712322106451	702	psychiatricDisorder
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	mood disorder	0.6712322106451	702	psychiatricDisorder
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	secondary hyperparathyroidism	0.6628175930313	274	metabolicEndocrine
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	Sepsis	0.6612711090907	66	infective
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	hypotension	0.6612423935077	103	cardioVascular
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	diabetes mellitus	0.6503387957345	50	metabolicEndocrine
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	adult acute lymphoblastic leukemia	0.6264758721618	42	cancer
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	combined immunodeficiency	0.6056619781946	71	immune
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	combined immunodeficiency	0.6056619781946	71	immune
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	myeloproliferative disorder	0.6008959180227	3170	cancer
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	response to tramadol	0.5994368905986	695	otherPhenotypes
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	response to tramadol	0.5994368905986	695	otherPhenotypes
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	gallbladder cancer	0.5934612972816	77	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	gallbladder cancer	0.5934612972816	77	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	gallbladder cancer	0.5934612972816	77	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	gallbladder cancer	0.5934612972816	77	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	gallbladder cancer	0.5934612972816	77	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	diabetic neuropathy	0.5850204572023	73	nervousSystem
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	cervical squamous cell carcinoma	0.5768924431085	118	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	cervical squamous cell carcinoma	0.5768924431085	118	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	cervical squamous cell carcinoma	0.5768924431085	118	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	cervical squamous cell carcinoma	0.5768924431085	118	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	cervical squamous cell carcinoma	0.5768924431085	118	cancer
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	heart disease	0.5744892428341	1627	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	heart disease	0.5744892428341	1627	cardioVascular
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	heart disease	0.5744892428341	1627	cardioVascular
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	thyroid carcinoma	0.5522484605199	10	cancer
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	targetBased	335531	328	nephrolithiasis	0.5424462695145	8	urinarySystem
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	eosinophil percentage of leukocytes	0.5357359281835	15	hematologic
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	B-cell non-Hodgkins lymphoma	0.5234572186721	233	cancer
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	obesity	0.5193543582675	9	metabolicEndocrine
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	hemoglobin measurement	0.5118851697251	28	hematologic
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	hemoglobin measurement	0.5118851697251	28	hematologic
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	hemoglobin measurement	0.5118851697251	28	hematologic
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	hemoglobin measurement	0.5118851697251	28	hematologic
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	hemoglobin measurement	0.5118851697251	28	hematologic
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	hemoglobin measurement	0.5118851697251	28	hematologic
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	pathwayBased	193400	1987	Dementia	0.5081212394352	31	psychiatricDisorder
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	pathwayBased	193714	1590	Dementia	0.5081212394352	31	psychiatricDisorder
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	targetBased	404343	257	Dementia	0.5081212394352	31	psychiatricDisorder
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	Crohn's disease	0.5018282116886	13	immune
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	Crohn's disease	0.5018282116886	13	immune
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	angiosarcoma	0.542272992084	75	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	angiosarcoma	0.542272992084	75	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	angiosarcoma	0.542272992084	75	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	angiosarcoma	0.542272992084	75	cancer
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	angiosarcoma	0.542272992084	75	cancer
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	breast neoplasm	0.517897767902	729	cancer
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	acute myeloid leukemia	0.694	594	cancer

Click on the graphs below to go through target-disease associations for different terapeutic areas.

Go to Nervous System Target-Disease Portfolio

Go to Infective Diseases Target-Disease Portfolio

Go to Immune Target-Disease Portfolio

Go to Cancer Target-Disease Portfolio

Go to Metabolic/Endocrine Target-Disease Portfolio

Go to Cardiovascular Target-Disease Portfolio